| | |
页数
|
| |||
其他信息
|
| | | | 1 | | |
关于本委托书/招股说明书
|
| | | | 2 | | |
行业和市场数据
|
| | | | 3 | | |
常用术语
|
| | | | 4 | | |
关于建议书的问答
|
| | | | 9 | | |
委托书/招股说明书摘要
|
| | | | 30 | | |
峰会历史财务数据精选
|
| | | | 51 | | |
YS BioPharma历史财务数据精选
|
| | | | 52 | | |
汇总未经审计的备考简明合并财务信息
|
| | | | 55 | | |
每股对比信息
|
| | | | 57 | | |
前瞻性陈述
|
| | | | 59 | | |
风险因素
|
| | | | 61 | | |
峰会股东特别大会
|
| | | | 142 | | |
企业合并协议
|
| | | | 148 | | |
与业务合并相关的协议
|
| | | | 158 | | |
1号提案 - 企业合并提案
|
| | | | 160 | | |
2号提案 - 合并提案
|
| | | | 185 | | |
提案3 - 休会提案
|
| | | | 186 | | |
峰会相关信息
|
| | | | 187 | | |
峰会管理层对财务状况和经营成果的讨论和分析
|
| | | | 202 | | |
YS BioPharma的市场机遇
|
| | | | 206 | | |
YS BioPharma的业务
|
| | | | 221 | | |
YS BioPharma管理层对财务状况和经营结果的讨论和分析
|
| | | | 305 | | |
未经审计的备考简明合并财务信息
|
| | | | 328 | | |
企业合并后的管理
|
| | | | 341 | | |
物料税考虑因素
|
| | | | 351 | | |
YS BioPharma证券介绍
|
| | | | 363 | | |
公司治理与股东权利比较
|
| | | | 368 | | |
证券的实益所有权
|
| | | | 375 | | |
某些关系和关联人交易
|
| | | | 377 | | |
有资格未来出售的股票
|
| | | | 380 | | |
证券股利信息价格区间
|
| | | | 382 | | |
考核权
|
| | | | 383 | | |
未来的股东提案和提名
|
| | | | 384 | | |
股东公关
|
| | | | 385 | | |
向股东交付文件
|
| | | | 386 | | |
转会代理和注册商
|
| | | | 387 | | |
您可以在哪里找到更多信息
|
| | | | 388 | | |
法律事务
|
| | | | 389 | | |
专家
|
| | | | 390 | | |
财务报表索引
|
| | | | F-1 | | |
| | |
页数
|
| |||
附件 | | | | | | | |
附件A:
业务合并协议
|
| | | | A-1 | | |
附件B:
修订和重新修订YS Biophma公司章程和章程
|
| | | | B-1 | | |
附件C:
首次合并计划
|
| | | | C-1 | | |
附件D:
ValueScope,Inc.的公平意见
|
| | | | D-1 | | |
| | |
场景1
假设 不赎回 |
| |
场景2
假设 50%赎回 |
| |
场景3
假设 100%赎回 |
| |||||||||||||||||||||||||||
|
数量:
普通 个共享 |
| |
共享
所有权 % |
| |
数量:
普通 个共享 |
| |
共享
所有权 % |
| |
数量:
普通 个共享 |
| |
共享
所有权 % |
| ||||||||||||||||||||
YS Biophma股东
|
| | | | 83,424,995 | | | | | | 73.53 | | | | | | 83,424,995 | | | | | | 80.63 | | | | | | 83,424,995 | | | | | | 90.51 | | |
峰会公众股东
|
| | | | 22,337,818 | | | | | | 19.69 | | | | | | 12,042,860 | | | | | | 11.64 | | | | | | — | | | | | | — | | |
远期买入投资者
|
| | | | 3,769,507 | | | | | | 3.32 | | | | | | 4,064,465 | | | | | | 3.93 | | | | | | 4,821,525 | | | | | | 5.23 | | |
赞助商和特定的
峰会董事身份 分组: |
| | | | 3,928,475 | | | | | | 3.46 | | | | | | 3,928,475 | | | | | | 3.80 | | | | | | 3,928,475 | | | | | | 4.26 | | |
形式上的普通股
杰出的(1) |
| | | | 113,460,795 | | | | | | 100.00 | | | | | | 103,460,795 | | | | | | 100.00 | | | | | | 92,174,995 | | | | | | 100.00 | | |
预计账面价值
股权 |
| | | | 2234,552,988元 | | | | | | | | | | | | 1520,312,246元 | | | | | | | | | | | | 806071503元 | | | | | | | | |
预计每股账面价值
|
| | | | RMB19.69 | | | | | | | | | | | | RMB14.69 | | | | | | | | | | | | RMB8.75 | | | | | | | | |
| | |
场景1
假设 不赎回 |
| |
场景2
假设 50%赎回 |
| |
场景3
假设 100%赎回 |
| |||||||||||||||||||||||||||
|
数量:
普通 个共享 |
| |
共享
所有权 % |
| |
数量:
普通 个共享 |
| |
共享
所有权 % |
| |
数量:
普通 个共享 |
| |
共享
所有权 % |
| ||||||||||||||||||||
YS Biophma
股东 |
| | | | 90,081,577 | | | | | | 74.99 | | | | | | 90,081,577 | | | | | | 81.80 | | | | | | 90,081,577 | | | | | | 91.15 | | |
峰会公众股东
|
| | | | 22,337,818 | | | | | | 18.60 | | | | | | 12,042,860 | | | | | | 10.94 | | | | | | — | | | | | | — | | |
远期买入投资者
|
| | | | 3,769,507 | | | | | | 3.14 | | | | | | 4,064,465 | | | | | | 3.69 | | | | | | 4,821,525 | | | | | | 4.88 | | |
作为一个群体的赞助商和某些峰会董事。
|
| | | | 3,928,475 | | | | | | 3.27 | | | | | | 3,928,475 | | | | | | 3.57 | | | | | | 3,928,475 | | | | | | 3.97 | | |
未偿还形式普通股
|
| | | | 120,117,377 | | | | | | 100.00 | | | | | | 110,117,377 | | | | | | 100.00 | | | | | | 98,831,577 | | | | | | 100.00 | | |
预计账面价值为
股权 |
| | | | 人民币2,250,791,944元 | | | | | | | | | | | | 1,536,551,202元 | | | | | | | | | | | | 822,310,459元 | | | | | | | | |
每个
的预计账面价值
共享 |
| | | | RMB18.74 | | | | | | | | | | | | RMB13.95 | | | | | | | | | | | | RMB8.32 | | | | | | | | |
| | |
场景1
假设没有赎回 |
| |
场景2
假设50%赎回 |
| |
场景3
假设100%赎回 |
| |||||||||||||||||||||||||||||||||||||||||||||
| | |
数量:
普通 个共享 |
| |
共享
所有权 % |
| |
数量:
普通 个共享 |
| |
共享
所有权 % |
| |
数量:
普通 个共享 |
| |
共享
所有权 % |
| ||||||||||||||||||||||||||||||||||||
| | | | | | | | |
(A)
|
| |
(B)
|
| | | | | | | |
(A)
|
| |
(B)
|
| | | | | | | |
(A)
|
| |
(B)
|
| ||||||||||||||||||
赞助商(1) | | | | | 3,853,475 | | | | | | 3.40 | | | | | | 3.21 | | | | | | 3,853,475 | | | | | | 3.72 | | | | | | 3.5 | | | | | | 3,853,475 | | | | | | 4.18 | | | | | | 3.9 | | |
保荐人总潜在所有权权益(2)
|
| | | | 11,353,475 | | | | | | 9.39 | | | | | | 8.9 | | | | | | 11,353,475 | | | | | | 10.23 | | | | | | 9.65 | | | | | | 11,353,475 | | | | | | 11.39 | | | | | | 10.68 | | |
赎回百分比(1)
|
| |
0.0%
|
| |
25.0%
|
| |
50.0%
|
| |
75.0%
|
| |
85.0%
|
| |
90.0%
|
| |
100.0%
|
| |||||||||||||||||||||
Summit公开股票未赎回的百分比
|
| | | | 100% | | | | | | 75% | | | | | | 50% | | | | | | 25% | | | | | | 15% | | | | | | 10% | | | | | | 0% | | |
剩余的Summit公共共享
|
| | | | 20,000,000 | | | | | | 15,000,000 | | | | | | 10,000,000 | | | | | | 5,000,000 | | | | | | 3,000,000 | | | | | | 2,000,000 | | | | | | 0 | | |
企业合并结束时峰会公开股票的假设价格($)
|
| | | | 10.00 | | | | | | 10.00 | | | | | | 10.00 | | | | | | 10.00 | | | | | | 10.00 | | | | | | 10.00 | | | | | | 10.00 | | |
信托账户大小(单位:百万美元)
|
| | | | 200 | | | | | | 150 | | | | | | 100 | | | | | | 50 | | | | | | 30 | | | | | | 20 | | | | | | 0 | | |
增发YS Biophma普通股
向非赎回峰会公众开放 股东 |
| | | | 2,337,818 | | | | | | 2,230,469 | | | | | | 2,042,860 | | | | | | 1,631,239 | | | | | | 1,285,800 | | | | | | 857,200 | | | | | | 0 | | |
远期购买投资者持有的峰会股票(2)
|
| | | | 3,375,000 | | | | | | 3,375,000 | | | | | | 3,375,000 | | | | | | 3,375,000 | | | | | | 3,375,000 | | | | | | 3,375,000 | | | | | | 3,375,000 | | |
可供投资者远期购买的额外YS Biophma普通股(3)
|
| | | | 394,507 | | | | | | 501,856 | | | | | | 689,465 | | | | | | 1,101,086 | | | | | | 1,446,525 | | | | | | 1,446,525 | | | | | | 1,446,525 | | |
A类交换比率
|
| | | | 1.1169 | | | | | | 1.1487 | | | | | | 1.2043 | | | | | | 1.3262 | | | | | | 1.4286 | | | | | | 1.4286 | | | | | | 1.4286 | | |
非赎回峰会公众股东持有的YS Biophma普通股每股隐含价格($)(4)
|
| | | | 8.95 | | | | | | 8.71 | | | | | | 8.30 | | | | | | 7.54 | | | | | | 7.00 | | | | | | 7.00 | | | | | | 7.00 | | |
远期购买投资者持有的YS Biophma普通股每股隐含价格($)(4)
|
| | | | 7.96 | | | | | | 7.74 | | | | | | 7.38 | | | | | | 6.70 | | | | | | 6.22 | | | | | | 6.22 | | | | | | 6.22 | | |
每股峰会公开股票隐含合并对价($)
|
| | | | 11.17 | | | | | | 11.49 | | | | | | 12.04 | | | | | | 13.26 | | | | | | 14.29 | | | | | | 14.29 | | | | | | 14.29 | | |
| | |
九人组
个月结束 9月30日 2022 |
| |
九人组
个月结束 9月30日 2021 |
| |
年终了
12月31日 2021 |
| |
用于
从 开始的期间 12月22日 2020(初始) 至 12月31日 2020 |
| ||||||||||||
| | |
(未经审计)
|
| | | | | | | | | | | | | |||||||||
损益表数据: | | | | | | | | | | | | | | | | | | | | | | | | | |
运营亏损
|
| | | $ | (1,225,560) | | | | | $ | (246,868) | | | | | $ | (549,179) | | | | | $ | (3,636) | | |
其他收入(费用)
|
| | | | 15,777,528 | | | | | | (3,399,399) | | | | | | 3,452 | | | | | | — | | |
净收益(亏损)
|
| | | $ | 14,551,968 | | | | | $ | (3,646,267) | | | | | $ | (545,727) | | | | | $ | (3,636) | | |
基本和稀释后加权平均流通股,A类普通股
|
| | | | 20,000,000 | | | | | | 8,205,128 | | | | | | 11,178,082 | | | | | | — | | |
每单位的基本和摊薄净收益(亏损)
A类普通股,受制于 可能的赎回 |
| | | $ | 0.57 | | | | | $ | (0.26) | | | | | $ | (0.03) | | | | | $ | — | | |
基本和稀释后加权平均流通股,B类普通股
|
| | | | 5,750,000 | | | | | | 5,750,000 | | | | | | 5,750,000 | | | | | | 5,750,000 | | |
每股基本和稀释后净收益(亏损),B类普通股
|
| | | $ | 0.57 | | | | | $ | (0.26) | | | | | $ | (0.03) | | | | | $ | (0.00) | | |
现金流数据: | | | | | | | | | | | | | | | | ||||||||||
经营活动提供的现金净额(用于)
|
| | | $ | (815,101) | | | | | $ | (423,286) | | | | | $ | (613,225) | | | | | $ | — | | |
用于投资的现金净额
活动 |
| | | | — | | | | | $ | (200,000,000) | | | | | | (200,000,000) | | | | | $ | — | | |
融资活动提供的现金净额
|
| | | | — | | | | | $ | 201,498,423 | | | | | | 201,498,423 | | | | | $ | — | | |
| | |
截至
9月30日 2022 |
| |
截至
12月31日 2021 |
| ||||||
| | |
(未经审计)
|
| | | | | | | |||
资产负债表数据: | | | | | | | | | | | | | |
现金
|
| | | $ | 70,097 | | | | | $ | 885,198 | | |
其他流动资产
|
| | | | 218,545 | | | | | | 141,677 | | |
信托账户中持有的投资
|
| | | | 201,200,243 | | | | | | 200,007,275 | | |
总资产
|
| | | $ | 201,488,885 | | | | | $ | 201,034,150 | | |
总负债
|
| | | $ | 6,254,766 | | | | | $ | 20,352,001 | | |
可能赎回的A类普通股
|
| | | | 201,200,243 | | | | | | 200,000,000 | | |
股东亏损总额
|
| | | $ | (5,966,124) | | | | | $ | (19,317,851) | | |
| | |
截至9月30日的6个月
|
| |
截至2009年3月31日的财政年度
|
| ||||||||||||||||||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |
2021
|
| |
2022
|
| |
2022
|
| ||||||||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| ||||||||||||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | | | | | | | | | | | | | |||||||||
收入 | | | | | 269,433,426 | | | | | | 399,534,723 | | | | | | $56,274,081 | | | | | | 257,015,929 | | | | | | 502,949,894 | | | | | | $ 79,227,166 | | |
收入成本
|
| | | | 63,599,621 | | | | | | 93,700,779 | | | | | | 13,197,665 | | | | | | 59,656,877 | | | | | | 117,066,090 | | | | | | 18,440,832 | | |
毛利
|
| | | | 205,833,805 | | | | | | 305,833,944 | | | | | | 43,076,416 | | | | | | 197,359,052 | | | | | | 385,883,804 | | | | | | 60,786,334 | | |
运营费用: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
销售
|
| | | | 86,265,281 | | | | | | 150,228,079 | | | | | | 21,159,480 | | | | | | 73,485,259 | | | | | | 185,999,704 | | | | | | 29,299,597 | | |
一般和行政
|
| | | | 51,664,591 | | | | | | 49,587,013 | | | | | | 6,984,283 | | | | | | 155,334,386 | | | | | | 107,620,500 | | | | | | 16,952,916 | | |
研发
|
| | | | 124,051,209 | | | | | | 123,861,107 | | | | | | 17,445,718 | | | | | | 94,387,144 | | | | | | 211,222,263 | | | | | | 33,272,780 | | |
总运营费用
|
| | | | 261,981,081 | | | | | | 323,676,199 | | | | | | 45,589,481 | | | | | | 323,206,789 | | | | | | 504,842,467 | | | | | | 79,525,293 | | |
运营亏损
|
| | | | (56,147,276) | | | | | | (17,842,255) | | | | | | (2,513,065) | | | | | | (125,847,737) | | | | | | (118,958,663) | | | | | | (18,738,959) | | |
其他收入(费用): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
所得税相关滞纳金
|
| | | | (112,420) | | | | | | — | | | | | | — | | | | | | (11,464,741) | | | | | | — | | | | | | — | | |
与所得税以外的税种相关的滞纳金
|
| | | | (1,396,221) | | | | | | (299,417) | | | | | | (42,173) | | | | | | (7,261,947) | | | | | | (231,231) | | | | | | (36,425) | | |
与社保相关的滞纳金
|
| | | | — | | | | | | — | | | | | | — | | | | | | (7,701,793) | | | | | | (1,852,378) | | | | | | (291,796) | | |
政府拨款
|
| | | | 19,600,822 | | | | | | 22,456,691 | | | | | | 3,163,003 | | | | | | 3,530,405 | | | | | | 23,020,413 | | | | | | 3,626,290 | | |
财务费用,净额
|
| | | | (352,694) | | | | | | (14,949,434) | | | | | | (2,105,613) | | | | | | (29,689,927) | | | | | | (2,717,433) | | | | | | (428,064) | | |
其他收入(支出),净额
|
| | | | (993,957) | | | | | | 74,675 | | | | | | 10,518 | | | | | | 4,063,743 | | | | | | (327,987) | | | | | | (51,666) | | |
其他(费用)收入合计,
净额 |
| | | | 16,745,530 | | | | | | 7,282,515 | | | | | | 1,025,735 | | | | | | (48,524,260) | | | | | | 17,891,384 | | | | | | 2,818,339 | | |
| | |
截至9月30日的6个月
|
| |
截至2009年3月31日的财政年度
|
| ||||||||||||||||||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |
2021
|
| |
2022
|
| |
2022
|
| ||||||||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| ||||||||||||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | | | | | | | | | | | | | |||||||||
所得税前亏损
|
| | | | (39,401,746) | | | | | | (10,559,740) | | | | | | (1,487,330) | | | | | | (174,371,997) | | | | | | (101,067,279) | | | | | | (15,920,620) | | |
所得税费用
|
| | | | (5,689,586) | | | | | | (565,625) | | | | | | (79,668) | | | | | | (17,454,245) | | | | | | (4,937,122) | | | | | | (777,720) | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | | (1,566,998) | | | | | | (191,826,242) | | | | | | (106,004,401) | | | | | | (16,698,340) | | |
增加可转换可赎回优先股的赎回价值
|
| | | | (65,013,751) | | | | | | (72,083,238) | | | | | | (10,152,855) | | | | |
|
(16,610,297)
|
| | | | | (130,662,326) | | | | |
|
(20,582,579)
|
| |
YS Biophma Co.Ltd.应占净亏损
|
| | | | (110,105,083) | | | | | | (83,208,603) | | | | | | $(11,719,853) | | | | | | (208,436,539) | | | | | | (236,666,727) | | | | | | $(37,280,919) | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | | $ (1,566,998) | | | | | | (191,826,242) | | | | | | (106,004,401) | | | | | | $(16,698,340) | | |
其他综合收益:外币折算
收获 |
| | | | 11,321,167 | | | | | | (168,653,952) | | | | | | (23,754,747) | | | | | | 22,455,217 | | | | | | 38,864,606 | | | | | | 6,122,146 | | |
全面亏损
|
| | | | (33,770,165) | | | | | | (179,779,317) | | | | | | $(25,321,745) | | | | | | (169,371,025) | | | | | | (67,139,795) | | | | | | $(10,576,194) | | |
每股亏损*: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | (0.18) | | | | | | (0.05) | | | | | | $ (0.01) | | | | | | (0.78) | | | | | | (0.43) | | | | | | $ (0.07) | | |
已发行普通股加权平均数*:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | 247,311,533 | | | | | | 247,141,861 | | | | | | 247,141,861 | | | | | | 247,311,533 | | | | | | 247,311,533 | | | | | | 247,311,533 | | |
|
| | |
截至9月30日
|
| |
截至3月31日
|
| ||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
2022
|
| |
2022
|
| ||||||||||||||||||
| | |
(人民币)
|
| |
($)
|
| |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | | | | | | | | | | | | | ||||||
资产 | | | | | | | | | | | | | | | | | | | | | | ||||||||||
流动资产
|
| | | | 871,552,683 | | | | | | 122,757,357 | | | | | | 733,204,286 | | | | | | 764,764,393 | | | | | | 120,469,486 | | |
非流动资产合计
|
| | | | 676,885,437 | | | | | | 95,338,663 | | | | | | 433,970,786 | | | | | | 676,988,748 | | | | | | 106,642,631 | | |
总资产
|
| | | | 1,548,438,120 | | | | | | $ 218,096,020 | | | | | | 1,167,175,072 | | | | | | 1,441,753,141 | | | | | | $ 227,112,117 | | |
负债、夹层股权和股东亏损
|
| | | | | | | | | | | | | | | | | | | | | ||||||||||
流动负债
|
| | | | 575,338,836 | | | | | | 81,035,921 | | | | | | 345,040,994 | | | | | | 475,914,160 | | | | | | 74,968,363 | | |
非流动负债
|
| | | | 315,222,809 | | | | | | 44,398,829 | | | | | | 45,538,214 | | | | | | 294,586,777 | | | | | | 46,404,772 | | |
总负债
|
| | | | 890,561,645 | | | | | | 125,434,750 | | | | | | 390,579,208 | | | | | | 770,500,937 | | | | | | 121,373,135 | | |
夹层股权
|
| | | | 1,608,561,727 | | | | | | 226,564,371 | | | | | | 1,285,458,571 | | | | | | 1,370,221,392 | | | | | | 215,844,081 | | |
股东亏损
|
| | | | (950,685,252) | | | | | | (133,903,101) | | | | | | (508,862,707) | | | | | | (698,969,188) | | | | | | (110,105,099) | | |
总负债、夹层权益和股东亏损
|
| | | | 1,548,438,120 | | | | | | $ 218,096,020 | | | | | | 1,167,175,072 | | | | | | 1,441,753,141 | | | | | | $ 227,112,117 | | |
| | |
截至9月30日的6个月
|
| |
截至2009年3月31日的财政年度
|
| ||||||||||||||||||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |
2021
|
| |
2022
|
| |
2022
|
| ||||||||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| ||||||||||||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | | | | | | | | | | | | | |||||||||
经营活动中使用的净现金:
|
| | | | (176,984,374) | | | | | | (107,395,153) | | | | | | (15,126,504) | | | | | | (246,610,437) | | | | | | (173,545,357) | | | | | | (27,337,727) | | |
投资活动中使用的净现金:
|
| | | | (203,390,377) | | | | | | (19,024,351) | | | | | | (2,679,561) | | | | | | (104,238,941) | | | | | | (298,923,958) | | | | | | (47,087,987) | | |
融资活动提供的净现金:
|
| | | | 43,885,865 | | | | | | 51,907,325 | | | | | | 7,311,097 | | | | | | 739,258,696 | | | | | | 364,558,145 | | | | | | 57,427,010 | | |
汇率对汇率的影响
现金储备 |
| | | | (4,446,301) | | | | | | 30,471,942 | | | | | | 4,291,943 | | | | | | (2,674) | | | | | | (11,478,411) | | | | | | (1,808,136) | | |
现金净增(减)
|
| | | | (340,935,187) | | | | | | (44,040,237) | | | | | | (6,203,025) | | | | | | 388,406,644 | | | | | | (119,389,581) | | | | | | (18,806,840) | | |
会计年度开始时的现金
|
| | | | 390,457,084 | | | | | | 271,067,503 | | | | | | 38,179,597 | | | | | | 2,050,440 | | | | | | 390,457,084 | | | | | | 61,506,740 | | |
财政年度末现金
|
| | | | 49,521,897 | | | | | | 227,027,266 | | | | | | $ 31,976,572 | | | | | | 390,457,084 | | | | | | 271,067,503 | | | | | | $ 42,699,900 | | |
| | |
形式组合
|
| |||||||||||||||||||||
| | |
假设没有
赎回 |
| |
假设没有
赎回 |
| |
假设
100% 赎回 |
| |
假设
100% 赎回 |
| ||||||||||||
| | |
(人民币)
|
| |
($)
|
| |
(人民币)
|
| |
($)
|
| ||||||||||||
未经审计的形式摘要浓缩
合并损益表数据 截至9月30日的6个月 2022 |
| | | | | | | | | | | | | | | | | | | | | | | | |
当期利润
|
| | | | 27,358,113 | | | | | $ | 3,853,364 | | | | | | 27,358,113 | | | | | $ | 3,853,364 | | |
亿盛生物普通股基本及摊薄后每股净收益
|
| | | | 0.24 | | | | | $ | 0.03 | | | | | | 0.30 | | | | | $ | 0.04 | | |
基本和稀释后加权平均流通股、亿盛生物普通股
|
| | | | 113,460,795 | | | | | | 113,460,795 | | | | | | 92,174,995 | | | | | | 92,174,995 | | |
未经审计的形式摘要浓缩
合并损益表数据 截至2022年3月31日的财政年度 |
| | | | | | | | | | | | | | | | | | | | | | | | |
本期亏损
|
| | | | (104,998,214) | | | | | $ | (16,539,841) | | | | | | (104,998,214) | | | | | $ | (16,539,841) | | |
基本和稀释后每股净亏损,YS和Biophma普通股
|
| | | | (0.93) | | | | | $ | (0.15) | | | | | | (1.14) | | | | | $ | (0.18) | | |
基本和稀释后加权平均流通股,YS Biophma普通股
|
| | | | 113,460,795 | | | | | | 113,460,795 | | | | | | 92,174,995 | | | | | | 92,174,995 | | |
截至2022年9月30日未经审计的备考简明合并资产负债表数据摘要
|
| | | | | | | | | | | | | | | | | | | | | | | | |
总资产
|
| | | | 3,158,872,521 | | | | | $ | 444,924,156 | | | | | | 1,730,391,036 | | | | | $ | 243,723,913 | | |
总负债
|
| | | | 924,319,533 | | | | | $ | 130,189,516 | | | | | | 924,319,533 | | | | | $ | 130,189,516 | | |
总股本
|
| | | | 2,234,552,988 | | | | | $ | 314,734,640 | | | | | | 806,071,503 | | | | | $ | 113,534,397 | | |
| | |
历史
|
| |
形式组合(7)
|
| ||||||||||||||||||||||||
| | |
峰会
|
| |
YS
Biophma |
| |
假设
否 赎回 |
| |
假设
100% 赎回 |
| ||||||||||||||||||
| | |
A类
个共享 |
| |
B类
个共享 |
| |
普通
个共享 |
| |
普通
个共享 |
| |
普通
个共享 |
| |||||||||||||||
截至2022年9月30日及截至2022年9月30日的6个月 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
每股账面价值(人民币)(1)(2)(3)
|
| | | | 不适用 | | | | | | (7.37) | | | | | | (2.85) | | | | | | 19.69 | | | | | | 8.74 | | |
每股账面价值($)
|
| | | | 不适用 | | | | | $ | (1.04) | | | | | $ | (0.40) | | | | | $ | 2.77 | | | | | $ | 1.23 | | |
每股净收益(亏损)-基本和稀释后(人民币)
|
| | | | 1.94 | | | | | | 1.94 | | | | | | (0.03) | | | | | | 0.24 | | | | | | 0.30 | | |
每股净收益(亏损)-基本单位和摊薄单位(美元)
|
| | | $ | 0.27 | | | | | $ | 0.27 | | | | | $ | (0.01) | | | | | $ | 0.03 | | | | | $ | 0.04 | | |
YS Biophma股东
|
| | | | — | | | | | | — | | | | | | — | | | | | | 83,424,995 | | | | | | 83,424,995 | | |
公众股东峰会(6)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 22,337,818 | | | | | | — | | |
赞助商和某些峰会董事(4)(5)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 3,928,475 | | | | | | 3,928,475 | | |
远期买入投资者(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 3,769,507 | | | | | | 4,821,525 | | |
加权平均流通股 - 基本和稀释
|
| | | | 20,000,000 | | | | | | 5,750,000 | | | | | | 333,699,980 | | | | | | 113,460,795(8) | | | | | | 92,174,995(8) | | |
截至2022年3月31日的财政年度 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
每股账面价值(人民币)(1)(2)(3)
|
| | | | 不适用 | | | | | | (21.33) | | | | | | (2.09) | | | | | | 17.87 | | | | | | 8.22 | | |
每股账面价值(单位:美元)
|
| | | | 不适用 | | | | | $ | (3.36) | | | | | $ | (0.33) | | | | | $ | 2.81 | | | | | $ | 1.29 | | |
每股净亏损-基本和稀释后(人民币)
|
| | | | 2.51 | | | | | | 2.51 | | | | | | (0.32) | | | | | | (0.93) | | | | | | (1.14) | | |
每股净亏损-基本和摊薄(单位:美元)
|
| | | $ | 0.40 | | | | | $ | 0.40 | | | | | $ | (0.05) | | | | | $ | (0.15) | | | | | $ | (0.18) | | |
YS Biophma股东
|
| | | | | | | | | | | | | | | | | | | | | | 83,424,995 | | | | | | 83,424,995 | | |
公众股东峰会(6)
|
| | | | | | | | | | | | | | | | | | | | | | 22,337,818 | | | | | | — | | |
赞助商和某些峰会董事(4)(5)
|
| | | | | | | | | | | | | | | | | | | | | | 3,928,475 | | | | | | 3,928,475 | | |
远期买入投资者(4)
|
| | | | | | | | | | | | | | | | | | | | | | 3,769,507 | | | | | | 4,821,525 | | |
加权平均流通股 - 基本和稀释
|
| | | | 20,000,000 | | | | | | 5,750,000 | | | | | | 333,699,980 | | | | | | 113,460,795(8) | | | | | | 92,174,995(8) | | |
| | |
截至3月31日的预计财政年度
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(百万元人民币)
|
| |
2023E
|
| |
2024E
|
| |
2025E
|
| |
2026E
|
| |
2027E
|
| |
2028E
|
| |
2029E
|
| |
2030E
|
| |
2031E
|
| |
2032E
|
| ||||||||||||||||||||||||||||||
收入* | | | | | 755 | | | | | | 1,074 | | | | | | 2,063 | | | | | | 2,223 | | | | | | 2,520 | | | | | | 2,886 | | | | | | 3,531 | | | | | | 3,931 | | | | | | 4,335 | | | | | | 4,483 | | |
销货成本
|
| | | | 136 | | | | | | 172 | | | | | | 421 | | | | | | 472 | | | | | | 535 | | | | | | 564 | | | | | | 512 | | | | | | 535 | | | | | | 578 | | | | | | 560 | | |
毛利
|
| | | | 619 | | | | | | 902 | | | | | | 1,642 | | | | | | 1,751 | | | | | | 1,985 | | | | | | 2,322 | | | | | | 3,019 | | | | | | 3,396 | | | | | | 3,777 | | | | | | 3,923 | | |
运营费用
|
| | | | 666 | | | | | | 802 | | | | | | 726 | | | | | | 714 | | | | | | 773 | | | | | | 856 | | | | | | 1,029 | | | | | | 1,147 | | | | | | 1,267 | | | | | | 1,312 | | |
EBITDA | | | | | (46) | | | | | | 100 | | | | | | 916 | | | | | | 1,037 | | | | | | 1,212 | | | | | | 1,466 | | | | | | 1,991 | | | | | | 2,249 | | | | | | 2,510 | | | | | | 2,611 | | |
折旧及摊销费用
|
| | | | 30 | | | | | | 31 | | | | | | 32 | | | | | | 32 | | | | | | 33 | | | | | | 34 | | | | | | 35 | | | | | | 36 | | | | | | 37 | | | | | | 38 | | |
息税前利润 | | | | | 77 | | | | | | 69 | | | | | | 884 | | | | | | 1,005 | | | | | | 1,179 | | | | | | 1,433 | | | | | | 1,956 | | | | | | 2,214 | | | | | | 2,474 | | | | | | 2,574 | | |
所得税
|
| | | | — | | | | | | — | | | | | | 96 | | | | | | 147 | | | | | | 174 | | | | | | 215 | | | | | | 293 | | | | | | 332 | | | | | | 371 | | | | | | 386 | | |
净收入
|
| | | | (76) | | | | | | 69 | | | | | | 788 | | | | | | 858 | | | | | | 1,005 | | | | | | 1,218 | | | | | | 1,662 | | | | | | 1,882 | | | | | | 2,102 | | | | | | 2,187 | | |
|
Ticker
|
| |
公司名称
|
| |
历史
测试版 |
| |
个共享
出色的 |
| |
共享
价格 |
| |
市值
|
| |
债务,首选
&Min Int. |
| |
平均。
债务/ 权益 |
| |
债务/
总计 帽子 |
| |
生效
税率 |
| |
未加杠杆的
测试版 |
|
| 深圳证券交易所:300122 | | | 重庆智飞生物制品有限公司 | | |
0.53
|
| |
1,600,000
|
| |
人民币16.57元
|
| |
人民币26512624元
|
| |
2414425元
|
| |
9.1%
|
| |
8.3%
|
| |
14.1%
|
| |
0.50
|
|
| 上交所:603392 | | | 北京万泰生物制药企业有限公司 | | |
0.51
|
| |
880,208
|
| |
23.18元
|
| |
20,404,568元
|
| |
488,319元
|
| |
2.4%
|
| |
2.3%
|
| |
10.9%
|
| |
0.50
|
|
| 深圳证券交易所:002007 | | |
华兰生物
工程公司 |
| |
0.43
|
| |
1,824,367
|
| |
3.40元
|
| |
人民币6208,940元
|
| |
人民币2666,743元
|
| |
43.0%
|
| |
30.0%
|
| |
14.6%
|
| |
0.32
|
|
| 深圳证券交易所:300601 | | | 深圳市康泰生物制品有限公司 | | |
0.45
|
| |
1,120,487
|
| |
6.74元
|
| |
人民币7556,554元
|
| |
2426448元
|
| |
32.1%
|
| |
24.3%
|
| |
11.4%
|
| |
0.35
|
|
| 深圳证券交易所:300142 | | | 沃尔瓦克斯生物科技有限公司 | | |
0.38
|
| |
1,601,572
|
| |
7.22元
|
| |
人民币11568378元
|
| |
2196870元
|
| |
19.0%
|
| |
16.0%
|
| |
21.5%
|
| |
0.33
|
|
| 深圳证券交易所:300841 | | |
成都康华
生物制品有限公司 |
| |
1.52
|
| |
134,592
|
| |
人民币17.23元
|
| |
2319,242元
|
| |
人民币40,755元
|
| |
1.8%
|
| |
1.7%
|
| |
9.7%
|
| |
1.50
|
|
| | | | 中位数 | | | | | | | | | | | |
人民币9562,466元
|
| | | | |
14.0%
|
| | | | | | | |
0.42
|
|
| | |
2023E
收入 倍数 |
| |
2024E
收入 倍数 |
| ||||||
佳信生物
|
| | | | 8.6x | | | | | | 6.7x | | |
Walvax生物技术
|
| | | | 8.5x | | | | | | 6.9x | | |
万泰生物医药
|
| | | | 8.3x | | | | | | 7.0x | | |
深圳康泰生物制品
|
| | | | 6.3x | | | | | | 5.0x | | |
平均 | | | | | 7.9x | | | | | | 6.4x | | |
名称
|
| |
年龄
|
| |
职位
|
|
伯坦 | | | 49 | | | 首席执行官、联席首席投资官和董事 | |
Ken Poon | | | 55 | | | 董事联席首席投资官总裁 | |
伊恩·斯通 | | | 71 | | | 独立董事 | |
托马斯·福林斯比 | | | 55 | | | 独立董事 | |
陶白 | | | 57 | | | 独立董事 | |
个人
|
| |
实体
|
| |
实体业务
|
| |
从属关系
|
|
Ken Poon | | | XCap Partners Limited | | | 财务咨询 | | | 创始合伙人 | |
伊恩·斯通 | | | 腾讯控股控股有限公司 | | |
科技投资管理
|
| | 独立董事 | |
托马斯·福林斯比
|
| | Optiest Canada Ltd | | | 私人投资 | | | 管理董事 | |
伯坦 | | | 汉努特资本 | | | 私募股权投资 | | | 创始合伙人 | |
排名
|
| |
疫苗
|
| |
数量:
批次发放 |
| |||
1
|
| |
狂犬病疫苗
|
| | | | 983 | | |
2
|
| |
乙肝疫苗
|
| | | | 565 | | |
3
|
| |
脑膜炎疫苗
|
| | | | 563 | | |
4
|
| |
流感疫苗(含HIB)
|
| | | | 553 | | |
5
|
| |
水痘疫苗
|
| | | | 471 | | |
6
|
| |
脊髓灰质炎疫苗
|
| | | | 339 | | |
7
|
| |
MMR疫苗
|
| | | | 281 | | |
8
|
| |
HPV疫苗
|
| | | | 254 | | |
9
|
| |
流行性乙型脑炎疫苗
|
| | | | 224 | | |
10
|
| |
百白破疫苗
|
| | | | 203 | | |
年
|
| |
2012
|
| |
2013
|
| |
2014
|
| |
2015
|
| |
2016
|
| |
2017
|
| |
2018
|
| |
2019
|
| |
2020
|
| |
2021
|
| ||||||||||||||||||||||||||||||
批次释放(百万剂)
|
| | | | 126.2 | | | | | | 73.3 | | | | | | 58.8 | | | | | | 77.8 | | | | | | 58.9 | | | | | | 78.2 | | | | | | 62.9 | | | | | | 58.8 | | | | | | 78.6 | | | | | | 88.0 | | |
系统机构类(SOC)
|
| |
首选术语(PT)
|
| |
拉比普尔
N=12 |
| |
鼠兔狂犬病
疫苗 (1-1-1-1) N=13 |
| |
鼠兔狂犬病
疫苗 (2-2-1) N=12 |
|
| | | | | |
(单位n(%))
|
| |
(单位n(%))
|
| |
(单位n(%))
|
|
胃肠道疾病
|
| | 腹泻 | | |
1 (8.33%)
|
| |
0 (0.00%)
|
| |
1 (8.33%)
|
|
| | | 恶心 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
全身疾病和用药部位情况
|
| | 硬化 | | |
1 (8.33%)
|
| |
0 (0.00%)
|
| |
0 (0.00%)
|
|
| | | 疲劳 | | |
1 (8.33%)
|
| |
0 (0.00%)
|
| |
0 (0.00%)
|
|
| | | 注射部位疼痛 | | |
0 (0.00%)
|
| |
6 (46.15%)
|
| |
3 (25.00%)
|
|
| | |
注射部位肿胀
|
| |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
| | | 发热 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
感染和侵扰
|
| |
淋巴腺感染
|
| |
1 (8.33%)
|
| |
0 (0.00%)
|
| |
0 (0.00%)
|
|
| | | 脓尿 | | |
0 (0.00%)
|
| |
2 (15.38%)
|
| |
1 (8.33%)
|
|
调查
|
| |
存在葡萄糖尿
|
| |
0 (0.00%)
|
| |
2 (15.38%)
|
| |
0 (0.00%)
|
|
肌肉骨骼和结缔组织
障碍 |
| | 肌痛 | | |
0 (0.00%)
|
| |
0 (0.00%)
|
| |
1 (8.33%)
|
|
神经系统疾病
|
| | 头晕 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
| | | 头痛 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
1 (8.33%)
|
|
| | | 昏昏欲睡 | | |
1 (8.33%)
|
| |
0 (0.00%)
|
| |
1 (8.33%)
|
|
肾脏和泌尿系疾病
|
| | 蛋白尿 | | |
0 (0.00%)
|
| |
2 (15.38%)
|
| |
0 (0.00%)
|
|
系统机构类(SOC)
|
| |
首选术语(PT)
|
| |
拉比普尔
N=12 |
| |
鼠兔狂犬病
疫苗 (1-1-1-1) N=13 |
| |
鼠兔狂犬病
疫苗 (2-2-1) N=12 |
|
| | | | | |
(单位n(%))
|
| |
(单位n(%))
|
| |
(单位n(%))
|
|
呼吸系统、胸腔和纵隔
障碍 |
| | 咳嗽 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
皮肤和皮下组织疾病
|
| | 多汗症 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
| | | 瘙痒症 | | |
0 (0.00%)
|
| |
1 (7.69%)
|
| |
0 (0.00%)
|
|
| | | 荨麻疹 | | |
0 (0.00%)
|
| |
0 (0.00%)
|
| |
1 (8.33%)
|
|
至少有一次不良事件的受试者总数
|
| | | | |
5 (41.67%)
|
| |
9 (69.23%)
|
| |
6 (50.00%)
|
|
| | |
拉比普尔
|
| |
鼠兔狂犬病
疫苗(1-1-1-1) |
| |
鼠兔狂犬病
疫苗(2-2-1) |
|
| | |
平均值±标准差
95%可信区间 |
| |
平均值±标准差
95%可信区间 |
| |
平均值±标准差
95%可信区间 |
|
中和
|
| |
9.72 ± 11.66
|
| |
12.07 ± 10.07
|
| |
20.06 ± 33.12
|
|
抗体效价
|
| |
(-2.67, 22.11)
|
| |
(-0.31, 24.46)
|
| |
(8.26, 33.04)
|
|
| | |
拉比普尔
|
| |
鼠兔狂犬病
疫苗(2-2-1) |
|
| | |
平均值±标准差
95%可信区间 |
| |
平均值±标准差
95%可信区间 |
|
中和抗体效价
|
| |
19.16 ± 13.53
|
| |
21.59 ± 46.90
|
|
| | |
(15.69, 22.62)
|
| |
(9.15, 34.04)
|
|
世卫组织标签
|
| |
Pango
血统 |
| |
GISAID
支系/世系 |
| |
下一个菌株
分支 |
| |
最早记录的样本
|
| |
日期:
称号 |
|
| | |
VOCs(1)
|
| | |||||||||||
Alpha
|
| |
B.1.1.7
|
| |
GRY(前身为
GR/501Y.V1) |
| |
20i(V1)
|
| |
英国,2020年9月
|
| |
2020年12月18日
|
|
测试版
|
| |
B.1.351
|
| |
GH/501Y.V2
|
| |
20H(V2)
|
| |
南非,2020年5月
|
| |
2020年12月18日
|
|
伽马
|
| |
P.1
|
| |
GR/501Y.V3
|
| |
20J(V3)
|
| |
巴西,2020年11月
|
| |
2021年1月11日
|
|
Delta
|
| |
B.1.617.2
|
| |
G/478K.V1
|
| |
21A
|
| |
印度,2020年10月
|
| |
VOI:2021年4月4日
VOC:2021年5月11日 |
|
| | | | | | | | |
vois(2)
|
| | | | | | |
Epsilon
|
| |
B.1.427/B.1.429
|
| |
GH/452R.V1
|
| |
21C
|
| |
美国,2020年3月
|
| |
2021年3月5日
|
|
泽塔
|
| |
P.2
|
| |
GR/484K.V2
|
| |
20B
|
| |
巴西,2020年4月
|
| |
2021年3月17日
|
|
埃塔
|
| |
B.1.525
|
| |
G/484K.V3
|
| |
21D
|
| |
多个国家,2020年12月
|
| |
2021年3月17日
|
|
Theta
|
| |
P.3
|
| |
GR/1092K.V1
|
| |
21E
|
| |
菲律宾,2021年1月
|
| |
2021年3月24日
|
|
IOTA
|
| |
B.1.526
|
| |
GH/253G.V1
|
| |
21F
|
| |
美国,2020年11月
|
| |
2021年3月24日
|
|
卡帕
|
| |
B.1.617.1
|
| |
G/452R.V3
|
| |
21B
|
| |
印度,2020年10月
|
| |
2021年4月4日
|
|
Lambda
|
| |
C.37
|
| |
GR/452Q.V1
|
| |
20D
|
| |
秘鲁,2020年8月
|
| |
2021年6月14日
|
|
参观(天)
|
| |
血清转换率(%)
低剂量 乙肝病毒-001 |
| |
高剂量
乙肝病毒-001 |
| |
Engerix-B
|
| |||||||||
基线
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | |
D 56
|
| | | | 87.5 | | | | | | 100 | | | | | | 66.7 | | |
D 84
|
| | | | 90 | | | | | | 100 | | | | | | 66.7 | | |
D 196
|
| | | | 90 | | | | | | 100 | | | | | | 88.9 | | |
动物模型
|
| |
代理
|
| |
T/C(%)
|
| |
IR(%)
|
| ||||||
乳腺癌4T1原位模型
|
| | 鼠兔YS-On-001 | | | | | 45.87 | | | | | | 42.26 | | |
| | | 多西紫杉醇 | | | | | 50.12 | | | | | | 35.55 | | |
Lewis肺癌LL/2移植瘤模型
|
| | 鼠兔YS-On-001 | | | | | 37.02 | | | | | | 60.88 | | |
| | | 顺铂鼠兔 | | | | | 47.46 | | | | | | 42.38 | | |
| | | YS-On-001+顺铂 | | | | | 28.38 | | | | | | 75.44 | | |
肝癌H22移植瘤模型
|
| | 鼠兔YS-On-001 | | | | | 18.84 | | | | | | 73.40 | | |
| | | Sorafenib Pika | | | | | 36.79 | | | | | | 53.73 | | |
| | | YS-On-001+索拉非尼 | | | | | 12.56 | | | | | | 88.19 | | |
结肠癌CT-26移植瘤模型
|
| | 鼠兔YS-On-001 | | | | | 5.38 | | | | | | 97.71 | | |
| | | PD-1 | | | | | 53.66 | | | | | | 47.05 | | |
前列腺癌RM-1移植瘤模型
|
| | 鼠兔YS-On-001 | | | | | 1.39 | | | | | | 98.56 | | |
| | | PD-1 | | | | | 57.62 | | | | | | 38.12 | | |
黑色素瘤B16-F10转移瘤模型 | | | | | | | | | | | | | | | | |
产品/技术
|
| |
专利名称
|
| |
所有者/申请人
|
| |
管辖权
|
| |
专利状态(1)
|
| |
专利到期
|
| |
专利类型
|
|
鼠兔佐剂
|
| |
聚肌苷-多胞苷酸佐剂
|
| |
新加坡益生
|
| |
澳大利亚、巴西、加拿大、古巴、欧盟、奥地利、比利时、瑞士、丹麦、法国、英国、爱尔兰、意大利、荷兰、波兰、土耳其、西班牙、瑞典、德国、印度尼西亚、以色列、印度、韩国、马来西亚、新西兰、菲律宾、俄罗斯、新加坡、泰国、台湾(中国)、美国、越南、南非
|
| |
已批准
|
| |
2025年至2027年
|
| |
物质的组成
|
|
|
新加坡益生
|
| | 美国、墨西哥 | | | 已批准 | | | 2025 | | | | | |||||
|
含有多肌苷酸-多胞苷酸佐剂的免疫原性物质
|
| |
新加坡益生
|
| |
中国、澳大利亚、香港、古巴、印度尼西亚、印度、墨西哥、马来西亚、新西兰、菲律宾、俄罗斯、新加坡、台湾(中国)、美国、越南、南非
|
| |
已批准
|
| |
2026至2028
|
| |
物质的组成
|
| ||
|
新加坡益生
|
| | 巴西、泰国 | | | 待定 | | | 不适用 | | | |||||||
|
含有多肌苷酸-多胞苷酸佐剂的粘膜免疫原性物质
|
| |
新加坡益生
|
| |
澳大利亚、加拿大、香港、古巴、印度尼西亚、韩国、马来西亚、新西兰、菲律宾、新加坡、南非
|
| |
已批准
|
| |
2026至2028
|
| |
物质的组成
|
| ||
| 北京益生 | | | 中国 | | | 已批准 | | | 2026 | | | |||||||
|
新加坡益生
|
| | 台湾(中国) | | | 已批准 | | | 2027 | | | |||||||
|
新加坡益生
|
| | 泰国、巴西 | | | 待定 | | | 不适用 | | | |||||||
鼠兔狂犬病疫苗(Vero细胞)
|
| |
一种含有鼠兔佐剂的狂犬病组合物
|
| |
新加坡益生
|
| |
中国、印度尼西亚、俄罗斯、南非
|
| |
已批准
|
| |
2034至2037
|
| |
物质的组成
|
|
|
新加坡益生
|
| |
巴西、印度、菲律宾、泰国、美国、越南
|
| | 待定 | | | 不适用 | | | |||||||
鼠兔YS-On-001(癌症)
|
| |
一种含有PIC的组合物,用于治疗癌症
|
| |
新加坡益生
|
| |
美国、欧盟、俄罗斯、南非
|
| |
已批准
|
| |
2037至2038
|
| |
物质的组成
|
|
|
新加坡益生
|
| |
澳大利亚、巴西、加拿大、香港、古巴、印度尼西亚、印度、韩国、墨西哥、马来西亚、新西兰、菲律宾、新加坡、泰国、美国、越南
|
| | 待定 | | | 不适用 | | |
项目
|
| |
施工
区域 |
| |
实际/预期
施工 开工 日期 |
| |
预期为
施工 完工日期 |
| |
预期为
制造 容量 |
|
| | |
(平方米)
|
| | | | | | | |
(总数为
剂量/年) |
|
新加坡一家鼠兔狂犬病疫苗生产车间 | | | 14,577 | | | 2023年10月 | | | 2025年3月 | | | 待定 | |
沈阳两家鼠疫重组新冠肺炎疫苗生产车间(中国) | | | 6,831 | | | 2021年3月 | | | 2023年3月 | | | 5亿 | |
产品
|
| |
许可证/许可证
|
| |
许可证/许可证
托架 |
| |
权威机构
|
| |
有效期
期间 |
|
YSJATM狂犬病疫苗 | | |
药品重新注册证书
|
| |
辽宁益生
|
| |
辽宁省医疗产品管理局
|
| |
2020.07.13 – 2025.07.12
|
|
YSJATM狂犬病疫苗/鼠兔重组COVID19疫苗 | | |
药品生产许可证
|
| |
辽宁益生
|
| |
辽宁省医疗产品管理局
|
| |
2022.06.15 – 2024.08.14
|
|
| | |
截至2022年9月30日
|
| |||||||||
函数
|
| |
数量:
员工 |
| |
占总数的%
|
| ||||||
研发
|
| | | | 206 | | | | | | 23.82 | | |
一般和行政
|
| | | | 172 | | | | | | 19.88 | | |
制造
|
| | | | 436 | | | | | | 50.40 | | |
销售、市场营销和患者服务
|
| | | | 51 | | | | | | 5.90 | | |
合计 | | | | | 865 | | | | | | 100 | | |
| | |
截至9月30日的6个月
|
| |
截至3月31日的财政年度
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |
2022
|
| |
2021
|
| |
差异
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | |
人民币
|
| |
$
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
$
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||||||||||||||||||||||||||
收入
|
| | | | 399,534,723 | | | | | | 56,274,081 | | | | | | 100.0 | | | | | | 269,433,426 | | | | | | 100.0 | | | | | | 130,101,297 | | | | | | 48.3 | | | | | | 502,949,894 | | | | | | 79,227,166 | | | | | | 100.0 | | | | | | 257,015,929 | | | | | | 100.0 | | | | | | 245,933,965 | | | | | | 95.7 | | |
收入成本
|
| | | | 93,700,779 | | | | | | 13,197,665 | | | | | | 100.0 | | | | | | 63,599,621 | | | | | | 100.0 | | | | | | 30,101,158 | | | | | | 47.3 | | | | | | 117,066,090 | | | | | | 18,440,832 | | | | | | 100.0 | | | | | | 59,656,877 | | | | | | 100.0 | | | | | | 57,409,213 | | | | | | 96.2 | | |
毛利
|
| | | | 305,833,944 | | | | | | 43,076,416 | | | | | | 76.5 | | | | | | 205,833,805 | | | | | | 76.4 | | | | | | 100,000,139 | | | | | | 48.6 | | | | | | 385,883,804 | | | | | | 60,786,334 | | | | | | 76.7 | | | | | | 197,359,052 | | | | | | 76.8 | | | | | | 188,524,752 | | | | | | 95.5 | | |
运营费用: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||
销售费用
|
| | | | 150,228,079 | | | | | | 21,159,480 | | | | | | 46.4 | | | | | | 86,265,281 | | | | | | 32.9 | | | | | | 63,962,798 | | | | | | 74.1 | | | | | | 185,999,704 | | | | | | 29,299,597 | | | | | | 36.8 | | | | | | 73,485,259 | | | | | | 22.7 | | | | | | 112,514,445 | | | | | | 153.1 | | |
一般和行政
费用 |
| | | | 49,587,013 | | | | | | 6,984,283 | | | | | | 15.3 | | | | | | 51,664,591 | | | | | | 19.7 | | | | | | (2,077,578) | | | | | | (4.0) | | | | | | 107,620,500 | | | | | | 16,952,916 | | | | | | 21.3 | | | | | | 155,334,386 | | | | | | 48.1 | | | | | | (47,713,886) | | | | | | (30.7) | | |
研发费用
|
| | | | 123,861,107 | | | | | | 17,445,718 | | | | | | 38.3 | | | | | | 124,051,209 | | | | | | 47.4 | | | | | | (190,102) | | | | | | (0.2) | | | | | | 211,222,263 | | | | | | 33,272,780 | | | | | | 41.9 | | | | | | 94,387,144 | | | | | | 29.2 | | | | | | 116,835,119 | | | | | | 123.8 | | |
总运营费用
|
| | | | 323,676,199 | | | | | | 45,589,481 | | | | | | 100.0 | | | | | | 261,981,081 | | | | | | 100.0 | | | | | | 61,695,118 | | | | | | 23.5 | | | | | | 504,842,467 | | | | | | 79,525,293 | | | | | | 100.0 | | | | | | 323,206,789 | | | | | | 100.0 | | | | | | 181,635,678 | | | | | | 56.2 | | |
运营亏损
|
| | | | (17,842,255) | | | | | | (2,513,065) | | | | | | (4.5) | | | | | | (56,147,276) | | | | | | (20.8) | | | | | | 38,305,021 | | | | | | (68.2) | | | | | | (118,958,663) | | | | | | (18,738,959) | | | | | | (23.7) | | | | | | (125,847,737) | | | | | | (49.0) | | | | | | 6,889,074 | | | | | | (5.5) | | |
其他收入(费用): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||
与
相关的滞纳金
所得税 |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (11,464,741) | | | | | | 23.6 | | | | | | 11,464,741 | | | | | | (100.0) | | |
与所得税以外的其他税收有关的滞纳金
税 |
| | | | — | | | | | | — | | | | | | — | | | | | | (112,420) | | | | | | (0.7) | | | | | | 112,420 | | | | | | (100.0) | | | | | | (231,231) | | | | | | (36,425) | | | | | | (1.3) | | | | | | (7,261,947) | | | | | | 15.0 | | | | | | 7,030,716 | | | | | | (96.8) | | |
社会保险相关滞纳金
|
| | | | (299,417) | | | | | | (42,173) | | | | | | (4.1) | | | | | | (1,396,221) | | | | | | (8.3) | | | | | | 1,096,804 | | | | | | (78.6) | | | | | | (1,852,378) | | | | | | (291,796) | | | | | | (10.4) | | | | | | (7,701,793) | | | | | | 15.9 | | | | | | 5,849,415 | | | | | | (75.9) | | |
政府拨款
|
| | | | 22,456,691 | | | | | | 3,163,003 | | | | | | 308.4 | | | | | | 19,600,822 | | | | | | 117.1 | | | | | | 2,855,869 | | | | | | 14.6 | | | | | | 23,020,413 | | | | | | 3,626,290 | | | | | | 128.7 | | | | | | 3,530,405 | | | | | | (7.3) | | | | | | 19,490,008 | | | | | | 552.1 | | |
财务费用净额
|
| | | | (14,949,434) | | | | | | (2,105,613) | | | | | | (205.3) | | | | | | (352,694) | | | | | | (2.2) | | | | | | (14,596,740) | | | | | | 4,138.6 | | | | | | (2,717,433) | | | | | | (428,064) | | | | | | (15.2) | | | | | | (29,689,927) | | | | | | 61.2 | | | | | | 26,972,494 | | | | | | (90.8) | | |
其他收入,净额
|
| | | | 74,675 | | | | | | 10,518 | | | | | | 1.0 | | | | | | (993,957) | | | | | | (5.9) | | | | | | 1,068,632 | | | | | | (107.5) | | | | | | (327,987) | | | | | | (51,666) | | | | | | (1.8) | | | | | | 4,063,743 | | | | | | (8.4) | | | | | | (4,391,730) | | | | | | (108.1) | | |
其他收入总额,净额
|
| | | | 7,282,515 | | | | | | 1,025,735 | | | | | | 100.0 | | | | | | 16,745,530 | | | | | | 100.0 | | | | | | (9,463,015) | | | | | | (56.5) | | | | | | 17,891,384 | | | | | | 2,818,339 | | | | | | 100.0 | | | | | | (48,524,260) | | | | | | 100.0 | | | | | | 66,415,644 | | | | | | (136.9) | | |
所得税前亏损
|
| | | | (10,559,740) | | | | | | (1,487,330) | | | | | | (2.6) | | | | | | (39,401,746) | | | | | | (14.6) | | | | | | 28,842,006 | | | | | | (73.2) | | | | | | (101,067,279) | | | | | | (15,920,620) | | | | | | (20.1) | | | | | | (174,371,997) | | | | | | (67.8) | | | | | | 73,304,718 | | | | | | (42.0) | | |
收入拨备
税费 |
| | | | (565,625) | | | | | | (79,668) | | | | | | (0.1) | | | | | | (5,689,586) | | | | | | (2.1) | | | | | | 5,123,961 | | | | | | (90.1) | | | | | | (4,937,122) | | | | | | (777,720) | | | | | | (1.0) | | | | | | (17,454,245) | | | | | | (6.8) | | | | | | 12,517,123 | | | | | | (71.7) | | |
净亏损
|
| | | | (11,125,365) | | | | | | (1,566,998) | | | | | | (2.7) | | | | | | (45,091,332) | | | | | | (16.7) | | | | | | 33,965,967 | | | | | | (75.3) | | | | | | (106,004,401) | | | | | | (16,698,340) | | | | | | (21.1) | | | | | | (191,826,242) | | | | | | (74.6) | | | | | | 85,821,841 | | | | | | (44.7) | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
推广和营销服务费
|
| | | | 138,166,922 | | | | | | 92.0 | | | | | | 77,896,957 | | | | | | 90.3 | | | | | | 60,269,965 | | | | | | 77.4 | | |
员工福利支出
|
| | | | 11,086,976 | | | | | | 7.4 | | | | | | 7,426,168 | | | | | | 8.6 | | | | | | 3,660,808 | | | | | | 49.3 | | |
其他
|
| | | | 974,181 | | | | | | 0.6 | | | | | | 942,156 | | | | | | 1.1 | | | | | | 32,025 | | | | | | 3.4 | | |
合计
|
| | | | 150,228,079 | | | | | | 100 | | | | | | 86,265,281 | | | | | | 100 | | | | | | 63,962,798 | | | | | | 74.1 | | |
截至9月30日的6个月
|
| |
0 - 90天
|
| |
90 - 180天
|
| |
180 - 365天
|
| |
>365天
|
| |
合计
|
| |||||||||||||||
2022(人民币)
|
| | | | 45,909,832 | | | | | | 50,517,783 | | | | | | 29,990,148 | | | | | | 11,328,780 | | | | | | 137,746,543 | | |
2022(美元)
|
| | | $ | 6,466,356 | | | | | $ | 7,115,381 | | | | | $ | 4,224,083 | | | | | $ | 1,595,648 | | | | | $ | 19,401,468 | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
员工福利支出
|
| | | | 20,634,246 | | | | | | 41.6 | | | | | | 18,778,964 | | | | | | 36.3 | | | | | | 1,855,282 | | | | | | 9.9 | | |
折旧和摊销费用
|
| | | | 3,500,469 | | | | | | 7.1 | | | | | | 3,085,724 | | | | | | 6.0 | | | | | | 414,745 | | | | | | 13.4 | | |
专业服务费
|
| | | | 5,048,114 | | | | | | 10.2 | | | | | | 15,508,682 | | | | | | 30.0 | | | | | | (10,460,568) | | | | | | (67.4) | | |
办公费
|
| | | | 1,329,449 | | | | | | 2.7 | | | | | | 1,019,819 | | | | | | 2.0 | | | | | | 309,630 | | | | | | 30.4 | | |
贸易应收账款准备
|
| | | | 6,447,110 | | | | | | 13.0 | | | | | | 2,888,417 | | | | | | 5.6 | | | | | | 3,558,693 | | | | | | 123.2 | | |
报废存货备抵
|
| | | | (323,492) | | | | | | (0.7) | | | | | | — | | | | | | — | | | | | | (323,492) | | | | | | (100.0) | | |
税费和附加费
|
| | | | 3,196,939 | | | | | | 6.4 | | | | | | 3,065,689 | | | | | | 5.9 | | | | | | 131,250 | | | | | | 4.3 | | |
银行手续费和汇兑差额
|
| | | | 5,120,896 | | | | | | 10.3 | | | | | | 1,636,971 | | | | | | 3.2 | | | | | | 3,483,925 | | | | | | 212.8 | | |
其他
|
| | | | 4,633,282 | | | | | | 9.3 | | | | | | 5,680,325 | | | | | | 11.0 | | | | | | (1,047,043) | | | | | | (18.4) | | |
合计
|
| | | | 49,587,013 | | | | | | 100.0 | | | | | | 51,664,591 | | | | | | 100.0 | | | | | | (2,077,578) | | | | | | (4.0) | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
检测和临床试验费用
|
| | | | 69,020,560 | | | | | | 55.7 | | | | | | 47,673,861 | | | | | | 38.4 | | | | | | 21,346,699 | | | | | | 44.8 | | |
咨询服务费
|
| | | | 8,411,505 | | | | | | 6.8 | | | | | | 41,536,873 | | | | | | 33.5 | | | | | | (33,125,368) | | | | | | (79.7) | | |
员工福利支出
|
| | | | 33,812,314 | | | | | | 27.3 | | | | | | 24,577,264 | | | | | | 19.8 | | | | | | 9,235,050 | | | | | | 37.6 | | |
折旧和摊销费用
|
| | | | 6,323,641 | | | | | | 5.1 | | | | | | 4,934,566 | | | | | | 4.0 | | | | | | 1,389,075 | | | | | | 28.1 | | |
办公楼和租赁费
|
| | | | 588,586 | | | | | | 0.5 | | | | | | 565,381 | | | | | | 0.5 | | | | | | 23,205 | | | | | | 4.1 | | |
其他
|
| | | | 5,704,501 | | | | | | 4.6 | | | | | | 4,763,264 | | | | | | 3.8 | | | | | | 941,237 | | | | | | 19.8 | | |
合计 | | | | | 123,861,107 | | | | | | 100.0 | | | | | | 124,051,209 | | | | | | 100.0 | | | | | | (190,102) | | | | | | (0.2) | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
鼠兔重组新冠肺炎疫苗
|
| | | | 82,214,199 | | | | | | 66.4 | | | | | | 80,241,252 | | | | | | 64.7 | | | | | | 1,972,947 | | | | | | 2.5 | | |
鼠兔狂犬病疫苗
|
| | | | 17,519,659 | | | | | | 14.1 | | | | | | 8,965,209 | | | | | | 7.2 | | | | | | 8,554,450 | | | | | | 95.4 | | |
鼠兔YS-0N-001
|
| | | | 4,854,187 | | | | | | 3.9 | | | | | | 10,982,320 | | | | | | 8.9 | | | | | | (6,128,133) | | | | | | (55.8) | | |
鼠兔乙肝疫苗
|
| | | | 5,940,696 | | | | | | 4.8 | | | | | | 9,007,328 | | | | | | 7.3 | | | | | | (3,066,632) | | | | | | (34.0) | | |
鼠兔佐剂
|
| | | | 4,054,248 | | | | | | 3.3 | | | | | | 4,344,773 | | | | | | 3.5 | | | | | | (290,525) | | | | | | (6.7) | | |
YSJATM狂犬病疫苗
|
| | | | 4,275,750 | | | | | | 3.5 | | | | | | 5,221,734 | | | | | | 4.2 | | | | | | (945,984) | | | | | | (18.1) | | |
其他
|
| | | | 5,002,368 | | | | | | 4.0 | | | | | | 5,288,593 | | | | | | 4.2 | | | | | | (286,225) | | | | | | (5.4) | | |
合计 | | | | | 123,861,107 | | | | | | 100.0 | | | | | | 124,051,209 | | | | | | 100.0 | | | | | | (190,102) | | | | | | (0.2) | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
推广和营销服务费
|
| | | | 162,461,330 | | | | | | 87.3 | | | | | | 64,770,329 | | | | | | 88.1 | | | | | | 97,691,001 | | | | | | 150.8 | | |
员工福利支出
|
| | | | 20,283,326 | | | | | | 10.9 | | | | | | 4,049,357 | | | | | | 5.5 | | | | | | 16,233,969 | | | | | | 400.9 | | |
其他
|
| | | | 3,255,048 | | | | | | 1.8 | | | | | | 4,665,573 | | | | | | 6.4 | | | | | | (1,410,525) | | | | | | (30.2) | | |
合计
|
| | |
|
185,999,704
|
| | | |
|
100.0
|
| | | |
|
73,485,259
|
| | | |
|
100.0
|
| | | |
|
112,514,445
|
| | | |
|
153.1
|
| |
截至2009年3月31日的财政年度
|
| |
0 - 90天
|
| |
90 - 180天
|
| |
180 - 365天
|
| |
>365天
|
| |
合计
|
| |||||||||||||||
2022(人民币)
|
| | | | 73,593,680 | | | | | | 64,397,895 | | | | | | 58,064,055 | | | | | | 7,184,920 | | | | | | 203,240,550 | | |
2022(美元)
|
| | | $ | 11,592,842 | | | | | $ | 10,144,276 | | | | | $ | 9,146,538 | | | | | $ | 1,131,804 | | | | | $ | 32,015,460 | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
员工福利支出
|
| | | | 41,599,522 | | | | | | 38.7 | | | | | | 89,872,239 | | | | | | 57.9 | | | | | | (48,272,717) | | | | | | (53.7) | | |
折旧和摊销费用
|
| | | | 5,998,308 | | | | | | 5.6 | | | | | | 9,489,983 | | | | | | 6.1 | | | | | | (3,491,675) | | | | | | (36.8) | | |
专业服务费
|
| | | | 30,680,853 | | | | | | 28.5 | | | | | | 33,649,233 | | | | | | 21.7 | | | | | | (2,968,380) | | | | | | (8.8) | | |
办公费
|
| | | | 2,766,021 | | | | | | 2.6 | | | | | | 4,020,338 | | | | | | 2.6 | | | | | | (1,254,317) | | | | | | (31.2) | | |
贸易应收账款准备
|
| | | | 5,082,725 | | | | | | 4.7 | | | | | | 6,998,818 | | | | | | 4.5 | | | | | | (1,916,093) | | | | | | (27.4) | | |
报废存货备抵
|
| | | | 4,393,629 | | | | | | 4.1 | | | | | | — | | | | | | — | | | | | | 4,393,629 | | | | | | 100.0 | | |
税费和附加费
|
| | | | 5,379,934 | | | | | | 5.0 | | | | | | 4,004,265 | | | | | | 2.6 | | | | | | 1,375,669 | | | | | | 34.4 | | |
其他
|
| | | | 11,719,508 | | | | | | 10.8 | | | | | | 7,299,510 | | | | | | 4.6 | | | | | | 4,419,998 | | | | | | 60.4 | | |
合计 | | | | | 107,620,500 | | | | | | 100.0 | | | | | | 155,334,386 | | | | | | 100 | | | | | | (47,713,886) | | | | | | (30.7) | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
检测和临床试验费用
|
| | | | 74,166,285 | | | | | | 35.1 | | | | | | 20,480,320 | | | | | | 21.7 | | | | | | 53,685,965 | | | | | | 262.1 | | |
咨询服务费
|
| | | | 59,975,917 | | | | | | 28.4 | | | | | | 31,492,876 | | | | | | 33.4 | | | | | | 28,483,041 | | | | | | 90.4 | | |
员工福利支出
|
| | | | 56,513,100 | | | | | | 26.8 | | | | | | 29,178,337 | | | | | | 30.9 | | | | | | 27,334,763 | | | | | | 93.7 | | |
折旧及摊销
|
| | | | 10,796,480 | | | | | | 5.1 | | | | | | 6,331,638 | | | | | | 6.7 | | | | | | 4,464,842 | | | | | | 70.5 | | |
办公楼和租赁费
|
| | | | 1,039,327 | | | | | | 0.5 | | | | | | 3,446,146 | | | | | | 3.7 | | | | | | (2,406,819) | | | | | | (69.8) | | |
其他
|
| | | | 8,731,154 | | | | | | 4.1 | | | | | | 3,457,827 | | | | | | 3.6 | | | | | | 5,273,327 | | | | | | 152.5 | | |
合计 | | | | | 211,222,263 | | | | | | 100.0 | | | | | | 94,387,144 | | | | | | 100.0 | | | | | | 116,835,119 | | | | | | 123.8 | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
差异
|
| |||||||||||||||||||||||||||
| | |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| |
人民币
|
| |
%
|
| ||||||||||||||||||
鼠兔重组新冠肺炎疫苗
|
| | | | 127,773,439 | | | | | | 60.5 | | | | | | 33,903,400 | | | | | | 35.9 | | | | | | 93,870,039 | | | | | | 276.9 | | |
鼠兔狂犬病疫苗
|
| | | | 24,272,368 | | | | | | 11.5 | | | | | | 13,718,774 | | | | | | 14.5 | | | | | | 10,553,594 | | | | | | 76.9 | | |
鼠兔YS-0N-001
|
| | | | 16,528,066 | | | | | | 7.8 | | | | | | 4,312,590 | | | | | | 4.6 | | | | | | 12,215,476 | | | | | | 283.3 | | |
鼠兔乙肝疫苗
|
| | | | 16,438,478 | | | | | | 7.8 | | | | | | 7,536,556 | | | | | | 8.0 | | | | | | 8,901,922 | | | | | | 118.1 | | |
鼠兔佐剂
|
| | | | 8,171,893 | | | | | | 3.9 | | | | | | 26,036,582 | | | | | | 27.6 | | | | | | (17,864,689) | | | | | | (68.6) | | |
YSJA-TM狂犬病疫苗
|
| | | | 7,579,877 | | | | | | 3.6 | | | | | | 3,939,781 | | | | | | 4.2 | | | | | | 3,640,096 | | | | | | 92.4 | | |
其他
|
| | | | 10,458,142 | | | | | | 4.9 | | | | | | 4,939,461 | | | | | | 5.2 | | | | | | 5,518,681 | | | | | | 111.7 | | |
合计 | | | | | 211,222,263 | | | | | | 100.0 | | | | | | 94,387,144 | | | | | | 100.0 | | | | | | 116,835,119 | | | | | | 123.8 | | |
| | |
截至9月30日的6个月
|
| |
截至2009年3月31日的财政年度
|
| ||||||||||||||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
2022
|
| |
2021
|
| ||||||||||||||||||||||||
| | |
人民币
|
| |
$
|
| |
人民币
|
| |
人民币
|
| |
$
|
| |
人民币
|
| ||||||||||||||||||
运营中使用的净现金
活动 |
| | | | (107,395,153) | | | | | | (15,126,504) | | | | | | (176,984,374) | | | | | | (173,545,357) | | | | | | (27,337,727) | | | | | | (246,610,437) | | |
用于投资的现金净额
活动 |
| | | | (19,024,351) | | | | | | (2,679,561) | | | | | | (203,390,377) | | | | | | (298,923,958) | | | | | | (47,087,987) | | | | | | (104,238,941) | | |
融资活动提供的现金净额
|
| | | | 51,907,325 | | | | | | 7,311,097 | | | | | | 43,885,865 | | | | | | 364,558,145 | | | | | | 57,427,010 | | | | | | 739,258,696 | | |
外汇汇率对现金及现金等价物的影响
|
| | | | 30,471,942 | | | | | | 4,291,943 | | | | | | (4,446,301) | | | | | | (11,478,411) | | | | | | (1,808,136) | | | | | | (2,674) | | |
现金和现金等价物净减少
|
| | | | (44,040,237) | | | | | | (6,203,025) | | | | | | (340,935,187) | | | | | | (119,389,581) | | | | | | (18,806,840) | | | | | | 388,406,644 | | |
会计年度开始时的现金和受限现金
|
| | | | 271,067,503 | | | | | | 38,179,597 | | | | | | 390,457,084 | | | | | | 390,457,084 | | | | | | 61,506,740 | | | | | | 2,050,440 | | |
财政年度末的现金和限制性现金
|
| | | | 227,027,266 | | | | | | 31,976,572 | | | | | | 49,521,897 | | | | | | 271,067,503 | | | | | | 42,699,900 | | | | | | 390,457,084 | | |
还款日
|
| |
分期付款
|
| |||
2025年4月7日
|
| | | $ | 6,400,000 | | |
2025年7月7日
|
| | | | 6,400,000 | | |
2025年10月7日
|
| | | | 6,400,000 | | |
2026年1月7日
|
| | | | 6,400,000 | | |
2026年4月7日
|
| | | | 6,400,000 | | |
2026年7月7日
|
| | | | 8,000,000 | | |
合计 | | | | $ | 40,000,000 | | |
净销售额层级
|
| |
版税
|
| |||
在一个财政年度内版税产品年净销售额低于或等于5亿元人民币的部分
|
| | | | 1.5% | | |
一个财政年度版税产品年净销售额大于5亿元人民币但小于等于10亿元人民币的部分
|
| | | | 3.0% | | |
一个财政年度版税产品年净销售额超过10亿元的部分
|
| | | | 3.5% | | |
净销售额层级
|
| |
版税
|
| |||
在一个财政年度内版税产品年净销售额低于或等于5亿元人民币的部分
|
| | | | 0.6% | | |
一个财政年度版税产品年净销售额大于5亿元人民币但小于等于10亿元人民币的部分
|
| | | | 1.2% | | |
净销售额层级
|
| |
版税
|
| |||
一个财政年度版税产品年净销售额超过10亿元的部分
|
| | | | 1.4% | | |
截至2009年3月31日的财政年度
|
| |
截至2022年3月31日
|
| |
截至2022年9月30日
|
| ||||||||||||||||||
| | |
(人民币)
|
| |
($)
|
| |
(人民币)
|
| |
($)
|
| ||||||||||||
2023
|
| | | | 4,947,481 | | | | | $ | 779,352 | | | | | | 5,748,070 | | | | | $ | 809,610 | | |
2024
|
| | | | 4,837,260 | | | | | | 761,989 | | | | | | 5,029,426 | | | | | | 708,390 | | |
2025
|
| | | | 4,922,251 | | | | | | 775,377 | | | | | | 3,921,138 | | | | | | 552,289 | | |
2026
|
| | | | 1,479,661 | | | | | | 233,084 | | | | | | 158,029 | | | | | | 22,257 | | |
2027年及以后
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
租赁支付总额
|
| | | | 16,186,653 | | | | | | 2,549,802 | | | | |
|
14,856,663
|
| | | |
|
2,092,546
|
| |
少:利息
|
| | | | (1,259,141) | | | | | | (198,346) | | | | | | (928,262) | | | | | | (130,744) | | |
经营租赁负债现值
|
| | | | 14,927,512 | | | | | $ | 2,351,456 | | | | |
|
13,928,401
|
| | | | $ | 1,961,802 | | |
| | |
峰会
医疗保健 收购 公司 (历史) |
| |
YS Biophma
(历史) |
| |
形式
调整(无 赎回 场景) |
| | | | |
形式
组合(否 赎回 场景) |
| |
形式
组合(否 赎回 场景) |
| |
形式
调整 (100% 赎回 场景) |
| | | | |
形式
组合 (100% 赎回 场景) |
| |
形式
组合 (100% 赎回 场景) |
| ||||||||||||||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| | | | |
(人民币)
|
| |
($)
|
| | | | | | | | | | |
(人民币)
|
| |
($)
|
| |||||||||||||||||||||
资产 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
流动资产: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
现金和现金
等价物 |
| | | | 497,675 | | | | | | 226,765,500 | | | | | | — | | | | | | | | | 227,263,175 | | | | | $ | 32,009,800 | | | | | | — | | | | | | | | | 227,263,175 | | | | | $ | 32,009,800 | | |
| | | | | — | | | | | | — | | | | | | 1,420,595,390 | | | |
(A)
(Aa)
|
| | | | 1,420,595,390 | | | | | | 200,089,494 | | | | | | (1,428,481,485) | | | |
(C)
|
| | | | (7,886,095) | | | | | | (1,110,749) | | |
| | | | | — | | | | | | — | | | | | | 212,994,000 | | | |
(F)
|
| | | | 212,994,000 | | | | | | 30,000,000 | | | | | | — | | | | | | | | | 212,994,000 | | | | | | 30,000,000 | | |
| | | | | — | | | | | | — | | | | | | (30,174,150) | | | |
(G)
|
| | | | (30,174,150) | | | | | | (4,250,000) | | | | | | — | | | | | | | | | (30,174,150) | | | | | | (4,250,000) | | |
| | | | | — | | | | | | — | | | | | | 4,969,860 | | | |
(J)
|
| | | | 4,969,860 | | | | | | 700,000 | | | | | | — | | | | | | | | | 4,969,860 | | | | | | 700,000 | | |
受限现金
|
| | | | — | | | | | | 261,766 | | | | | | — | | | | | | | | | 261,766 | | | | | | 36,869 | | | | | | — | | | | | | | | | 261,766 | | | | | | 36,869 | | |
应收账款净额
|
| | | | — | | | | | | 468,359,388 | | | | | | — | | | | | | | | | 468,359,388 | | | | | | 65,967,969 | | | | | | — | | | | | | | | | 468,359,388 | | | | | | 65,967,969 | | |
预付款给供应商,
净额 |
| | | | — | | | | | | 7,556,142 | | | | | | — | | | | | | | | | 7,556,142 | | | | | | 1,064,275 | | | | | | — | | | | | | | | | 7,556,142 | | | | | | 1,064,275 | | |
库存
|
| | | | — | | | | | | 161,667,187 | | | | | | — | | | | | | | | | 161,667,187 | | | | | | 22,770,668 | | | | | | — | | | | | | | | | 161,667,187 | | | | | | 22,770,668 | | |
预付费用和其他流动资产
|
| | | | 1,551,626 | | | | | | 6,942,700 | | | | | | — | | | | | | | | | 8,494,326 | | | | | | 1,196,418 | | | | | | — | | | | | | | | | 8,494,326 | | | | | | 1,196,418 | | |
流动资产总额
|
| | | | 2,049,301 | | | | | | 871,552,683 | | | | | | 1,608,385,100 | | | | | | | | | 2,481,987,084 | | | | | | 349,585,493 | | | | | | (1,428,481,485) | | | | | | | | | 1,053,505,599 | | | | | | 148,385,250 | | |
信托账户中持有的投资
|
| | | | 1,428,481,485 | | | | | | — | | | | | | (1,428,481,485) | | | |
(A)
|
| | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | | | | | — | | |
财产和设备,
净额 |
| | | | — | | | | | | 557,366,853 | | | | | | — | | | | | | | | | 557,366,853 | | | | | | 78,504,585 | | | | | | — | | | | | | | | | 557,366,853 | | | | | | 78,504,585 | | |
无形资产净值
|
| | | | — | | | | | | 81,314,933 | | | | | | — | | | | | | | | | 81,314,933 | | | | | | 11,453,130 | | | | | | — | | | | | | | | | 81,314,933 | | | | | | 11,453,130 | | |
经营性租赁使用权资产,净额
|
| | | | — | | | | | | 13,067,129 | | | | | | — | | | | | | | | | 13,067,129 | | | | | | 1,840,493 | | | | | | — | | | | | | | | | 13,067,129 | | | | | | 1,840,493 | | |
递延税金资产净额
|
| | | | — | | | | | | 2,473,459 | | | | | | — | | | | | | | | | 2,473,459 | | | | | | 348,384 | | | | | | — | | | | | | | | | 2,473,459 | | | | | | 348,384 | | |
其他资产,非
当前 |
| | | | — | | | | | | 22,663,063 | | | | | | — | | | | | | | | | 22,663,063 | | | | | | 3,192,071 | | | | | | — | | | | | | | | | 22,663,063 | | | | | | 3,192,071 | | |
总资产
|
| | | | 1,430,530,786 | | | | | | 1,548,438,120 | | | | | | 179,903,615 | | | | | | | | | 3,158,872,521 | | | | | $ | 444,924,156 | | | | | | (1,428,481,485) | | | | | | | | | 1,730,391,036 | | | | | $ | 243,723,913 | | |
负债和权益(赤字)
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
流动负债: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
短期贷款
|
| | | | — | | | | | | 163,641,078 | | | | | | — | | | | | | | | | 163,641,078 | | | | | $ | 23,048,688 | | | | | | — | | | | | | | | | 163,641,078 | | | | | $ | 23,048,688 | | |
应付账款
|
| | | | — | | | | | | 37,394,178 | | | | | | — | | | | | | | | | 37,394,178 | | | | | | 5,266,934 | | | | | | — | | | | | | | | | 37,394,178 | | | | | | 5,266,934 | | |
应计费用和其他负债
|
| | | | — | | | | | | 367,283,321 | | | | | | — | | | | | | | | | 367,283,321 | | | | | | 51,731,502 | | | | | | — | | | | | | | | | 367,283,321 | | | | | | 51,731,502 | | |
相关应收金额
派对 |
| | | | 212,994 | | | | | | — | | | | | | — | | | | | | | | | 212,994 | | | | | | 30,000 | | | | | | — | | | | | | | | | 212,994 | | | | | | 30,000 | | |
当前运营部分
租赁负债 |
| | | | — | | | | | | 3,524,558 | | | | | | — | | | | | | | | | 3,524,558 | | | | | | 496,431 | | | | | | — | | | | | | | | | 3,524,558 | | | | | | 496,431 | | |
延期政府拨款-当前
|
| | | | — | | | | | | 3,495,701 | | | | | | — | | | | | | | | | 3,495,701 | | | | | | 492,366 | | | | | | — | | | | | | | | | 3,495,701 | | | | | | 492,366 | | |
应计产品成本和费用
|
| | | | 4,259,568 | | | | | | — | | | | | | — | | | | | | | | | 4,259,568 | | | | | | 599,956 | | | | | | — | | | | | | | | | 4,259,568 | | | | | | 599,956 | | |
流动负债总额
|
| | | | 4,472,562 | | | | | | 575,338,836 | | | | | | — | | | | | | | | | 579,811,398 | | | | | | 81,665,877 | | | | | | — | | | | | | | | | 579,811,398 | | | | | | 81,665,877 | | |
非流动负债: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
长期贷款
|
| | | | — | | | | | | 283,992,000 | | | | | | — | | | | | | | | | 283,992,000 | | | | | | 40,000,000 | | | | | | — | | | | | | | | | 283,992,000 | | | | | | 40,000,000 | | |
经营租赁负债的非流动部分
|
| | | | — | | | | | | 10,403,843 | | | | | | — | | | | | | | | | 10,403,843 | | | | | | 1,465,371 | | | | | | — | | | | | | | | | 10,403,843 | | | | | | 1,465,371 | | |
延期的政府拨款-非当前
|
| | | | — | | | | | | 20,826,966 | | | | | | — | | | | | | | | | 20,826,966 | | | | | | 2,933,458 | | | | | | — | | | | | | | | | 20,826,966 | | | | | | 2,933,458 | | |
FPA责任
|
| | | | 22,789,847 | | | | | | — | | | | | | — | | | | | | | | | 22,789,847 | | | | | | 3,209,928 | | | | | | — | | | | | | | | | 22,789,847 | | | | | | 3,209,928 | | |
保修责任
|
| | | | 17,145,179 | | | | | | — | | | | | | (10,649,700) | | | |
(I)
|
| | | | 6,495,479 | | | | | | 914,882 | | | | | | — | | | | | | | | | 6,495,479 | | | | | | 914,882 | | |
总负债
|
| | | | 44,407,588 | | | | | | 890,561,645 | | | | | | (10,649,700) | | | | | | | | | 924,319,533 | | | | | | 130,189,516 | | | | | | — | | | | | | | | | 924,319,533 | | | | | | 130,189,516 | | |
| | |
峰会
医疗保健 收购 公司 (历史) |
| |
YS Biophma
(历史) |
| |
形式
调整(无 赎回 场景) |
| | | | |
形式
组合(否 赎回 场景) |
| |
形式
组合(否 赎回 场景) |
| |
形式
调整 (100% 赎回 场景) |
| | | | |
形式
组合 (100% 赎回 场景) |
| |
形式
组合 (100% 赎回 场景) |
| ||||||||||||||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| | | | |
(人民币)
|
| |
($)
|
| | | | | | | | | | |
(人民币)
|
| |
($)
|
| |||||||||||||||||||||
股东亏损 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
普通股可能会被赎回
|
| | | | 1,428,481,485 | | | | | | — | | | | | | (1,428,481,485) | | | |
(B)
|
| | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | | | | | — | | |
系列A可赎回可兑换汽车
优先股 |
| | | | — | | | | | | 551,004,725 | | | | | | (551,004,725) | | | |
(C)
|
| | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | | | | | — | | |
B系列可赎回可转换优先股
|
| | | | — | | | | | | 1,057,557,002 | | | | | | (1,057,557,002) | | | |
(C)
|
| | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | | | | | — | | |
股东(亏损)
股权: |
| | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | | | | | — | | |
A类普通股
|
| | | | — | | | | | | — | | | | | | 3,839 | | | |
(D)
|
| | | | 3,839 | | | | | | 541 | | | | | | (3,022) | | | |
(E)
|
| | | | 816 | | | | | | 115 | | |
| | | | | — | | | | | | — | | | | | | 7,978 | | | |
(E)
|
| | | | 7,978 | | | | | | 1,124 | | | | | | — | | | | | | | | | 7,978 | | | | | | 1,124 | | |
| | | | | — | | | | | | — | | | | | | 589 | | | |
(F)
|
| | | | 589 | | | | | | 83 | | | | | | 149 | | | | | | | | | 738 | | | | | | 104 | | |
| | | | | — | | | | | | — | | | | | | 3,087 | | | |
(C)
|
| | | | 3,087 | | | | | | 435 | | | | | | — | | | | | | | | | 3,087 | | | | | | 435 | | |
| | | | | — | | | | | | — | | | | | | 1 | | | |
(G)
|
| | | | 1 | | | | | | — | | | | | | — | | | | | | | | | 1 | | | | | | — | | |
| | | | | — | | | | | | — | | | | | | 1,420 | | | |
(I)
|
| | | | 1420 | | | | | | 200 | | | | | | — | | | | | | | | | 1420 | | | | | | 200 | | |
| | | | | — | | | | | | — | | | | | | 99 | | | |
(J)
|
| | | | 99 | | | | | | 14 | | | | | | — | | | | | | | | | 99 | | | | | | 14 | | |
B类普通股
|
| | | | 4,082 | | | | | | — | | | | | | (4,082) | | | |
(D)
|
| | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | | | | | — | | |
亿盛普通股
|
| | | | — | | | | | | 7,978 | | | | | | (7,978) | | | |
(E)
|
| | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | | | | | — | | |
额外实收
大写 |
| | | | — | | | | | | 808,648,509 | | | | | | — | | | | | | | | | 808,648,509 | | | | | | 113,897,365 | | | | | | — | | | | | | | | | 808,648,509 | | | | | | 113,897,365 | | |
| | | | | — | | | | | | — | | | | | | 1,428,481,485 | | | |
(B)
|
| | | | 1,428,481,485 | | | | | | 201,200,243 | | | | | | (1,428,481,485) | | | |
(C)
|
| | | | — | | | | | | — | | |
| | | | | — | | | | | | — | | | | | | 1,608,558,640 | | | |
(C)
|
| | | | 1,608,558,640 | | | | | | 226,563,937 | | | | | | — | | | | | | | | | 1,608,558,640 | | | | | | 226,563,937 | | |
| | | | | — | | | | | | — | | | | | | 212,993,411 | | | |
(F)
|
| | | | 212,993,411 | | | | | | 29,999,917 | | | | | | (149) | | | | | | | | | 212,993,262 | | | | | | 29,999,896 | | |
| | | | | — | | | | | | — | | | | | | (42,362,369) | | | |
(H)
|
| | | | (42,362,369) | | | | | | (5,966,699) | | | | | | — | | | | | | | | | (42,362,369) | | | | | | (5,966,699) | | |
| | | | | — | | | | | | — | | | | | | (30,174,151) | | | |
(G)
|
| | | | (30,174,151) | | | | | | (4,250,000) | | | | | | — | | | | | | | | | (30,174,151) | | | | | | (4,250,000) | | |
| | | | | — | | | | | | — | | | | | | 60,427,882 | | | |
(I)
|
| | | | 60,427,882 | | | | | | 8,511,209 | | | | | | — | | | | | | | | | 60,427,882 | | | | | | 8,511,209 | | |
| | | | | — | | | | | | — | | | | | | 4,969,761 | | | |
(J)
|
| | | | 4,969,761 | | | | | | 699,986 | | | | | | — | | | | | | | | | 4,969,761 | | | | | | 699,986 | | |
累计亏损
|
| | | | (42,362,369) | | | | | | (1,673,775,766) | | | | | | (7,885,852) | | | |
(D)
(Aa) |
| | | | (1,724,023,987) | | | | | | (242,827,120) | | | | | | 3,022 | | | |
(E)
|
| | | | (1,724,090,964) | | | | | | (242,826,694) | | |
| | | | | — | | | | | | — | | | | | | 42,362,369 | | | |
(H)
|
| | | | 42,362,369 | | | | | | 5,966,699 | | | | | | — | | | | | | | | | 42,362,369 | | | | | | 5,966,699 | | |
| | | | | — | | | | | | — | | | | | | (49,779,602) | | | |
(I)
|
| | | | (49,779,602) | | | | | | (7,011,409) | | | | | | — | | | | | | | | | (49,779,602) | | | | | | (7,011,409 | | |
累计其他综合损失
|
| | | | — | | | | | | (85,565,973) | | | | | | — | | | | | | | | | (85,565,973) | | | | | | (12,051,885) | | | | | | — | | | | | | | | | (85,565,973) | | | | | | (12,051,885) | | |
股东(赤字)合计
股权 |
| | | | (42,358,287) | | | | | | (950,685,252) | | | | | | 3,227,596,527 | | | | | | | | | 2,234,552,988 | | | | | | 314,734,640 | | | | | | (1,428,481,485) | | | | | | | | | 806,071,503 | | | | | | 113,534,397 | | |
总负债、可转换优先股和股东(亏损)权益
|
| | | | 1,430,530,786 | | | | | | 1,548,438,120 | | | | | | 179,903,615 | | | | | | | | | 3,158,872,521 | | | | | $ | 444,924,156 | | | | | | (1,428,481,485) | | | | | | | | | 1,730,391,036 | | | | | | 243,723,913 | | |
|
| | |
峰会
医疗保健 收购 公司 (历史) |
| |
YS Biophma
(历史) |
| |
形式
调整(无 赎回 场景) |
| | | | |
形式
组合(否 赎回 场景) |
| |
形式
组合(否 赎回 场景) |
| |
形式
调整(100% 赎回 场景) |
| |
形式
合计(100% 赎回 场景) |
| |
形式
合计(100% 赎回 场景) |
| ||||||||||||||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| | | | |
(人民币)
|
| |
($)
|
| | | | | | | |
(人民币)
|
| |
($)
|
| |||||||||||||||||||||
收入 | | | | | — | | | | | | 399,534,723 | | | | | | — | | | | | | | | | 399,534,723 | | | | | $ | 56,274,081 | | | | | | — | | | | | | 399,534,723 | | | | | $ | 56,274,081 | | |
收入成本
|
| | |
|
—
|
| | | | | 93,700,779 | | | | | | — | | | | | | | | | 93,700,779 | | | | | | 13,197,665 | | | | | | — | | | | | | 93,700,779 | | | | | | 13,197,665 | | |
毛利
|
| | |
|
—
|
| | | |
|
305,833,944
|
| | | | | — | | | | | | | |
|
305,833,944
|
| | | |
|
43,076,416
|
| | | | | — | | | | |
|
305,833,944
|
| | | |
|
43,076,416
|
| |
运营费用: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
销售
|
| | | | — | | | | | | 150,228,079 | | | | | | — | | | | | | | | | 150,228,079 | | | | | | 21,159,480 | | | | | | — | | | | | | 150,228,079 | | | | | | 21,159,480 | | |
一般和行政
|
| | | | 6,669,240 | | | | | | 49,587,013 | | | | | | — | | | | | | | | | 56,256,253 | | | | | | 7,923,639 | | | | | | — | | | | | | 56,256,253 | | | | | | 7,923,639 | | |
研发
|
| | | | — | | | | | | 123,861,107 | | | | | | — | | | | | | | | | 123,861,107 | | | | | | 17,445,718 | | | | | | — | | | | | | 123,861,107 | | | | | | 17,445,718 | | |
总运营费用
|
| | |
|
6,669,240
|
| | | |
|
323,676,199
|
| | | | | — | | | | | | | |
|
330,345,439
|
| | | |
|
46,528,837
|
| | | | | — | | | | |
|
330,345,439
|
| | | |
|
46,528,837
|
| |
| | | | | | | | | | | | | | | | | — | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
运营亏损
|
| | | | (6,669,240) | | | | | | (17,842,255) | | | | | | — | | | | | | | | | (24,511,495) | | | | | | (3,452,421) | | | | | | — | | | | | | (24,511,495) | | | | | | (3,452,421) | | |
其他(费用)收入: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
与社保相关的滞纳金
保险 |
| | | | — | | | | | | (299,417) | | | | | | — | | | | | | | | | (299,417) | | | | | | (42,173) | | | | | | — | | | | | | (299,417) | | | | | | (42,173) | | |
政府拨款
|
| | | | — | | | | | | 22,456,691 | | | | | | — | | | | | | | | | 22,456,691 | | | | | | 3,163,003 | | | | | | — | | | | | | 22,456,691 | | | | | | 3,163,003 | | |
利息支出,净额
|
| | | | | | | | | | (14,949,434) | | | | | | | | | | | | | | | (14,949,434) | | | | | | (2,105,613) | | | | | | | | | | | | (14,949,434) | | | | | | (2,105,613) | | |
其他收入(支出),净额
|
| | | | — | | | | | | 74,675 | | | | | | — | | | | | | | | | 74,675 | | | | | | 10,518 | | | | | | — | | | | | | 74,675 | | | | | | 10,518 | | |
FPA公允价值变动
|
| | | | (3,709,066) | | | | | | — | | | | | | — | | | | | | | | | (3,709,066) | | | | | | (522,418) | | | | | | — | | | | | | (3,709,066) | | | | | | (522,418) | | |
权证负债公允价值变动
|
| | | | 5,350,784 | | | | | | — | | | | | | (3,557,000) | | | |
(J)
|
| | | | 1,793,784 | | | | | | 252,653 | | | | | | — | | | | | | 1,793,784 | | | | | | 252,653 | | |
信托账户中的投资赚取利息
|
| | | | 7,886,095 | | | | | | — | | | | | | (7,886,095) | | | |
(Aa)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
延期承销佣金终止时确认的收益
|
| | | | 47,068,000 | | | | | | — | | | | | | — | | | | | | | | | 47,068,000 | | | | | | 6,629,483 | | | | | | — | | | | | | 47,068,000 | | | | | | 6,629,483 | | |
其他(费用)收入合计
|
| | |
|
56,595,813
|
| | | |
|
7,282,515
|
| | | |
|
(11,443,095)
|
| | | | | | |
|
52,435,233
|
| | | |
|
7,385,453
|
| | | | | — | | | | |
|
52,435,233
|
| | | |
|
7,385,453
|
| |
息前收入/(亏损)
税费 |
| | | | 49,926,573 | | | | | | (10,559,740) | | | | | | (11,443,095) | | | | | | | | | 27,923,738 | | | | | | 3,933,032 | | | | | | — | | | | | | 27,923,738 | | | | | | 3,933,032 | | |
所得税费用
|
| | | | — | | | | | | (565,625) | | | | | | — | | | | | | | | | (565,625) | | | | | | (79,668) | | | | | | — | | | | | | (565,625) | | | | | | (79,668) | | |
净收益/(亏损)
|
| | | | 49,926,573 | | | | | | (11,125,365) | | | | | | (11,443,095) | | | | | | | | | 27,358,113 | | | | | | 3,853,364 | | | | | | — | | | | | | 27,358,113 | | | | | | 3,853,364 | | |
增加到赎回价值
可兑换可赎回 优先股 |
| | | | — | | | | | | (72,083,238) | | | | | | — | | | | | | | | | (72,083,238) | | | | | | (10,152,855) | | | | | | — | | | | | | (72,083,238) | | | | | | (10,152,855) | | |
易升生物股份有限公司净亏损
|
| | | | 49,926,573 | | | | | | (83,208,603) | | | | | | (11,443,095) | | | | | | | | | (44,725,125) | | | | | $ | (6,299,491) | | | | | | — | | | | | | (44,725,125) | | | | | $ | (6,299,491) | | |
净收益/(亏损)
|
| | | | 49,926,573 | | | | | | (11,125,365) | | | | | | (11,443,095) | | | | | | | | | 27,358,113 | | | | | | 3,853,364 | | | | | | — | | | | | | 27,358,113 | | | | | | 3,853,364 | | |
外币折算
亏损 |
| | | | — | | | | | | (168,653,952) | | | | | | — | | | | | | | | | (168,653,952) | | | | | | (23,754,747) | | | | | | — | | | | | | (168,653,952) | | | | | | (23,754,747) | | |
总综合收益/(亏损)
|
| | |
|
49,926,573
|
| | | |
|
(179,779,317)
|
| | | |
|
(11,443,095)
|
| | | | | | |
|
(141,295,839)
|
| | | |
|
(19,901,383)
|
| | | | | — | | | | |
|
(141,295,839)
|
| | | |
|
(19,901,383)
|
| |
每股亏损*: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | 1.94 | | | | | | (0.03) | | | | | | — | | | | | | | | | 0.24 | | | | | $ | 0.03 | | | | | | — | | | | | | 0.30 | | | | | $ | 0.04 | | |
已发行普通股加权平均数*:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | 25,750,000 | | | | | | 333,699,980 | | | | | | — | | | | | | | | | 113,460,795 | | | | | | 113,460,795 | | | | | | — | | | | | | 92,174,995 | | | | | | 92,174,995 | | |
| | |
峰会
医疗保健 收购 公司 (历史) |
| |
益生比奥
(历史) |
| |
形式
调整(无 赎回 场景) |
| | | | | | | |
形式
组合(否 赎回 场景) |
| |
形式
组合(否 赎回 场景) |
| |
形式
调整(100% 赎回 场景) |
| |
形式
合计(100% 赎回 场景) |
| |
形式
合计(100% 赎回 场景) |
| ||||||||||||||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| | | | | | | |
(人民币)
|
| |
($)
|
| | | | | | | |
(人民币)
|
| |
($)
|
| |||||||||||||||||||||
收入 | | | | | — | | | | | | 502,949,894 | | | | | | — | | | | | | | | | | | | 502,949,894 | | | | | $ | 79,227,166 | | | | | | — | | | | | | 502,949,894 | | | | | $ | 79,227,166 | | |
收入成本
|
| | |
|
—
|
| | | | | 117,066,090 | | | | | | — | | | | | | | | | | | | 117,066,090 | | | | | | 18,440,832 | | | | |
|
—
|
| | | | | 117,066,090 | | | | | | 18,440,832 | | |
毛利
|
| | | | — | | | | |
|
385,883,804
|
| | | | | — | | | | | | | | | | |
|
385,883,804
|
| | | |
|
60,786,334
|
| | | | | — | | | | |
|
385,883,804
|
| | | |
|
60,786,334
|
| |
运营费用: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
销售
|
| | | | — | | | | | | 185,999,704 | | | | | | — | | | | | | | | | | | | 185,999,704 | | | | | | 29,299,597 | | | | | | — | | | | | | 185,999,704 | | | | | | 29,299,597 | | |
一般和行政
|
| | | | 5,057,268 | | | | | | 107,620,500 | | | | | | — | | | | | | | | | | | | 112,677,768 | | | | | | 17,749,562 | | | | | | — | | | | | | 112,677,768 | | | | | | 17,749,562 | | |
研发
|
| | | | | | | | | | 211,222,263 | | | | | | — | | | | | | | | | | | | 211,222,263 | | | | | | 33,272,780 | | | | | | — | | | | | | 211,222,263 | | | | | | 33,272,780 | | |
总运营费用
|
| | | | 5,057,268 | | | | | | 504,842,467 | | | | | | — | | | | | | | | | | | | 509,899,735 | | | | | | 80,321,939 | | | | | | — | | | | | | 509,899,735 | | | | | | 80,321,939 | | |
| | | | | | | | | | | — | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
运营亏损
|
| | | | (5,057,268) | | | | | | (118,958,663) | | | | | | — | | | | | | | | | | | | (124,015,931) | | | | | | (19,535,605) | | | | | | — | | | | | | (124,015,931) | | | | | | (19,535,605) | | |
其他(费用)收入:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
与所得税以外的税种相关的滞纳金
|
| | | | — | | | | | | (231,231) | | | | | | — | | | | | | | | | | | | (231,231) | | | | | | (36,425) | | | | | | — | | | | | | (231,231) | | | | | | (36,425) | | |
与社保相关的滞纳金
|
| | | | — | | | | | | (1,852,378) | | | | | | — | | | | | | | | | | | | (1,852,378) | | | | | | (291,796) | | | | | | — | | | | | | (1,852,378) | | | | | | (291,796) | | |
政府
助学金 |
| | | | — | | | | | | 23,020,413 | | | | | | — | | | | | | | | | | | | 23,020,413 | | | | | | 3,626,290 | | | | | | — | | | | | | 23,020,413 | | | | | | 3,626,290 | | |
利息支出
|
| | | | | | | | | | (2,717,433) | | | | | | | | | | | | | | | | | | (2,717,433) | | | | | | (428,064) | | | | | | | | | | | | (2,717,433) | | | | | | (428,064 | | |
其他费用,
净额 |
| | | | — | | | | | | (327,987) | | | | | | — | | | | | | | | | | | | (327,987) | | | | | | (51,666) | | | | | | — | | | | | | (327,987) | | | | | | (51,666) | | |
FPA公允价值变动
|
| | | | (17,172,164) | | | | | | — | | | | | | — | | | | | | | | | | | | (17,172,164) | | | | | | (2,705,045) | | | | | | — | | | | | | (17,172,164) | | | | | | (2,705,045) | | |
权证公允价值变动
责任 |
| | | | 67,842,809 | | | | | | — | | | | | | (41,329,378) | | | | | | (J) | | | | | | 26,513,431 | | | | | | 4,176,527 | | | | | | — | | | | | | 26,513,431 | | | | | | 4,176,527 | | |
权证可分配的交易成本
|
| | | | (3,277,812) | | | | | | — | | | | | | — | | | | | | | | | | | | (3,277,812) | | | | | | (516,337) | | | | | | | | | | | | (3,277,812) | | | | | | (516,337) | | |
从
获得的利息
持有的投资 信托帐户 |
| | | | 177,095 | | | | | | — | | | | | | (177,095) | | | | | | (Aa) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
其他收入合计/(费用)
|
| | | | 47,569,928 | | | | | | 17,891,384 | | | | | | (41,506,473) | | | | | | | | | | | | 23,954,839 | | | | | | 3,773,484 | | | | | | — | | | | | | 23,954,839 | | | | | | 3,773,484 | | |
所得税前收入/(亏损)
|
| | | | 42,512,660 | | | | | | (101,067,279) | | | | | | (41,506,473) | | | | | | | | | | | | (100,061,092) | | | | | | (15,762,121) | | | | | | — | | | | | | (100,061,092) | | | | | | (15,762,121) | | |
所得税费用
|
| | | | — | | | | | | (4,937,122) | | | | | | — | | | | | | | | | | | | (4,937,122) | | | | | | (777,720) | | | | | | — | | | | | | (4,937,122) | | | | | | (777,720) | | |
净收益/(亏损)
|
| | | | 42,512,660 | | | | | | (106,004,401) | | | | | | (41,506,473) | | | | | | | | | | | | (104,998,214) | | | | | | (16,539,841) | | | | | | — | | | | | | (104,998,214) | | | | | | (16,539,841) | | |
增加可转换可赎回优先股的赎回价值
|
| | | | — | | | | | | (130,662,326) | | | | | | — | | | | | | | | | | | | (130,662,326) | | | | | | (20,582,579) | | | | | | — | | | | | | (130,662,326) | | | | | | (20,582,579) | | |
益生生物股份有限公司的净收益/(亏损)
有限公司 |
| | | | 42,512,660 | | | | | | (236,666,727) | | | | | | (41,506,473) | | | | | | | | | | | | (235,660,540) | | | | | $ | (37,122,420) | | | | | | — | | | | | | (235,660,540 | | | | | $ | (37,122,420) | | |
| | |
峰会
医疗保健 收购 公司 (历史) |
| |
益生比奥
(历史) |
| |
形式
调整(无 赎回 场景) |
| | | | |
形式
组合(否 赎回 场景) |
| |
形式
组合(否 赎回 场景) |
| |
形式
调整(100% 赎回 场景) |
| |
形式
合计(100% 赎回 场景) |
| |
形式
合计(100% 赎回 场景) |
| ||||||||||||||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| | | | |
(人民币)
|
| |
($)
|
| | | | | | | |
(人民币)
|
| |
($)
|
| |||||||||||||||||||||
净收益/(亏损)
|
| | |
|
42,512,660
|
| | | | | (106,004,401) | | | | |
|
(41,506,473)
|
| | | | | | | | (104,998,214) | | | | | $ | (16,539,841) | | | | | | — | | | | | | (104,998,214) | | | | | $ | (16,539,841) | | |
外币折算收益
|
| | | | — | | | | | | 38,864,606 | | | | | | — | | | | | | | | | 38,864,606 | | | | | | 6,122,146 | | | | | | — | | | | | | 38,864,606 | | | | | | 6,122,146 | | |
总综合收益/(亏损)
|
| | | | 42,512,660 | | | | | | (67,139,795) | | | | | | (41,506,473) | | | | | | | | | (66,133,608) | | | | | $ | (10,417,695) | | | | | | — | | | | | | (66,133,608) | | | | | $ | (10,417,695) | | |
每股亏损*: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
-基本和
稀释后的 |
| | | | 2.51 | | | | | | (0.32) | | | | | | — | | | | | | | | | (0.93) | | | | | $ | (0.15) | | | | | | — | | | | | | (1.14) | | | | | | (0.18) | | |
已发行普通股加权平均数*:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
-基本和
稀释后的 |
| | | | 16,928,082 | | | | | | 333,699,980 | | | | | | — | | | | | | | | | 113,460,795 | | | | | | 113,460,795 | | | | | | — | | | | | | 92,174,995 | | | | | | 92,174,995 | | |
|
| | |
历史
|
| |
形式组合(4)
|
| ||||||||||||||||||||||||
| | |
峰会
|
| |
YS
Biophma |
| |
假设
否 赎回 |
| |
假设
100% 赎回 |
| ||||||||||||||||||
| | |
A类
个共享 |
| |
B类
个共享 |
| |
普通
个共享 |
| |
普通
个共享 |
| |
普通
个共享 |
| |||||||||||||||
截至和过去六个月
截至2022年9月30日 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
每单位净收益(亏损)
股票-基本和稀释(在 中 人民币) |
| | | | 1.94 | | | | | | 1.94 | | | | | | (0.03) | | | | | | 0.24 | | | | | | 0.30 | | |
每股净收益(亏损)-基本单位和摊薄单位(美元)
|
| | | $ | 0.27 | | | | | $ | 0.27 | | | | | $ | (0.01) | | | | | $ | 0.03 | | | | | $ | 0.04 | | |
截至本财年及本财年的时间
截至2022年3月31日 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
每单位净收益(亏损)
股票-基本和稀释(在 中 人民币) |
| | | | 2.51 | | | | | | 2.51 | | | | | | (0.32) | | | | | | (0.93) | | | | | | (1.14) | | |
每股净收益(亏损)-基本单位和摊薄单位(美元)
|
| | | $ | 0.40 | | | | | $ | 0.40 | | | | | $ | (0.05) | | | | | $ | (0.15) | | | | | $ | (0.18) | | |
YS Biophma股东
|
| | | | — | | | | | | — | | | | | | — | | | | | | 83,424,995 | | | | | | 83,424,995 | | |
公共股东峰会(3)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 22,337,818 | | | | | | — | | |
赞助商和某些峰会负责人(1)(2)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 3,928,475 | | | | | | 3,928,475 | | |
远期买入投资者(1)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 3,769,507 | | | | | | 4,821,525 | | |
加权平均流通股 - 基本和稀释
|
| | | | 20,000,000 | | | | | | 5,750,000 | | | | | | 333,699,980 | | | | | | 113,460,795(5) | | | | | | 92,174,995(5) | | |
名称
|
| |
年龄
|
| |
职位/头衔
|
|
张 | | |
66
|
| | 董事和董事长 | |
邵辉博士 | | |
54
|
| |
董事、总裁和首席执行官
|
|
林瑞琳女士* | | |
51
|
| | 董事 | |
陈志晨先生* | | |
40
|
| | 董事 | |
陈伯丹先生** | | |
49
|
| | 董事任命 | |
阿吉特·谢蒂博士 | | |
76
|
| | 独立董事 | |
维伦·梅塔博士 | | |
72
|
| | 独立董事 | |
斯坦利·常毅博士 | | |
64
|
| | 独立董事 | |
童少京先生** | | |
51
|
| | 董事独立任命 | |
Zenaida Reynoso Mojares博士 | | |
64
|
| | 首席医疗官 | |
吴春元女士 | | |
45
|
| | 首席财务官 | |
刘元元博士 | | |
36
|
| | 疫苗研究负责人 | |
Gang Li先生 | | |
41
|
| | 市场销售主管 | |
承保人姓名
|
| |
YS Biophma
普通股 底层 选项获奖 |
| |
练习
每YS价格 Biophma 普通 分享($) |
| |
授予日期
|
| |
过期日期
|
| ||||||
张毅先生
|
| | | | 1,037,549 | | | | | | 2.1956 – 8.276 | | | |
2020年12月31日
|
| |
2030年12月30日
|
|
刘元元博士
|
| | | | 23,811 | | | | | | 4.0724 – 8.276 | | | |
2020年12月31日
|
| |
2030年12月30日
|
|
Gang Li先生
|
| | | | 10,965 | | | | | | 4.0724 – 8.276 | | | |
2020年12月31日
|
| |
2030年12月30日
|
|
其他450多名员工
|
| | | | 2,399,221 | | | | | | 4.0724 – 8.276 | | | |
2020年12月31日
|
| |
2030年12月30日
|
|
|
峰会
|
| |
YS Biophma
|
|
|
法定股本
|
| |||
|
峰会的法定股本为55,500美元,分为每股面值0.0001美元的5亿股峰会公开股票、每股面值0.0001美元的5亿股方正股票和每股面值0.0001美元的500万股优先股。
|
| |
YS Biophma的法定股本为50,000美元,分为2,500,000,000股,每股面值0.00002美元。
|
|
|
优先股权利
|
| |||
|
在遵守峰会章程、峰会股东在股东大会上可能发出的任何指示的情况下,以及在适用的情况下,纳斯达克、美国证券交易委员会和/或任何其他主管监管机构的规则和条例或适用法律下的其他规定,并且在不损害任何现有峰会股票附带的任何权利的情况下,峰会董事会可以配发、发行、授予期权或以其他方式处置峰会股票,包括或不包括优先、递延或其他权利或限制,无论是关于股息或其他分配、投票、资本返还或其他方面的权利或限制。惟峰会董事会不得作出任何可能影响峰会将方正股份转换为峰会公开股份的能力的行为,一如峰会章程所载。
|
| |
在经修订YS Biophma细则的规限下,董事可从未发行股份(授权但未发行的YS Biophma普通股除外)中提供一系列优先股,并厘定组成该系列的股份数目及任何投票权、权力、优先权及相对、参与、选择及其他特别权利,以及该系列的任何资格、限制及限制。
|
|
|
董事的人数和资格
|
| |||
|
峰会股东可以通过普通决议确定峰会董事会的最高和最低董事人数,但除非这样的人数固定,否则最低董事人数为一人,最高董事人数不受限制。
在峰会之前,董事不需要持有峰会的任何股份
|
| |
除非YS Biophma股东以普通决议案另有决定,否则董事人数不得少于三名。
董事将不需要持有YS Biophma的任何股份。
|
|
|
峰会
|
| |
YS Biophma
|
|
|
股东大会确定董事必须持有的最低持股比例。
|
| | | |
|
选举/罢免董事
|
| |||
|
董事可以任命任何人为董事,以填补空缺或作为额外的董事,条件是任命不会导致董事人数超过峰会章程确定或根据峰会章程确定的最高董事人数。
峰会股东可通过普通决议任命任何人为董事,并可通过普通决议罢免任何董事,但在初始业务合并结束之前,只有方正股份持有人才有权投票决定董事的任免。在初始业务合并结束之前,顶峰公众股份的持有者无权就董事的任免进行投票。
|
| |
YS Biophma股东可通过普通决议任命任何人为董事股东。董事可委任任何人士为董事成员,以填补临时空缺或加入现有董事会,并可由出席董事会并于董事会投票的其余董事以过半数赞成。
|
|
|
累计投票
|
| |||
|
Summit股票的持有者将不具有累计投票权。
|
| |
YS Biophma普通股的持有者将不拥有累计投票权。
|
|
|
董事会空缺
|
| |||
|
任何董事的职位在以下情况下应腾出:
(A)该董事以书面通知峰会辞职;
(B)该董事本人(为免生疑问,未经其委派的代表或其指定的替代董事)未经其他董事特别许可而缺席峰会董事会连续三次会议,其他董事通过决议,宣布其因此而离任;
(C)董事一般死亡、破产或与债权人达成任何安排或债务重整;
(D)发现这样的董事精神不健全或变得不健全;
(E)所有其他董事(不少于两名)决定,应通过所有其他董事在按照峰会章程正式召开的董事会议上通过的决议或由所有其他董事签署的书面决议,将该董事作为董事予以撤销;或
(F)董事根据峰会章程的任何其他规定被免职,包括由峰会股东根据
项概述的规定以普通决议方式免职
|
| |
任何董事的职位在以下情况下应腾出:
(A)上述董事以书面方式向YS Biophma辞职;
(B)该董事破产或与该董事的债权人达成任何安排或和解;
(C)这样的董事死亡或被发现精神不健全;
(D)上述董事在其最后为人所知的日期向上述董事发出通知而被免职
地址,并由所有联席董事(不少于两名)签字;或
(E)根据经修订的YS Biophma章程的规定,免去该董事的职务。
|
|
|
峰会
|
| |
YS Biophma
|
|
| 上面的“选举/罢免董事”。 | | | | |
|
公司章程修正案
|
| |||
|
根据《开曼群岛公司法》,只能由股东通过特别决议(如《首脑会议章程》所界定的)修改《首脑会议章程》;但在初始企业合并结束前,如果对峰会章程作出任何修订:(A)修改峰会允许赎回与企业合并相关的义务的实质或时间,或在峰会完成首次公开募股后24个月内或根据峰会章程批准的较晚时间内完成企业合并的情况下,赎回100%的峰会公众股份;或(B)关于峰会章程细则中与峰会公开股份持有人的权利或企业合并前活动有关的任何其他规定,每一峰会公众股东(不是发起人,应向创始人、高管或董事提供机会,在任何此类修订获得批准或生效后,以每股现金价格赎回所持有的峰会公开股票,该价格相当于当时存放在信托账户中的总金额,包括在信托账户中赚取的未用于支付所得税的利息,除以当时已发行的峰会公众股票数量,但峰会不得在赎回之后赎回峰会公开股票,赎回金额不得导致峰会的有形资产净值低于5,000,001美元。
|
| |
YS Biophma可随时及不时以特别决议案(根据开曼群岛公司法的定义)更改或修订经修订的YS Biophma全部或部分细则。
|
|
|
法定人数
|
| |||
|
股东。除非出席股东大会的股东达到法定人数,否则不得在任何股东大会上处理任何事务。有权投票的一名或多名股东亲自出席或由正式授权的代表或受委代表出席,合共持有不少于峰会已发行股份总数三分之一的股份,即为峰会股东大会的法定人数。
董事会。首脑会议理事会处理事务的法定人数可由首脑会议董事确定,除非这样确定,否则应为当时在任的首脑会议董事的过半数。
|
| |
股东。任何股东大会将不会处理任何事务,除非在会议开始处理事务时出席股东人数达到法定人数。就任何目的而言,持有YS Biophma已发行股份总额不少于三分之一投票权并有权投票的一名或多名股东将构成法定人数。
董事会。YS Biophma董事会处理业务所需的法定人数可由董事厘定,除非如此厘定,否则为当时在任董事的过半数。
|
|
|
峰会
|
| |
YS Biophma
|
|
|
股东大会
|
| |||
|
峰会可能,但不会(除非《开曼群岛公司法》要求)必须举行年度股东大会。
除年度股东大会外的所有股东大会均称为特别股东大会。
股东大会可由峰会董事、首席执行官或峰会董事会主席召集,并将在峰会董事指定的时间和地点举行。股东无权召开股东大会。
|
| |
根据《开曼群岛公司法》,YS Biophma没有义务召开股东年度股东大会。经修订的YS Biophma章程规定,YS Biophma可(但无义务)每年举行一次股东大会作为其周年大会,在此情况下,YS Biophma须在召开大会的通知中指明该会议,而周年大会应在YS Biophma董事决定的时间和地点举行。
董事可于其认为适当的时间召开股东特别大会,并须在YS Biophma股东的要求下召开股东特别大会,股东须持有至少三分之一的投票权,或(A)董事会主席(“主席”);或(B)全体董事会过半数成员。
|
|
|
股东大会通知
|
| |||
|
任何股东大会应至少提前五整天发出通知。晴天是指不包括收到或被视为收到通知之日,以及发出通知之日或生效之日。每份通知应指明会议的地点、日期和时间以及在大会上进行的事务的一般性质,并将以下文所述的方式或高峰会议股东通过普通决议规定的其他方式向根据高峰会议章程有权接收该等通知的人士发出通知;但高峰会议股东大会如获同意,不论通知条文是否已获遵守,均视为已妥为召开:
(A)如属周年股东大会,所有有权出席并在会上投票的股东;及
(Br)(B)如为特别股东大会,有权出席会议及于会上投票的股东人数过半数,合共持有给予该项权利的峰会股份面值不少于95%。
|
| |
任何股东大会将至少提前七个历日发出通知。每份通知将不包括发出或视为发出的日期,并将指明会议的地点、日期及时间以及将在会上进行的一般事务的性质,并将以下文所述的方式或YS Biophma股东通过普通决议规定的其他方式发出;惟YS Biophma的股东大会(不论通知条文是否已获遵守)如获有权出席会议及于会上投票的三分之二股东(或其委托人)如此同意,将被视为已正式召开。
|
|
|
董事和高级职员的赔偿、责任保险
|
| |||
|
每一位董事和峰会官员(为免生疑问,不包括峰会的审计师),以及每一位前董事和峰会前官员(每一位都是受保障的人),应从峰会的资产中对任何责任、诉讼、法律程序、索赔进行赔偿。
|
| |
在适用法律允许的最大范围内,YS Biophma的每个董事和高级管理人员都将获得赔偿,并确保他们不会因其本人的不诚实而招致或承担的所有行为、诉讼、费用、收费、费用、损失、损害或责任造成损害。
|
|
|
峰会
|
| |
YS Biophma
|
|
|
索偿、费用、损害赔偿或开支,包括法律费用,不论他们或他们中的任何人因履行其职能时的任何作为或不作为而招致的任何后果,但因其本身的实际欺诈、故意疏忽或故意过失而可能招致的法律责任(如有的话)除外。任何人不得被认定犯有实际欺诈、故意违约或故意疏忽行为,除非或直到有管辖权的法院作出相关裁决。
Summit应向每位受保障者垫付合理的律师费以及其他费用和开支,这些律师费和其他费用与辩护涉及该受保障者的任何诉讼、诉讼、法律程序或调查有关,而根据峰会条款,这些诉讼、诉讼、法律程序或调查将要求或可能要求赔偿。
董事可代表峰会购买和维护保险,以保障峰会董事或高管的利益,承担任何法律责任,否则该人可能会因与峰会有关的任何疏忽、过失、失职或失信行为而承担法律责任。
|
| |
在YS Biophma的业务或事务(包括任何判断错误)的进行中或在执行或履行其职责、权力、权限、酌情决定权时故意违约或欺诈,包括在不损害前述规定的一般性的原则下,在开曼群岛或其他地方的任何法院就关于YS Biophma或其事务的任何民事法律程序进行抗辩(无论是否成功)而招致的任何费用、开支、损失或法律责任。
|
|
|
分红
|
| |||
|
在开曼群岛公司法及峰会章程细则的规限下,除非峰会股份附带的权利另有规定,否则峰会董事可议决就峰会已发行股份支付股息及其他分派,并授权从峰会合法可用资金中支付股息或其他分派。股息将被视为中期股息,除非首脑会议董事决定支付这种股息的决议条款明确指出,这种股息将是末期股息。除峰会的已实现或未实现利润、股票溢价账户或法律允许的其他情况外,不会支付任何股息或其他分配。
|
| |
在符合《开曼群岛公司法》、任何类别股份所附带的权利和限制以及经修订的YS Biophma细则的情况下,董事可不时宣布派发YS Biophma已发行普通股的股息和其他分派,并授权从YS Biophma可合法动用的资金中支付股息和其他分派。
在任何类别股份附带的权利和限制以及经修订的YS Biophma章程的规限下,YS Biophma股东可通过普通决议案宣布股息,但股息不得超过董事建议的金额。
董事按照前款规定向股东支付股利时,可以现金或实物支付。
|
|
|
收盘
|
| |||
|
《峰会章程》规定,如果峰会在首次公开募股完成后二十四个月内仍未完成企业合并(如峰会章程所界定),峰会将停止所有业务,但出于清盘的目的,将在合理可能的范围内尽快赎回峰会公开发行的股票,赎回时间不得超过十个工作日,赎回价格为每股现金,相当于当时的总金额
|
| |
在清盘中,受任何股份所附权利的限制:
(A)如果可供股东分配的资产不足以偿还YS Biophma的全部已发行股本,则此类资产的分配将尽可能使损失由股东按其所持股份的面值比例承担;或
|
|
|
峰会
|
| |
YS Biophma
|
|
|
存入信托账户,包括从信托账户中持有的资金赚取的利息(减去应缴税款和用于支付解散费用的高达100,000美元的利息)除以当时已发行的公开股票数量,赎回将完全消除公众股东作为股东的权利(包括获得进一步清算分派的权利,如果有);在赎回之后,在获得Summit剩余股东和董事的批准后,尽快进行清算和解散。
在清盘中,受任何股份所附权利的限制:
(A)如果股东之间可供分配的资产不足以偿还Summit的全部已发行股本,则此类资产的分配应尽可能使损失由股东按其所持股份的面值比例承担;或
(B)如果可供股东分配的资产足以偿还Summit在清盘开始时的全部已发行股本,盈余应按股东在清盘开始时持有的股份面值的比例分配给股东,但须从应付款项的股份中扣除应支付给Summit的所有款项或其他款项。
如果Summit清盘,清盘人可在任何股份所附权利的规限下,经开曼群岛公司法批准及任何其他批准,将Summit的全部或任何部分资产(不论该等资产是否由同类财产组成)以实物分配予股东,并可为此目的对任何资产进行估值及决定如何在股东或不同类别股东之间进行分拆。清盘人经同样批准后,可将该等资产的全部或任何部分转归清盘人经同样批准而认为合适的信托受托人,以使股东受益,但不会强迫任何股东接受任何有负债的资产。
|
| |
(B)如可供股东分派的资产足以于清盘开始时偿还YS Biophma的全部已发行股本,盈余将按股东于清盘开始时所持股份的面值按比例分配,但须从应付款项的股份中扣除应付YS Biophma的所有未缴催缴股款或其他款项。
如YS Biophma清盘,清盘人可在任何股份所附权利的规限下及经特别决议案批准,将YS Biophma的全部或任何部分资产以实物分派予股东,而不论该等资产是否由单一类别的财产组成,并可为此目的为任何一类或多类财产厘定清盘人认为公平的价值,并决定如何在股东之间进行分派。清盘人经同样批准后,可将该等资产的任何部分转归清盘人认为适当的信托受托人,以使股东受益,但不会强迫任何股东接受任何有负债的资产。
|
|
|
绝对多数投票条款
|
| |||
|
需要不少于三分之二票数的特别决议(并且在企业合并结束之前,涉及对
|
| |
需要YS和Biophma股东不少于三分之二投票的特别决议:
|
|
|
峰会
|
| |
YS Biophma
|
|
|
Summit章程中有关初始业务合并前董事任免的规定,也需要获得创始人股份的简单多数批准),要求:
(A)修改或增加峰会文章;
(B)更改峰会名称;
(C)就《首脑会议备忘录》规定的任何宗旨、权力或其他事项修改或增加;
(D)将峰会的注册变更为开曼群岛以外的司法管辖区;
(E)与一个或多个其他成员公司合并或合并峰会;
(F)减少Summit的股本或任何资本赎回准备金;以及
(G)在清盘中,批准清盘人在股东之间分配顶峰的资产,为此目的对资产进行估值,并决定如何在股东或不同类别的股东之间进行分割,或将该等资产的全部或任何部分归属清盘人认为适合的信托受托人,但不得强迫任何股东接受任何有负债的资产。
此外,在初始业务合并结束之前,只有方正股份的持有者才有权投票表决董事的任免。
|
| |
(A)修改修改后的YS Biophma条款;
(B)更改YS Biophma的名称;
(C)将YS Biophma的注册变更为开曼群岛以外的司法管辖区;
(D)将YS Biophma与一个或多个其他组成公司合并或合并;
(E)减少YS Biophma的股本和任何资本赎回准备金;以及
(F)在清盘中,指示清盘人将YS Biophma的资产分派给股东,为此目的对资产进行估值,并决定如何在股东或不同类别的股东之间进行分拆。
|
|
|
反收购条款
|
| |||
|
峰会章程条款授权峰会董事会不时发行及设定投票权及其他优先股,以及峰会股份的条款及权利。
|
| |
修订后的YS Biophma章程授权董事会不时发行和设定投票权和其他优先股权利。
|
|
| | |
YS普通股
Biophma实益拥有 紧接在关闭之前 业务组合的 |
| |
YS Biophma的普通股立即实益拥有
企业合并结束时 |
| ||||||||||||||||||||||||||||||||||||||||||
| | |
无赎回场景
|
| |
100%兑换场景
|
| ||||||||||||||||||||||||||||||||||||||||||
| | |
编号
|
| |
%
|
| |
数量:
普通 个共享 |
| |
占总数的%
普通 个共享 |
| |
%的投票率
电源† |
| |
数量:
普通 个共享 |
| |
占总数的%
普通 个共享 |
| |
%的投票率
电源† |
| ||||||||||||||||||||||||
董事和高管(1):
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
张毅先生(1)
|
| | | | 48,615,000 | | | | | | 58.27 | | | | | | 48,615,000 | | | | | | 42.85 | | | | | | 42.85 | | | | | | 48,615,000 | | | | | | 52.74 | | | | | | 52.74 | | |
邵辉博士(3)
|
| | | | 2,002,780 | | | | | | 2.40 | | | | | | 2,002,780 | | | | | | 1.77 | | | | | | 1.77 | | | | | | 2,002,780 | | | | | | 2.17 | | | | | | 2.17 | | |
博坦先生(4)
|
| | | | — | | | | | | — | | | | | | 3,853,475 | | | | | | 3.40 | | | | | | 3.40 | | | | | | 3,853,475 | | | | | | 4.18 | | | | | | 4.18 | | |
阿吉特·谢蒂博士
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
维伦·梅塔博士
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
斯坦利·常毅博士
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
童少京先生
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
泽纳伊达·雷诺索·莫哈雷斯博士
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
吴春元女士
|
| | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | | | | | * | | |
袁柳博士
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Gang Li先生
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
作为一个组的所有董事和高管
|
| | | | 51,004,891 | | | | | | 61.14 | | | | | | 54,858,366 | | | | | | 48.35 | | | | | | 48.35 | | | | | | 54,858,366 | | | | | | 59.52 | | | | | | 59.52 | | |
主要股东: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
张毅先生及其附属实体(1)
|
| | | | 48,615,000 | | | | | | 58.27 | | | | | | 48,615,000 | | | | | | 42.85 | | | | | | 42.85 | | | | | | 48,615,000 | | | | | | 52.74 | | | | | | 52.74 | | |
OrbiMed实体(5)
|
| | | | 4,298,465 | | | | | | 5.15 | | | | | | 4,298,465 | | | | | | 3.79 | | | | | | 3.79 | | | | | | 4,298,465 | | | | | | 4.66 | | | | | | 4.66 | | |
| | |
截至2009年3月31日的年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
关联方应付金额: | | | | | | | | | | | | | | | | | | | |
益生生物医药控股(香港)有限公司 | | | | | | | | | | | | | | | | | | | |
YS集团代收应收账款
|
| | | | 30,088,833 | | | | | | 2,966,777 | | | | | $ | 459,412 | | |
还款给YS集团
|
| | | | | | | | | | 33,055,610 | | | | | $ | 5,118,732 | | |
内容
|
| |
第(S)页
|
| |||
截至2022年9月30日(未经审计)和2021年12月31日的简明资产负债表
|
| | | | F-2 | | |
截至2022年9月30日和2021年9月30日的三个月和九个月未经审计的经营简明报表
|
| | | | F-3 | | |
截至2022年9月30日的三个月和九个月未经审计的股东赤字变动简明报表
|
| | | | F-4 | | |
截至2021年9月30日的三个月和九个月未经审计的股东权益(亏损)简明变动表
|
| | | | F-5 | | |
截至2022年9月30日的9个月未经审计的现金流量简明报表
和2021年 |
| | | | F-6 | | |
未经审计的简明财务报表附注
|
| | | | F-7 | | |
独立注册会计师事务所报告(PCAOB ID 100)
|
| | | | F-23 | | |
财务报表 | | | | | | | |
截至2021年12月31日和2020年12月31日的资产负债表
|
| | | | F-24 | | |
截至2021年12月31日的年度和2020年12月22日(初始)至2020年12月31日的经营报表
|
| | | | F-25 | | |
截至2021年12月31日的年度和2020年12月22日(初始)至2020年12月31日期间的股东权益变动表
|
| | | | F-26 | | |
截至2021年12月31日的年度及2020年12月22日(初始)至2020年12月31日期间的现金流量表
|
| | | | F-27 | | |
财务报表附注
|
| | | | F-28 | | |
内容
|
| |
页
|
| |||
独立注册会计师事务所报告(PCAOB ID 2388)
|
| | | | F-42 | | |
截至2022年和2021年3月31日的综合资产负债表
|
| | | | F-43 | | |
截至2022年和2021年3月31日止年度的综合经营报表和全面亏损报表
|
| | | | F-45 | | |
截至2022年3月31日的年度股东赤字变动综合报表
和2021年 |
| | | | F-46 | | |
截至2022年和2021年3月31日止年度合并现金流量表
|
| | | | F-47 | | |
合并财务报表附注
|
| | | | F-48 | | |
截至2022年9月30日(未经审计)和2022年3月31日的简明综合资产负债表
|
| | | | F-81 | | |
截至2022年和2021年9月30日的六个月未经审计的简明综合经营报表和全面亏损
|
| | | | F-82 | | |
截至2022年9月30日和2021年9月30日的六个月未经审计的股东赤字变化简明综合报表
|
| | | | F-83 | | |
截至2022年和2021年9月30日止六个月未经审计的现金流量简明综合报表
|
| | | | F-84 | | |
未经审计的简明合并财务报表附注
|
| | | | F-85 | | |
| | |
9月30日
2022 |
| |
12月31日
2021 |
| ||||||
| | |
(未经审计)
|
| | | | | | | |||
资产 | | | | | | | | | | | | | |
流动资产: | | | | | | | | | | | | | |
现金
|
| | | $ | 70,097 | | | | | $ | 885,198 | | |
预付费用
|
| | | | 218,545 | | | | | | 141,677 | | |
流动资产总额
|
| | | | 288,642 | | | | | | 1,026,875 | | |
信托账户中持有的投资
|
| | | | 201,200,243 | | | | | | 200,007,275 | | |
总资产
|
| | | $ | 201,488,885 | | | | | $ | 201,034,150 | | |
负债、可能赎回的A类普通股和股东亏损
|
| | | | | | | | | | | | |
流动负债: | | | | | | | | | | | | | |
应计费用
|
| | | $ | 599,956 | | | | | $ | 142,631 | | |
因关联方原因
|
| | | | 30,000 | | | | | | — | | |
流动负债总额
|
| | | | 629,956 | | | | | | 142,631 | | |
FPA责任
|
| | | | 3,209,928 | | | | | | 2,785,941 | | |
保修责任
|
| | | | 2,414,882 | | | | | | 10,423,429 | | |
延期承销佣金
|
| | | | — | | | | | | 7,000,000 | | |
总负债
|
| | | | 6,254,766 | | | | | | 20,352,001 | | |
承付款和或有事项(注7) | | | | | | | | | | | | | |
可能赎回的A类普通股,面值0.0001美元;截至2022年9月30日和2021年12月31日,已发行和流通股2000万股,赎回价值分别为每股10.06美元和10.00美元
|
| | | | 201,200,243 | | | | | | 200,000,000 | | |
股东亏损 | | | | | | | | | | | | | |
优先股,面值0.0001美元;授权500万股;未发行或已发行
|
| | | | — | | | | | | — | | |
A类普通股,面值0.0001美元;授权发行5亿股;
截至2022年9月30日,已发行和已发行股票2,000万股, 2021年12月31日,所有这些都可能被赎回 |
| | | | — | | | | | | — | | |
B类普通股,面值0.0001美元;授权发行5000万股;截至2022年9月30日和2021年12月31日,已发行和已发行股票575万股
|
| | | | 575 | | | | | | 575 | | |
累计亏损
|
| | | | (5,966,699) | | | | | | (19,318,426) | | |
股东亏损总额
|
| | | | (5,966,124) | | | | | | (19,317,851) | | |
总负债、可能赎回的A类普通股和股东亏损
|
| | | $ | 201,488,885 | | | | | $ | 201,034,150 | | |
| | |
截止三个月
9月30日 |
| |
截至9个月
9月30日 |
| ||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
2022
|
| |
2021
|
| ||||||||||||
一般和行政费用
|
| | | $ | 581,189 | | | | | $ | 202,904 | | | | | $ | 1,225,560 | | | | | $ | 246,868 | | |
运营亏损
|
| | | | (581,189) | | | | | | (202,904) | | | | | | (1,225,560) | | | | | | (246,868) | | |
其他收入(费用): | | | | | | | | | | | | | | | | | | | | | | | | | |
FPA公允价值变动
|
| | | | (409,888) | | | | | | (561,983) | | | | | | (423,987) | | | | | | (2,807,021) | | |
权证负债公允价值变动
|
| | | | (1,206,319) | | | | | | 1,797,111 | | | | | | 8,008,547 | | | | | | (88,010) | | |
权证可分配的交易成本
|
| | | | — | | | | | | — | | | | | | — | | | | | | (507,417) | | |
信托账户中的投资赚取利息
|
| | | | 902,750 | | | | | | 2,573 | | | | | | 1,192,968 | | | | | | 3,049 | | |
延期承销佣金终止时确认的收益
|
| | | | 7,000,000 | | | | | | — | | | | | | 7,000,000 | | | | | | — | | |
其他收入(费用)合计,净额
|
| | | | 6,286,543 | | | | | | 1,237,701 | | | | | | 15,777,528 | | | | | | (3,399,399) | | |
净收益(亏损)
|
| | | $ | 5,705,354 | | | | | $ | 1,034,797 | | | | | $ | 14,551,968 | | | | | $ | (3,646,267) | | |
基本和稀释后加权平均流通股,A类普通股
|
| | | | 20,000,000 | | | | | | 20,000,000 | | | | | | 20,000,000 | | | | | | 8,205,128 | | |
可能赎回的A类普通股每股基本和稀释后净收益(亏损)
|
| | | $ | 0.22 | | | | | $ | 0.04 | | | | | $ | 0.57 | | | | | $ | (0.26) | | |
基本和稀释后加权平均流通股,B类普通股
|
| | | | 5,750,000 | | | | | | 5,750,000 | | | | | | 5,750,000 | | | | | | 5,750,000 | | |
每股基本和稀释后净收益(亏损),B类普通股
|
| | | $ | 0.22 | | | | | $ | 0.04 | | | | | $ | 0.57 | | | | | $ | (0.26) | | |
| | |
A类
普通股 |
| |
B类
普通股 |
| |
额外的
实收 大写 |
| |
累计
赤字 |
| |
合计
股东的 赤字 |
| |||||||||||||||||||||||||||
| | |
个共享
|
| |
金额
|
| |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||
截至2021年12月31日的余额
|
| | | | — | | | | | $ | — | | | | | | 5,750,000 | | | | | $ | 575 | | | | | $ | — | | | | | $ | (19,318,426) | | | | | $ | (19,317,851) | | |
净收入
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 7,126,838 | | | | | | 7,126,838 | | |
截至2022年3月31日的余额
|
| | | | — | | | | | | — | | | | | | 5,750,000 | | | | | | 575 | | | | | $ | — | | | | | | (12,191,588) | | | | | | (12,191,013) | | |
净收入
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,719,777 | | | | | | 1,719,777 | | |
账面价值到赎回价值的增值-利息
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (297,492) | | | | | | (297,492) | | |
截至2022年6月30日的余额
|
| | | | — | | | | | | — | | | | | | 5,750,000 | | | | | | 575 | | | | | $ | — | | | | | | (10,769,303) | | | | | | (10,768,728) | | |
净收入
|
| | |
|
—
|
| | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,705,354 | | | | | | 5,705,354 | | |
账面价值到赎回价值的增值-利息
|
| | |
|
—
|
| | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (902,750) | | | | | | (902,750) | | |
截至2022年9月30日的余额
|
| | | | | | | | | $ | | | | | | 5,750,000 | | | | | $ | 575 | | | | | $ | — | | | | | $ | (5,966,699) | | | | | $ | (5,966,124) | | |
| | |
A类
普通股 |
| |
B类
普通股 |
| |
额外的
实收 大写 |
| |
累计
赤字 |
| |
合计
股东的 股权(赤字) |
| |||||||||||||||||||||||||||
| | |
个共享
|
| |
金额
|
| |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||
截至2020年12月31日的余额
|
| | | | — | | | | | $ | — | | | | | | 6,500,000 | | | | | $ | 650 | | | | | $ | 24,350 | | | | | $ | (3,636) | | | | | $ | 21,364 | | |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
截至2021年3月31日的余额
|
| | | | — | | | | | | — | | | | | | 6,500,000 | | | | | | 650 | | | | | | 24,350 | | | | | | (3,636) | | | | | | 21,364 | | |
A类普通股增持至赎回价值
|
| | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | |
|
—
|
| | | | | (24,350) | | | | | | (18,769,138) | | | | | | (18,793,488) | | |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (4,681,064) | | | | | | (4,681,064) | | |
截至2021年6月30日的余额
|
| | | | — | | | | | | — | | | | | | 6,500,000 | | | | | | 650 | | | | | | — | | | | | | (23,453,838) | | | | | | (23,453,188) | | |
方正股份被没收
|
| | | | — | | | | | | — | | | | | | (750,000) | | | | | | (75) | | | | | | — | | | | | | 75 | | | | | | — | | |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,034,797 | | | | | | 1,034,797 | | |
截至2021年9月30日的余额
|
| | | | — | | | | | $ | — | | | | | | 5,750,000 | | | | | $ | 575 | | | | | $ | — | | | | | $ | (22,418,966) | | | | | $ | (22,418,391) | | |
| | |
九人组
个月结束 2022年9月30日 |
| |
九人组
个月结束 2021年9月30日 |
| ||||||
经营活动现金流: | | | | | | | | | | | | | |
净收益(亏损)
|
| | | $ | 14,551,968 | | | | | $ | (3,646,267) | | |
将净收益(亏损)与经营活动中使用的现金净额进行调整:
|
| | | | | | | | | | | | |
信托账户中的投资赚取利息
|
| | | | (1,192,968) | | | | | | (3,049) | | |
财务保险负债公允价值变动
|
| | | | 423,987 | | | | | | 2,807,021 | | |
权证负债公允价值变动
|
| | | | (8,008,547) | | | | | | 88,010 | | |
权证可分配的交易成本
|
| | | | — | | | | | | 507,417 | | |
延期承销佣金终止时确认的收益
|
| | | | (7,000,000) | | | | | | — | | |
经营性资产和负债变动: | | | | | | | | | | | | | |
预付费用
|
| | | | (76,868) | | | | | | (221,704) | | |
应计产品成本和费用
|
| | | | 457,327 | | | | | | 7,619 | | |
因关联方原因
|
| | | | 30,000 | | | | | | 37,667 | | |
经营活动中使用的净现金
|
| | | | (815,101) | | | | | | (423,286) | | |
投资活动产生的现金流 | | | | | | | | | | | | | |
信托账户现金投资
|
| | | | — | | | | | | (200,000,000) | | |
投资活动中使用的净现金
|
| | | | — | | | | | | (200,000,000) | | |
融资活动的现金流: | | | | | | | | | | | | | |
从首次公开募股收到的收益,扣除承销商的折扣后的净额
|
| | | | — | | | | | | 196,000,000 | | |
私募收益
|
| | | | — | | | | | | 6,000,000 | | |
支付产品费用
|
| | | | — | | | | | | (140,554) | | |
偿还关联方应付票据
|
| | | | — | | | | | | (361,023) | | |
融资活动提供的现金净额
|
| | | | — | | | | | | 201,498,423 | | |
现金净变化
|
| | | | (815,101) | | | | | | 1,075,137 | | |
期初现金
|
| | | | 885,198 | | | | | | | | |
现金,期末
|
| | | $ | 70,097 | | | | | $ | 1,075,137 | | |
补充披露非现金投融资活动 | | | | | | | | | | | | | |
保荐人根据本票支付的延期发行费用
|
| | | $ | — | | | | | $ | 135,544 | | |
延期承销佣金计入额外实收资本
|
| | | $ | — | | | | | $ | 7,000,000 | | |
|
毛收入
|
| | | $ | 200,000,000 | | |
|
减去:分配给公募认股权证的收益
|
| | | | (8,511,409) | | |
|
减:A类普通股发行成本
|
| | | | (11,080,524) | | |
|
添加:账面价值增加到赎回价值
|
| | | | 19,591,933 | | |
|
可能于2021年12月31日赎回的A类普通股
|
| | | | 200,000,000 | | |
|
添加:账面价值增加到赎回价值
|
| | | | 1,200,243 | | |
|
可能于2022年9月30日赎回的A类普通股
|
| | | $ | 201,200,243 | | |
| | |
截至2009年9月30日的三个月
|
| |||||||||||||||||||||
| | |
2022
|
| |
2021
|
| ||||||||||||||||||
| | |
A类
|
| |
B类
|
| |
A类
|
| |
B类
|
| ||||||||||||
基本和稀释后每股净收益: | | | | | | | | | | | | | | | | | | | | | | | | | |
分子: | | | | | | | | | | | | | | | | | | | | | | | | | |
净收入分配
|
| | | $ | 4,431,344 | | | | | $ | 1,274,011 | | | | | $ | 803,726 | | | | | $ | 231,071 | | |
分母: | | | | | | | | | | | | | | | | | | | | | | | | | |
加权平均流通股
|
| | | | 20,000,000 | | | | | | 5,750,000 | | | | | | 20,000,000 | | | | | | 5,750,000 | | |
每股基本和稀释后净收益
|
| | | $ | 0.22 | | | | | $ | 0.22 | | | | | $ | 0.04 | | | | | $ | 0.04 | | |
| | |
截至9月30日的9个月
|
| |||||||||||||||||||||
| | |
2022
|
| |
2021
|
| ||||||||||||||||||
| | |
A类
|
| |
B类
|
| |
A类
|
| |
B类
|
| ||||||||||||
每股基本和稀释后净收益(亏损): | | | | | | | | | | | | | | | | | | | | | | | | | |
分子: | | | | | | | | | | | | | | | | | | | | | | | | | |
净收益(亏损)分摊
|
| | | $ | 11,302,500 | | | | | $ | 3,249,469 | | | | | $ | (2,143,878) | | | | | $ | (1,502,389) | | |
分母: | | | | | | | | | | | | | | | | | | | | | | | | | |
加权平均流通股
|
| | | | 20,000,000 | | | | | | 5,750,000 | | | | | | 8,205,128 | | | | | | 5,750,000 | | |
每股基本和稀释后净收益(亏损)
|
| | | $ | 0.57 | | | | | $ | 0.57 | | | | | $ | (0.26) | | | | | $ | (0.26) | | |
| | |
(一级)
|
| |
(二级)
|
| |
(三级)
|
| |||||||||
资产 | | | | | | | | | | | | | | | | | | | |
信托账户中持有的投资
|
| | | $ | 201,200,243 | | | | | $ | — | | | | | $ | — | | |
负债 | | | | | | | | | | | | | | | | | | | |
公开认股权证
|
| | | $ | — | | | | | $ | 1,500,000 | | | | | $ | — | | |
私募认股权证
|
| | | $ | — | | | | | $ | — | | | | | $ | 914,882 | | |
FPA责任
|
| | | $ | — | | | | | $ | — | | | | | $ | 3,209,928 | | |
总负债
|
| | | $ | 1,500,000 | | | | | $ | — | | | | | $ | 4,124,810 | | |
| | |
(一级)
|
| |
(二级)
|
| |
(三级)
|
| |||||||||
资产 | | | | | | | | | | | | | | | | | | | |
信托账户中持有的投资
|
| | | $ | 200,007,275 | | | | | $ | — | | | | | $ | — | | |
负债 | | | | | | | | | | | | | | | | | | | |
公开认股权证
|
| | | $ | 6,500,000 | | | | | $ | — | | | | | $ | — | | |
私募认股权证
|
| | | $ | — | | | | | $ | — | | | | | $ | 3,923,429 | | |
FPA责任
|
| | | $ | — | | | | | $ | — | | | | | $ | 2,785,941 | | |
总负债
|
| | | $ | 6,500,000 | | | | | $ | — | | | | | $ | 6,709,370 | | |
输入
|
| |
9月30日
2022 |
| |
12月31日
2021 |
| ||||||
无风险费率
|
| | | | 4.04% | | | | | | 1.29% | | |
股价
|
| | | $ | 9.82 | | | | | $ | 9.72 | | |
估计。剩余期限(年)
|
| | | | 5.55 | | | | | | 5.35 | | |
| | |
公共
认股权证 |
| |
私人
认股权证 |
| |
认股权证
责任 |
| |||||||||
2021年12月31日的公允价值
|
| | | $ | — | | | | | $ | 3,923,429 | | | | | $ | 3,923,429 | | |
公允价值变动
|
| | | | — | | | | | | (2,713,773 | | | | | | (2,713,773) | | |
2022年3月31日的公允价值
|
| | | $ | — | | | | | $ | 1,209,656 | | | | | $ | 1,209,656 | | |
公允价值变动
|
| | | | — | | | | | | (751,093) | | | | | | (751,093) | | |
2022年6月30日的公允价值
|
| | | $ | — | | | | | $ | 458,563 | | | | | $ | 458,563 | | |
公允价值变动
|
| | | | — | | | | | | 456,319 | | | | | | 456,319 | | |
2022年9月30日的公允价值
|
| | | $ | — | | | | | $ | 914,882 | | | | | $ | 914,882 | | |
| | |
公共
认股权证 |
| |
私人
认股权证 |
| |
认股权证
责任 |
| |||||||||
2020年12月31日的公允价值
|
| | | $ | — | | | | | $ | — | | | | | $ | — | | |
首次公开募股时权证负债初始值(2021年6月11日)
|
| | | | 8,511,409 | | | | | | 5,201,555 | | | | | | 13,712,964 | | |
公允价值变动
|
| | | | 1,212,798 | | | | | | 672,323 | | | | | | 1,885,121 | | |
2021年6月30日的公允价值
|
| | | $ | 9,724,207 | | | | | $ | 5,873,878 | | | | | $ | 15,598,085 | | |
公允价值变动
|
| | | | (1,123,207) | | | | | | (673,904) | | | | | | (1,797,111) | | |
将公募认股权证从第3级转至第1级
|
| | | | (8,601,000) | | | | | | — | | | | | | (8,601,000) | | |
2021年9月30日的公允价值
|
| | | $ | — | | | | | $ | 5,199,974 | | | | | $ | 5,199,974 | | |
输入
|
| |
9月30日
2022 |
| |
12月31日
2021 |
| ||||||
股价
|
| | | $ | 9.82 | | | | | $ | 9.72 | | |
保修价
|
| | | $ | 0.150 | | | | | $ | 0.65 | | |
估计。期限到业务合并(年)
|
| | | | 0.55 | | | | | | 0.33 | | |
业务合并的可能性
|
| | | | 85% | | | | | | 85% | | |
FPA单元采购价
|
| | | $ | 10.00 | | | | | $ | 10.00 | | |
折扣率
|
| | | | 3.93% | | | | | | 0.04% | | |
| | |
FPA责任
|
| |||
2021年12月31日的公允价值
|
| | | $ | 2,785,941 | | |
公允价值变动
|
| | | | (127,629) | | |
2022年3月31日的公允价值
|
| | | $ | 2,658,312 | | |
公允价值变动
|
| | | | 141,728 | | |
2022年6月30日的公允价值
|
| | | $ | 2,800,040 | | |
公允价值变动
|
| | | | 409,888 | | |
2022年9月30日的公允价值
|
| | | $ | 3,209,928 | | |
| | |
FPA责任
|
| |||
2020年12月31日的公允价值
|
| | | $ | — | | |
首次公开募股时FPA负债初值(2021年6月11日)
|
| | | | 2,322,741 | | |
公允价值变动
|
| | | | (77,703) | | |
2021年6月30日的公允价值
|
| | | $ | 2,245,038 | | |
公允价值变动
|
| | | | 561,983 | | |
2021年9月30日的公允价值
|
| | | $ | 2,807,021 | | |
| | |
12月31日
2021 |
| |
12月31日
2020 |
| ||||||
资产 | | | | | | | | | | | | | |
流动资产: | | | | | | | | | | | | | |
现金
|
| | | $ | 885,198 | | | | | $ | — | | |
预付费用
|
| | | | 141,677 | | | | | | — | | |
流动资产总额
|
| | | | 1,026,875 | | | | | | — | | |
延期发售成本
|
| | | | — | | | | | | 91,374 | | |
信托账户中持有的投资
|
| | | | 200,007,275 | | | | | | — | | |
总资产
|
| | | $ | 201,034,150 | | | | | $ | 91,374 | | |
负债、可能赎回的A类普通股和股东(亏损)股权
|
| | | | | | | | | | | | |
流动负债: | | | | | | | | | | | | | |
应计产品成本和费用
|
| | | $ | 142,631 | | | | | $ | 65,000 | | |
应付票据 - 关联方
|
| | | | — | | | | | | 5,010 | | |
流动负债总额
|
| | | | 142,631 | | | | | | 70,010 | | |
FPA责任
|
| | | | 2,785,941 | | | | | | — | | |
保修责任
|
| | | | 10,423,429 | | | | | | — | | |
延期承销佣金
|
| | | | 7,000,000 | | | | | | — | | |
总负债
|
| | | | 20,352,001 | | | | | | 70,010 | | |
承付款和或有事项(注7) | | | | | | | | | | | | | |
可能赎回的A类普通股,面值0.0001美元;
20,000,000股和-0股按赎回价值发行和发行 每股10.00美元 |
| | | | 200,000,000 | | | | | | — | | |
股东(亏损)权益: | | | | | | | | | | | | | |
优先股,面值0.0001美元;授权发行500万股;未发行
或未偿还的 |
| | | | — | | | | | | — | | |
A类普通股,面值0.0001美元;授权发行5亿股;
|
| | | | — | | | | | | — | | |
B类普通股,面值0.0001美元;授权发行5,000万股;分别于2021年12月31日和2020年12月31日发行和发行5,750,000股和6,500,000股
|
| | | | 575 | | | | | | 650(1) | | |
新增实收资本
|
| | | | — | | | | | | 24,350 | | |
累计亏损
|
| | | | (19,318,426) | | | | | | (3,636) | | |
股东(亏损)总股本
|
| | | | (19,317,851) | | | | | | 21,364 | | |
总负债、可能赎回的A类普通股和股东(亏损)权益
|
| | | $ | 201,034,150 | | | | | $ | 91,374 | | |
| | |
年
截至2010年12月31日 2021 |
| |
期间
12月22日起 2020(初始) 至 2020年12月31日 |
| ||||||
一般和行政费用
|
| | | $ | 549,179 | | | | | $ | 3,636 | | |
运营亏损
|
| | | | (549,179) | | | | | | (3,636) | | |
其他收入(费用): | | | | | | | | | | | | | |
FPA公允价值变动
|
| | | | (2,785,941) | | | | | | — | | |
权证负债公允价值变动
|
| | | | 3,289,535 | | | | | | — | | |
权证可分配的交易成本
|
| | | | (507,417) | | | | | | — | | |
信托账户中的投资赚取利息
|
| | | | 7,275 | | | | | | — | | |
其他收入(亏损)
|
| | | | 3,452 | | | | | | — | | |
净亏损
|
| | | $ | (545,727) | | | | | $ | (3,636) | | |
基本和稀释后加权平均流通股,A类普通股
可能赎回的股票 |
| | | | 11,178,082 | | | | | | — | | |
可能赎回的普通股、A类普通股每股基本及摊薄净亏损
|
| | | $ | (0.03) | | | | | $ | — | | |
基本和稀释后加权平均流通股,B类普通股
个共享 |
| | | | 5,750,000 | | | | | | 5,750,000 | | |
基本和稀释后每股净亏损,B类普通股
|
| | | $ | (0.03) | | | | | $ | (0.00) | | |
| | |
A类
普通股 |
| |
B类
普通股 |
| |
额外的
实收 大写 |
| |
累计
赤字 |
| |
合计
股东的 (赤字)股权 |
| |||||||||||||||||||||||||||
| | |
个共享
|
| |
金额
|
| |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||
截至2020年12月22日的余额(初始)
|
| | |
|
—
|
| | | |
$
|
—
|
| | | | | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
向初始股东发行的B类普通股
|
| | |
|
—
|
| | | |
|
—
|
| | | | | 6,500,000 | | | | | $ | 650 | | | | | $ | 24,350 | | | | | $ | — | | | | | $ | 25,000 | | |
净亏损
|
| | |
|
—
|
| | | |
|
—
|
| | | | | — | | | | | | — | | | | | | — | | | | | | (3,636) | | | | | | (3,636) | | |
截至2020年12月31日的余额
|
| | | | — | | | | | $ | — | | | | | | 6,500,000 | | | | | $ | 650 | | | | | $ | 24,350 | | | | | $ | (3,636) | | | | | $ | 21,364 | | |
超过公允价值的私募收益作为出资额
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 798,445 | | | | | | — | | | | | | 798,445 | | |
A类普通股增持至赎回价值
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (822,795) | | | | | | (18,769,138) | | | | | | (19,591,933) | | |
方正股份被没收
|
| | | | — | | | | | | — | | | | | | (750,000) | | | | | | (75) | | | | | | — | | | | | | 75 | | | | | | — | | |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (545,727) | | | | | | (545,727) | | |
截至2021年12月31日的余额
|
| | | | — | | | | | $ | — | | | | | | 5,750,000 | | | | | $ | 575 | | | | | $ | — | | | | | $ | (19,318,426) | | | | | $ | (19,317,851) | | |
| | |
年
已结束 12月31日 2021 |
| |
期间
12月22日起 2020 (初始) 至 12月31日 2020 |
| ||||||
经营活动现金流: | | | | | | | | | | | | | |
净亏损
|
| | | $ | (545,727) | | | | | $ | (3,636) | | |
将净亏损与经营活动提供的现金净额进行调整:
|
| | | | | | | | | | | | |
信托账户中的投资赚取利息
|
| | | | (7,275) | | | | | | 3,636 | | |
财务保险负债公允价值变动
|
| | | | 2,785,941 | | | | | | — | | |
权证负债公允价值变动
|
| | | | (3,289,535) | | | | | | — | | |
权证可分配的交易成本
|
| | | | 507,417 | | | | | | — | | |
经营性资产和负债变动: | | | | | | | | | | | | | |
预付费用
|
| | | | (141,677) | | | | | | — | | |
应计产品成本和费用
|
| | | | 77,631 | | | | | | — | | |
经营活动中使用的净现金
|
| | | | (613,225) | | | | | | — | | |
投资活动产生的现金流 | | | | | | | | | | | | | |
信托账户现金投资
|
| | | | (200,000,000) | | | | | | — | | |
投资活动中使用的净现金
|
| | | | (200,000,000) | | | | | | — | | |
融资活动的现金流: | | | | | | | | | | | | | |
从首次公开募股收到的收益,扣除承销商的折扣后的净额
|
| | | | 196,000,000 | | | | | | — | | |
私募收益
|
| | | | 6,000,000 | | | | | | — | | |
支付产品费用
|
| | | | (140,554) | | | | | | — | | |
偿还关联方应付票据
|
| | | | (361,023) | | | | | | — | | |
融资活动提供的现金净额
|
| | | | 201,498,423 | | | | | | — | | |
现金净变化
|
| | | | 885,198 | | | | | | — | | |
期初现金
|
| | | | — | | | | | | — | | |
现金,期末
|
| | | $ | 885,198 | | | | | $ | — | | |
现金流量信息补充性非现金披露: | | | | | | | | | | | | | |
保荐人根据本票支付的延期发行费用
|
| | | $ | 135,544 | | | | | $ | 1,374 | | |
保荐人为换取发行B类普通股而支付的延期发行费用
|
| | | $ | — | | | | | $ | 25,000 | | |
延期承保折扣
|
| | | $ | 7,000,000 | | | | | $ | — | | |
应计延期发售成本
|
| | | $ | — | | | | | $ | 65,000 | | |
|
毛收入
|
| | | $ | 200,000,000 | | |
|
减去:分配给公募认股权证的收益
|
| | | | (8,511,409) | | |
|
减:A类普通股发行成本
|
| | | | (11,080,524) | | |
|
添加:账面价值增加到赎回价值
|
| | | | 19,591,933 | | |
|
可能赎回的A类普通股
|
| | | $ | 200,000,000 | | |
| | |
截至本年度的年度业绩
2021年12月31日 |
| |
期间
2020年12月22日起 (初始)至 2020年12月31日 |
| ||||||||||||||||||
| | |
A类
|
| |
B类
|
| |
A类
|
| |
B类
|
| ||||||||||||
基本和稀释后每股净收益: | | | | | | | | | | | | | | | | | | | | | | | | | |
分子: | | | | | | | | | | | | | | | | | | | | | | | | | |
净亏损分摊
|
| | | $ | (360,359) | | | | | $ | (185,368) | | | | | $ | — | | | | | $ | (3,636) | | |
分母: | | | | | | | | | | | | | | | | | | | | | | | | | |
加权平均流通股
|
| | | | 11,178,082 | | | | | | 5,750,000 | | | | | | — | | | | | | 5,750,000 | | |
每股基本和摊薄净亏损
|
| | | $ | (0.03) | | | | | $ | (0.03) | | | | | $ | — | | | | | $ | (0.00) | | |
| | |
(一级)
|
| |
(二级)
|
| |
(三级)
|
| |||||||||
资产 | | | | | | | | | | | | | | | | | | | |
信托账户中持有的投资
|
| | | $ | 200,007,275 | | | | | $ | — | | | | | $ | — | | |
负债 | | | | | | | | | | | | | | | | | | | |
公开认股权证
|
| | | $ | — | | | | | $ | 6,500,000 | | | | | $ | — | | |
私募认股权证
|
| | | $ | — | | | | | $ | — | | | | | $ | 3,923,429 | | |
FPA责任
|
| | | $ | — | | | | | $ | — | | | | | $ | 2,785,941 | | |
输入
|
| |
06月11日
2021 |
| |
12月31日
2021 |
| ||||||
波动性
|
| | | | 16.30% | | | | | | 13.4% | | |
无风险费率
|
| | | | 0.89% | | | | | | 1.29% | | |
股价
|
| | | $ | 9.57 | | | | | $ | 9.72 | | |
估计。剩余期限(年)
|
| | | | 5.65 | | | | | | 5.35 | | |
| | |
保修期
负债 |
| |||
2021年1月1日的公允价值
|
| | | $ | — | | |
首次公开募股日的初始值
|
| | | | 13,712,964 | | |
公允价值变动
|
| | | | (3,289,535) | | |
将公募认股权证从第3级转至第1级
|
| | | | (6,500,000) | | |
2021年12月31日的公允价值
|
| | | $ | 3,923,429 | | |
输入
|
| |
06月11日
2021 |
| |
12月31日
2021 |
| ||||||
波动性
|
| | | | 16.30% | | | | | | 13.4% | | |
股价
|
| | | $ | 9.57 | | | | | $ | 9.72 | | |
保修价
|
| | | $ | 0.85 | | | | | $ | 0.65 | | |
估计。期限到业务合并(年)
|
| | | | 0.65 | | | | | | 0.33 | | |
业务合并的可能性
|
| | | | 85% | | | | | | 85% | | |
FPA单元采购价
|
| | | $ | 10.00 | | | | | $ | 10.00 | | |
| | |
FPA责任
|
| |||
2021年1月1日的公允价值
|
| | | $ | — | | |
首次公开募股日的初始值
|
| | | | 2,322,741 | | |
公允价值变动
|
| | | | 463,200 | | |
2021年12月31日的公允价值
|
| | | $ | 2,785,941 | | |
内容
|
| |
页
|
| |||
独立注册会计师事务所报告(PCA0B 2388)
|
| | | | F-42 | | |
截至2022年和2021年3月31日的综合资产负债表
|
| | | | F-43 | | |
截至2022年和2021年3月31日止年度的综合经营报表和全面亏损报表
|
| | | | F-45 | | |
截至2022年3月31日的年度股东赤字变动综合报表
和2021年 |
| | | | F-46 | | |
截至2022年和2021年3月31日止年度合并现金流量表
|
| | | | F-47 | | |
合并财务报表附注
|
| | | | F-48 | | |
截至2022年9月30日(未经审计)和2022年3月31日的简明综合资产负债表
|
| | | | F-81 | | |
截至2022年和2021年9月30日的六个月未经审计的简明综合经营报表和全面亏损
|
| | | | F-82 | | |
截至2022年9月30日和2021年9月30日的六个月未经审计的股东赤字变化简明综合报表
|
| | | | F-83 | | |
截至2022年和2021年9月30日止六个月未经审计的现金流量简明综合报表
|
| | | | F-84 | | |
未经审计的简明合并财务报表附注
|
| | | | F-85 | | |
|
|
|
|
|
独立注册会计师事务所报告
|
| ||
|
致
董事会和股东 益生生物股份有限公司 |
| |||
|
对财务报表的意见
我们审计了亿盛生物股份有限公司及其附属公司(“本公司”)截至2022年3月31日、2021年3月31日和2021年3月31日的合并资产负债表,以及截至2022年3月31日的两年期间各年度的相关综合经营报表和全面亏损、股东赤字变动、现金流量以及相关附注(统称财务报表)。我们认为,财务报表在所有重要方面都公平地反映了本公司截至2022年3月31日、2022年3月31日和2021年3月31日的财务状况,以及截至2022年3月31日的两年期间各年度的经营结果和现金流量,符合美国公认的会计原则。
|
| |||
|
方便翻译
我们的审计还包括将人民币金额转换为美元金额,我们认为,此类转换符合财务报表附注3所述的基础。这样的美元数额,完全是为了方便人民Republic of China以外的读者。
|
| |||
| 意见基础 | | |||
|
这些财务报表由公司管理层负责。我们的责任是根据我们的审计对公司的财务报表发表意见。我们是一家在美国上市公司会计监督委员会(PCAOB)注册的公共会计师事务所,根据美国联邦证券法以及美国证券交易委员会和PCAOB的适用规则和法规,我们必须与公司保持独立。
|
| |||
|
我们按照PCAOB的标准进行审核。这些标准要求我们计划和执行审计,以获得关于财务报表是否没有重大错报的合理保证,无论是由于错误还是舞弊。本公司并无被要求对其财务报告的内部控制进行审计,我们也没有受聘进行审计。作为我们审计的一部分,我们被要求了解财务报告的内部控制,但不是为了对公司财务报告内部控制的有效性发表意见。因此,我们不表达这样的意见。
|
| |||
|
我们的审计包括执行评估财务报表重大错报风险的程序,无论是由于错误还是欺诈,以及执行应对这些风险的程序。这些程序包括在测试的基础上审查与财务报表中的数额和披露有关的证据。我们的审计还包括评价管理层使用的会计原则和作出的重大估计,以及评价财务报表的整体列报。我们相信,我们的审计为我们的观点提供了合理的基础。
/S/魏伟,有限责任公司
纽约法拉盛 2022年9月28日
自2022年以来,我们一直担任本公司的审计师。
|
|
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
资产 | | | | | | | | | | | | | | | | | | | |
流动资产 | | | | | | | | | | | | | | | | | | | |
现金
|
| | | | 390,457,084 | | | | | | 271,067,503 | | | | | $ | 42,699,900 | | |
应收账款净额
|
| | | | 214,502,737 | | | | | | 308,555,105 | | | | | | 48,605,133 | | |
预付款给供应商
|
| | | | 11,458,564 | | | | | | 10,648,306 | | | | | | 1,677,374 | | |
关联方应付金额
|
| | | | 30,088,833 | | | | | | — | | | | | | — | | |
库存,净额
|
| | | | 81,439,883 | | | | | | 166,505,565 | | | | | | 26,228,784 | | |
预付费用和其他流动资产
|
| | | | 5,257,185 | | | | | | 7,987,914 | | | | | | 1,258,295 | | |
流动资产总额
|
| | | | 733,204,286 | | | | | | 764,764,393 | | | | | | 120,469,486 | | |
非流动资产 | | | | | | | | | | | | | | | | | | | |
财产、厂房和设备,净额
|
| | | | 236,204,959 | | | | | | 550,153,110 | | | | | | 86,662,851 | | |
经营性租赁使用权资产,净额
|
| | | | 17,245,924 | | | | | | 14,850,283 | | | | | | 2,339,290 | | |
递延税金资产净额
|
| | | | 7,976,206 | | | | | | 3,039,084 | | | | | | 478,732 | | |
无形资产净值
|
| | | | 83,778,603 | | | | | | 80,717,978 | | | | | | 12,715,097 | | |
其他非流动资产
|
| | | | 88,765,094 | | | | | | 28,228,293 | | | | | | 4,446,661 | | |
非流动资产合计
|
| | | | 433,970,786 | | | | | | 676,988,748 | | | | | | 106,642,631 | | |
总资产
|
| | | | 1,167,175,072 | | | | | | 1,441,753,141 | | | | | $ | 227,112,117 | | |
负债、夹层股权和股东亏损
|
| | | | | | | | | | | | | | | | | | |
流动负债 | | | | | | | | | | | | | | | | | | | |
银行贷款和其他借款 - Current
|
| | | | — | | | | | | 111,733,754 | | | | | $ | 17,600,856 | | |
应付账款
|
| | | | 16,383,236 | | | | | | 30,811,100 | | | | | | 4,853,518 | | |
应计费用和其他负债
|
| | | | 322,750,471 | | | | | | 326,751,353 | | | | | | 51,471,496 | | |
经营租赁负债 - 流动
|
| | | | 3,785,642 | | | | | | 4,322,252 | | | | | | 680,863 | | |
延期政府拨款 - Current
|
| | | | 2,121,645 | | | | | | 2,295,701 | | | | | | 361,630 | | |
流动负债总额
|
| | | | 345,040,994 | | | | | | 475,914,160 | | | | | | 74,968,363 | | |
非流动负债 | | | | | | | | | | | | | | | | | | | |
银行贷款和其他借款 - 非流动
|
| | | | 1,103,609 | | | | | | 253,928,000 | | | | | | 40,000,000 | | |
经营性租赁负债 - 非流动
|
| | | | 13,550,359 | | | | | | 10,605,260 | | | | | | 1,670,593 | | |
延期政府拨款 - 非当前
|
| | | | 30,884,246 | | | | | | 30,053,517 | | | | | | 4,734,179 | | |
非流动负债合计
|
| | | | 45,538,214 | | | | | | 294,586,777 | | | | | | 46,404,772 | | |
总负债
|
| | | | 390,579,208 | | | | | | 770,500,937 | | | | | | 121,373,135 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
夹层股权 | | | | | | | | | | | | | | | | | | | |
A系列和A-1系列可赎回可转换优先股(每股面值0.000005美元,授权50,000,000股;已发行和已发行21,548,589股)
|
| | | | 410,327,208 | | | | | | 458,074,468 | | | | | | 72,158,166 | | |
B系列可赎回可转换优先股
(每股面值0.000005美元,1亿股 授权;已发行65,414,858股, 未完成) |
| | | | 875,131,363 | | | | | | 912,146,924 | | | | | | 143,685,915 | | |
夹层总股本
|
| | | | 1,285,458,571 | | | | | | 1,370,221,392 | | | | | | 215,844,081 | | |
承付款和或有事项
|
| | | | — | | | | | | — | | | | | | — | | |
股东亏损 | | | | | | | | | | | | | | | | | | | |
普通股,每股面值0.000005美元,授权股份99.5亿股,已发行和已发行股份247,311,533股*
|
| | | | 7,978 | | | | | | 7,978 | | | | | | 1,257 | | |
新增实收资本
|
| | | | 800,806,378 | | | | | | 808,502,018 | | | | | | 127,359,254 | | |
累计亏损
|
| | | | (1,353,900,436) | | | | | | (1,590,567,163) | | | | | | (250,554,041) | | |
累计其他综合收益
|
| | | | 44,223,373 | | | | | | 83,087,979 | | | | | | 13,088,431 | | |
股东亏损总额
|
| | | | (508,862,707) | | | | | | (698,969,188) | | | | | | (110,105,099) | | |
总负债、夹层权益和股东亏损
|
| | | | 1,167,175,072 | | | | | | 1,441,753,141 | | | | | $ | 227,112,117 | | |
|
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
收入 | | | | | 257,015,929 | | | | | | 502,949,894 | | | | | $ | 79,227,166 | | |
收入成本
|
| | | | 59,656,877 | | | | | | 117,066,090 | | | | | | 18,440,832 | | |
毛利
|
| | | | 197,359,052 | | | | | | 385,883,804 | | | | | | 60,786,334 | | |
运营费用: | | | | | | | | | | | | | | | | | | | |
销售
|
| | | | 73,485,259 | | | | | | 185,999,704 | | | | | | 29,299,597 | | |
一般和行政
|
| | | | 155,334,386 | | | | | | 107,620,500 | | | | | | 16,952,916 | | |
研发
|
| | | | 94,387,144 | | | | | | 211,222,263 | | | | | | 33,272,780 | | |
总运营费用
|
| | | | 323,206,789 | | | | | | 504,842,467 | | | | | | 79,525,293 | | |
运营亏损
|
| | | | (125,847,737) | | | | | | (118,958,663) | | | | | | (18,738,959) | | |
其他收入(费用): | | | | | | | | | | | | | | | | | | | |
所得税相关滞纳金
|
| | | | (11,464,741) | | | | | | — | | | | | | — | | |
与所得税以外的税种相关的滞纳金
|
| | | | (7,261,947) | | | | | | (231,231) | | | | | | (36,425) | | |
与社保相关的滞纳金
|
| | | | (7,701,793) | | | | | | (1,852,378) | | | | | | (291,796) | | |
政府拨款
|
| | | | 3,530,405 | | | | | | 23,020,413 | | | | | | 3,626,290 | | |
财务费用,净额
|
| | | | (29,689,927) | | | | | | (2,717,433) | | | | | | (428,064) | | |
其他收入(支出),净额
|
| | | | 4,063,743 | | | | | | (327,987) | | | | | | (51,666) | | |
其他(费用)收入合计,净额
|
| | | | (48,524,260) | | | | | | 17,891,384 | | | | | | 2,818,339 | | |
所得税前亏损
|
| | | | (174,371,997) | | | | | | (101,067,279) | | | | | | (15,920,620) | | |
所得税费用
|
| | | | (17,454,245) | | | | | | (4,937,122) | | | | | | (777,720) | | |
净亏损
|
| | | | (191,826,242) | | | | | | (106,004,401) | | | | | | (16,698,340) | | |
增加可转换可赎回优先股的赎回价值
|
| | | | (16,610,297) | | | | | | (130,662,326) | | | | | | (20,582,579) | | |
易升生物股份有限公司净亏损
|
| | | | (208,436,539) | | | | | | (236,666,727) | | | | | $ | (37,280,919) | | |
净亏损
|
| | | | (191,826,242) | | | | | | (106,004,401) | | | | | $ | (16,698,340) | | |
其他综合收益:外币折算
收获 |
| | | | 22,455,217 | | | | | | 38,864,606 | | | | | | 6,122,146 | | |
全面亏损
|
| | | | (169,371,025) | | | | | | (67,139,795) | | | | | $ | (10,576,194) | | |
每股亏损*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | (0.78) | | | | | | (0.43) | | | | | $ | (0.07) | | |
已发行普通股加权平均数*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | 247,311,533 | | | | | | 247,311,533 | | | | | | 247,311,533 | | |
| | |
普通股*
|
| |
额外的
实收 大写 |
| |
赤字
|
| |
累计
其他 全面 收入 |
| |
合计
股东的 赤字 |
| |||||||||||||||||||||
| | |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||
| | | | | | | | |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |||||||||||||||
截至2020年3月31日的余额
|
| | | | 212,883,618 | | | | | | 6,797 | | | | | | 276,368,115 | | | | | | (1,145,463,897) | | | | | | 21,768,156 | | | | | | (847,320,829) | | |
股东的贡献
|
| | | | 34,427,915 | | | | | | 1,181 | | | | | | 447,681,763 | | | | | | — | | | | | | — | | | | |
|
447,682,944
|
| |
增加到赎回价值
可兑换可赎回优先选项 个共享 |
| | | | — | | | | | | — | | | | | | — | | | | | | (16,610,297) | | | | | | — | | | | |
|
(16,610,297)
|
| |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | (191,826,242) | | | | | | | | | | |
|
(191,826,242)
|
| |
基于股份的薪酬
|
| | | | — | | | | | | — | | | | | | 76,756,500 | | | | | | — | | | | | | — | | | | |
|
76,756,500
|
| |
外币折算调整
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 22,455,217 | | | | |
|
22,455,217
|
| |
截至2021年3月31日的余额
|
| | | | 247,311,533 | | | | | | 7,978 | | | | | | 800,806,378 | | | | | | (1,353,900,436) | | | | | | 44,223,373 | | | | | | (508,862,707) | | |
增加到赎回价值
可兑换可赎回优先选项 个共享 |
| | | | — | | | | | | — | | | | | | — | | | | | | (130,662,326) | | | | | | — | | | | |
|
(130,662,326)
|
| |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | (106,004,401) | | | | | | — | | | | |
|
(106,004,401)
|
| |
基于股份的薪酬
|
| | | | — | | | | | | — | | | | | | 7,764,448 | | | | | | — | | | | | | — | | | | |
|
7,764,448
|
| |
外币折算调整
|
| | | | — | | | | | | — | | | | | | (68,808) | | | | | | — | | | | | | 38,864,606 | | | | |
|
38,795,798
|
| |
截至2022年3月31日的余额(单位:人民币)
|
| | | | 247,311,533 | | | | | | 7,978 | | | | | | 808,502,018 | | | | | | (1,590,567,163) | | | | | | 83,087,979 | | | | | | (698,969,188) | | |
截至2022年3月31日的余额(单位:美元)
|
| | | | 247,311,533 | | | | | $ | 1,257 | | | | | $ | 127,359,254 | | | | | $ | (250,554,041) | | | | | $ | 13,088,431 | | | | | $ | (110,105,099) | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
经营活动现金流: | | | | | | | | | | | | | | | | | | | |
净亏损
|
| | | | (191,826,242) | | | | | | (106,004,401) | | | | | $ | (16,698,340) | | |
将净亏损与经营活动中使用的现金净额进行调整: | | | | | | | | | | | | | | | | | | | |
递延所得税
|
| | | | 17,454,245 | | | | | | 4,937,120 | | | | | | 777,720 | | |
财产、厂房和设备折旧
|
| | | | 22,240,060 | | | | | | 24,475,736 | | | | | | 3,855,540 | | |
无形资产摊销
|
| | | | 5,665,735 | | | | | | 6,678,233 | | | | | | 1,051,988 | | |
处置财产、厂房和设备的损失
|
| | | | 24,876 | | | | | | 273,982 | | | | | | 43,159 | | |
基于股份的薪酬
|
| | | | 76,756,500 | | | | | | 7,764,448 | | | | | | 1,223,094 | | |
应收账款减值
|
| | | | 6,414,634 | | | | | | 5,084,925 | | | | | | 801,003 | | |
将存货减记为可变现净值
|
| | | | 1,109,400 | | | | | | 4,393,630 | | | | | | 692,106 | | |
非现金租赁费用
|
| | | | 2,233,089 | | | | | | 3,787,628 | | | | | | 596,646 | | |
经营性资产和负债变动: | | | | | | | | | | | | | | | | | | | |
库存
|
| | | | (68,728,378) | | | | | | (89,459,313) | | | | | | (14,092,075) | | |
应收账款
|
| | | | (220,734,141) | | | | | | (99,137,291) | | | | | | (15,616,599) | | |
关联方应付金额
|
| | | | (3,086,330) | | | | | | 30,088,833 | | | | | | 4,739,742 | | |
预付费用和其他流动资产
|
| | | | 146,767,686 | | | | | | 59,229,801 | | | | | | 9,330,172 | | |
应付账款
|
| | | | (4,424,337) | | | | | | 14,427,864 | | | | | | 2,272,749 | | |
应付关联方金额
|
| | | | (245,808) | | | | | | — | | | | | | — | | |
应计费用和其他负债
|
| | | | 140,210 | | | | | | (35,633,487) | | | | | | (5,613,164) | | |
延期政府拨款
|
| | | | (44,290) | | | | | | (656,673) | | | | | | (103,442) | | |
应付所得税
|
| | | | (34,105,055) | | | | | | — | | | | | | — | | |
经营性租赁负债
|
| | | | (2,222,291) | | | | | | (3,796,392) | | | | | | (598,027) | | |
经营活动中使用的净现金
|
| | | | (246,610,437) | | | | | | (173,545,357) | | | | | | (27,337,727) | | |
投资活动现金流: | | | | | | | | | | | | | | | | | | | |
处置财产、厂房和设备所得收益
|
| | | | 644,842 | | | | | | 8,000 | | | | | | 1,260 | | |
购置房产、厂房和设备
|
| | | | (104,883,783) | | | | | | (295,314,351) | | | | | | (46,519,384) | | |
购买无形资产
|
| | | | — | | | | | | (3,617,607) | | | | | | (569,863) | | |
投资活动中使用的净现金
|
| | | | (104,238,941) | | | | | | (298,923,958) | | | | | | (47,087,987) | | |
融资活动的现金流: | | | | | | | | | | | | | | | | | | | |
发行夹层股权所得收益
|
| | | | 729,412,999 | | | | | | — | | | | | | — | | |
股东的贡献
|
| | | | 1,589,236 | | | | | | — | | | | | | — | | |
银行贷款和其他借款的收益
|
| | | | 32,253,609 | | | | | | 414,116,587 | | | | | | 65,233,702 | | |
偿还银行贷款和其他借款
|
| | | | (160,407,571) | | | | | | (49,558,442) | | | | | | (7,806,692) | | |
关联方借款收益
|
| | | | 299,757,219 | | | | | | — | | | | | | — | | |
偿还关联方借款
|
| | | | (163,346,796) | | | | | | — | | | | | | — | | |
融资活动提供的现金净额
|
| | | | 739,258,696 | | | | | | 364,558,145 | | | | | | 57,427,010 | | |
汇率对现金的影响
|
| | | | (2,674) | | | | | | (11,478,411) | | | | | | (1,808,136) | | |
现金净增(减)
|
| | | | 388,406,644 | | | | | | (119,389,581) | | | | | | (18,806,840) | | |
年初现金
|
| | | | 2,050,440 | | | | | | 390,457,084 | | | | | | 61,506,740 | | |
年终现金
|
| | | | 390,457,084 | | | | | | 271,067,503 | | | | | $ | 42,699,900 | | |
现金流量信息补充披露: | | | | | | | | | | | | | | | | | | | |
缴纳所得税
|
| | | | 34,105,055 | | | | | | — | | | | | $ | — | | |
已支付利息
|
| | | | 8,124,572 | | | | | | 2,404,357 | | | | | $ | 378,746 | | |
非现金交易: | | | | | | | | | | | | | | | | | | | |
增加可转换可赎回优先股的赎回价值
|
| | | | 16,610,297 | | | | | | 130,662,326 | | | | | $ | 20,582,579 | | |
为相关经营租赁负债确认的经营权资产
|
| | | | 15,048,446 | | | | | | 1,516,478 | | | | | $ | 238,883 | | |
免除对关联方的欠款
|
| | | | 446,092,527 | | | | | | — | | | | | $ | — | | |
|
法人
|
| |
业务性质
|
| |
注册日期
|
| |
公司注册地
|
|
|
益生生物股份有限公司
(“YS Biophma”) |
| | 控股公司 | | |
2020年11月16日
|
| | 开曼群岛 | |
|
亿盛生物(香港)控股有限公司
(“香港益生生物”) |
| | 控股公司 | | |
2020年12月28日
|
| | 香港 | |
| [br]益生生物(新加坡)有限公司有限公司
(“新加坡益生”)* |
| | 疫苗和治疗性生物制品的研究和开发 | | |
2009年11月28日
|
| | 新加坡 | |
|
益生美国生物制药有限公司
(“美国益生”) |
| | 疫苗和治疗性生物制品的研究 | | |
2009年9月29日
|
| | 美国 | |
|
辽宁益生生物制药有限公司
(“辽宁益生”)** |
| | 疫苗和治疗性生物制品的研发、制造和商业化 | | | 1994年5月26日 | | | 中华人民共和国 | |
|
北京益生生物科技有限公司
(“北京益生”) |
| | 疫苗和治疗性生物制品的研究和开发 | | | 2021年2月4日 | | | 中华人民共和国 | |
| | |
截至3月31日
|
| |
截至的年度
3月31日 |
| ||||||||||||||||||
| | |
2022
|
| |
2021
|
| |
2022
|
| |
2021
|
| ||||||||||||
外币
|
| |
资产负债表
|
| |
资产负债表
|
| |
损益
|
| |
损益
|
| ||||||||||||
人民币:1us$
|
| | | | 6.3482 | | | | | | 6.5713 | | | | | | 6.4598 | | | | | | 6.8282 | | |
人民币:1美元
|
| | | | 4.6932 | | | | | | 4.8768 | | | | | | 4.7850 | | | | | | 4.9246 | | |
类别
|
| |
预计使用寿命
|
|
厂房和建筑 | | | 6 - 20年 | |
机械设备 | | | 5年 - 10年 | |
家具和固定装置 | | | 3年 - 7年 | |
机动车辆 | | | 4 - 5年 | |
租赁改进 | | | 资产的租赁期限或寿命较短 | |
| | |
截至2022年3月31日
|
| |||||||||||||||
| | |
(人民币)
|
| |
(美元)
|
| | | | | | | ||||||
供应商A
|
| | | | 35,172,250 | | | | | $ | 5,540,508 | | | | | | 20.9% | | |
供应商B
|
| | | | 16,227,146 | | | | | | 2,556,181 | | | | | | 9.6% | | |
供应商C
|
| | | | 9,995,189 | | | | | | 1,574,492 | | | | | $ | 5.9% | | |
供应商D
|
| | | | 7,426,500 | | | | | | 1,169,859 | | | | | | 4.4% | | |
供应商E
|
| | | | 6,621,300 | | | | | | 1,043,020 | | | | | | 3.9% | | |
合计 | | | | | 75,442,385 | | | | | $ | 11,884,060 | | | | | | 44.7% | | |
| | |
截至2021年3月31日
|
| |||||||||||||||
| | |
(人民币)
|
| |
(美元)
|
| | | | | | | ||||||
供应商A
|
| | | | 32,063,500 | | | | | $ | 4,879,324 | | | | | | 37.9% | | |
供应商F
|
| | | | 5,781,888 | | | | | | 879,870 | | | | | | 6.8% | | |
供应商G
|
| | | | 4,862,320 | | | | | | 739,933 | | | | | $ | 5.7% | | |
供应商C
|
| | | | 4,568,088 | | | | | | 695,157 | | | | | | 5.4% | | |
供应商H
|
| | | | 3,199,200 | | | | | | 486,844 | | | | | | 3.8% | | |
合计 | | | | | 50,474,996 | | | | | $ | 7,681,128 | | | | | | 59.6% | | |
| | |
截至2022年3月31日
|
| |||||||||||||||
| | |
(人民币)
|
| |
(美元)
|
| | | | | | | ||||||
供应商E
|
| | | | 1,420,549 | | | | | $ | 223,772 | | | | | | 4.6% | | |
合计 | | | | | 1,420,549 | | | | | $ | 223,772 | | | | | | 4.6% | | |
| | |
截至2021年3月31日
|
| |||||||||||||||
| | |
(人民币)
|
| |
(美元)
|
| | | | | | | ||||||
供应商A
|
| | | | 1,225,510 | | | | | $ | 186,494 | | | | | | 8.3% | | |
合计 | | | | | 1,225,510 | | | | | $ | 186,494 | | | | | | 8.3% | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
贸易应收账款
|
| | | | 223,033,688 | | | | | | 322,170,980 | | | | | $ | 50,749,973 | | |
坏账准备
|
| | | | (8,530,951) | | | | | | (13,615,875) | | | | | | (2,144,840) | | |
应收账款净额
|
| | | | 214,502,737 | | | | | | 308,555,105 | | | | | $ | 48,605,133 | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
年初余额
|
| | | | 2,116,317 | | | | | | 8,530,951 | | | | | $ | 1,343,838 | | |
添加内容
|
| | | | 6,414,634 | | | | | | 5,084,924 | | | | | | 801,002 | | |
年终余额
|
| | | | 8,530,951 | | | | | | 13,615,875 | | | | | $ | 2,144,840 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
原材料
|
| | | | 20,865,093 | | | | | | 57,926,980 | | | | | $ | 9,124,946 | | |
正在进行的工作
|
| | | | 23,453,665 | | | | | | 40,795,744 | | | | | | 6,426,348 | | |
成品
|
| | | | 78,422,922 | | | | | | 73,285,870 | | | | | | 11,544,354 | | |
对移动缓慢或陈旧的库存进行备抵
|
| | | | (41,301,797) | | | | | | (5,503,029) | | | | | | (866,864) | | |
库存,净额
|
| | | | 81,439,883 | | | | | | 166,505,565 | | | | | $ | 26,228,784 | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
年初余额
|
| | | | 76,661,332 | | | | | | 41,301,797 | | | | | $ | 6,506,064 | | |
添加内容
|
| | | | 950,261 | | | | | | 4,393,629 | | | | | | 692,106 | | |
存货已核销
|
| | | | (36,309,796) | | | | | | (40,192,397) | | | | | | (6,331,306) | | |
年终余额
|
| | | | 41,301,797 | | | | | | 5,503,029 | | | | | $ | 866,864 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
成本 | | | | | | | | | | | | | | | | | | | |
施工中
|
| | | | 40,158,349 | | | | | | 318,000,074 | | | | |
$
|
50,092,951
|
| |
厂房和建筑物
|
| | | | 153,845,452 | | | | | | 170,206,987 | | | | | | 26,811,850 | | |
机械设备
|
| | | | 174,933,799 | | | | | | 194,875,303 | | | | | | 30,697,726 | | |
电子设备
|
| | | | 8,442,743 | | | | | | 10,107,578 | | | | | | 1,592,196 | | |
机动车辆
|
| | | | 2,814,066 | | | | | | 2,978,155 | | | | | | 469,134 | | |
办公设备和家具
|
| | | | 14,241,207 | | | | | | 29,888,526 | | | | | | 4,708,189 | | |
租赁改进
|
| | | | 3,889,957 | | | | | | 4,390,980 | | | | | | 691,689 | | |
总成本
|
| | | | 398,325,573 | | | | | | 730,447,603 | | | | | | 115,063,735 | | |
减去:累计折旧
|
| | | | (132,228,718) | | | | | | (150,402,597) | | | | | | (23,692,164) | | |
减值:资产减值
|
| | | | (29,891,896) | | | | | | (29,891,896) | | | | | | (4,708,720) | | |
财产和设备,净额
|
| | | | 236,204,959 | | | | | | 550,153,110 | | | | | $ | 86,662,851 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
应收贷款(1)
|
| | | | 2,966,778 | | | | | | — | | | | | $ | — | | |
存款(2) | | | | | 1,362,270 | | | | | | 2,807,847 | | | | | | 442,306 | | |
员工晋升(3)
|
| | | | 290,024 | | | | | | 383,251 | | | | | | 60,372 | | |
员工社会保障(4)
|
| | | | 190,253 | | | | | | 615,581 | | | | | | 96,969 | | |
可退还的增值税(5)
|
| | | | 148,705 | | | | | | 3,442,733 | | | | | | 542,316 | | |
其他应收账款(6)
|
| | | | 414,898 | | | | | | 854,245 | | | | | | 134,564 | | |
津贴(7) | | | | | (115,743) | | | | | | (115,743) | | | | | | (18,232) | | |
合计 | | | | | 5,257,185 | | | | | | 7,987,914 | | | | | $ | 1,258,295 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
成本 | | | | | | | | | | | | | | | | | | | |
专利
|
| | | | 79,608,000 | | | | | | 79,608,000 | | | | |
$
|
12,540,248
|
| |
许可证、软件和实验室信息系统
|
| | | | 2,526,272 | | | | | | 6,143,880 | | | | | | 967,814 | | |
土地使用权
|
| | | | 67,181,860 | | | | | | 67,181,860 | | | | | | 10,582,820 | | |
总成本
|
| | | | 149,316,132 | | | | | | 152,933,740 | | | | | | 24,090,882 | | |
减去:累计摊销
|
| | | | (65,537,529) | | | | | | (72,215,762) | | | | | | (11,375,785) | | |
无形资产净值
|
| | | | 83,778,603 | | | | | | 80,717,978 | | | | | $ | 12,715,097 | | |
| | |
截至3月31日
|
| | | | | | | | | | |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |
到期日
|
| |
利率
|
| ||||||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| | | | | | | | | | |||||||||
中国广发银行股份有限公司 - 沈阳分行(1)
|
| | | | — | | | | | | 46,456,142 | | | | | | 7,318,002 | | | | 2022/9/16 – 2022/12/16 | | | | | 5.66% | | |
上海浦东发展银行股份有限公司沈阳分行(2)
|
| | | | — | | | | | | 64,647,870 | | | | | | 10,183,654 | | | | 2022/7/19 – 2022/12/1 | | | | | 5.30% | | |
花旗银行(3)
|
| | | | — | | | | | | 234,743 | | | | | | 36,978 | | | | 2022/5/1 | | | | | 1.00% | | |
R-Bridge Healthcare Fund,LP(4)
|
| | | | — | | | | | | 394,999 | | | | | | 62,222 | | | | 2026/9/15 | | | | | 4.00% | | |
一年内到期的银行贷款
|
| | | | — | | | | | | 111,733,754 | | | | | | 17,600,856 | | | | | | | | | | | |
花旗银行(3)
|
| | | | 1,103,609 | | | | | | — | | | | | | — | | | | 2022/5/1 | | | | | 1.00% | | |
R-Bridge Healthcare Fund,LP(4)
|
| | | | — | | | | | | 253,928,000 | | | | | | 40,000,000 | | | | 2026/9/15 | | | | | 4.00% | | |
长期银行贷款
|
| | | | 1,103,609) | | | | | | 253,928,000 | | | | | | 40,000,000 | | | | | | | | | | | |
银行贷款总额
|
| | | | 1,103,609 | | | | | | 365,661,754 | | | | | | 57,600,856 | | | | | | | | | | | |
还款日
|
| |
分期付款
|
|
2025年4月7日
|
| |
US$ 6,400,000
|
|
2025年7月7日
|
| |
6,400,000
|
|
2025年10月7日
|
| |
6,400,000
|
|
2026年1月7日
|
| |
6,400,000
|
|
2026年4月7日
|
| |
6,400,000
|
|
2026年7月7日
|
| |
8,000,000
|
|
合计 | | |
40,000,000美元
|
|
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
经营租赁ROU资产
|
| | | | 17,245,924 | | | | | | 14,850,283 | | | | | $ | 2,339,290 | | |
经营租赁负债 - 流动
|
| | | | 3,785,642 | | | | | | 4,322,252 | | | | | | 680,863 | | |
经营性租赁负债 - 非流动
|
| | | | 13,550,359 | | | | | | 10,605,260 | | | | | $ | 1,670,593 | | |
加权平均剩余租期
|
| | | | 4.4 | | | | | | 3.4 | | | | | | 3.4 | | |
加权平均贴现率
|
| | | | 5.0% | | | | | | 4.8% | | | | | | 4.8% | | |
| | |
截至2009年3月31日的年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
运营租赁成本
|
| | | | 2,643,917 | | | | | | 4,594,967 | | | | | $ | 723,822 | | |
经营租赁支付的现金
|
| | | | 2,601,625 | | | | | | 4,587,894 | | | | | $ | 722,708 | | |
截至2009年3月31日的财政年度
|
| |
截至2022年3月31日
|
| |||||||||
| | |
(人民币)
|
| |
(美元)
|
| ||||||
2023
|
| | | | 4,947,481 | | | | | $ | 779,352 | | |
2024
|
| | | | 4,837,260 | | | | | | 761,989 | | |
2025
|
| | | | 4,922,251 | | | | | | 775,377 | | |
2026
|
| | | | 1,479,661 | | | | | | 233,084 | | |
2027年及以后
|
| | | | — | | | | | | — | | |
租赁支付总额
|
| | | | 16,186,653 | | | | | | 2,549,802 | | |
少:利息
|
| | | | (1,259,141) | | | | | | (198,346) | | |
经营租赁负债现值
|
| | | | 14,927,512 | | | | | $ | 2,351,456 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
应付工资和社会保险(1)
|
| | | | 86,818,418 | | | | | | 57,459,273 | | | | | $ | 9,051,270 | | |
促销服务费(2)
|
| | | | 58,358,838 | | | | | | 64,883,477 | | | | | | 10,220,768 | | |
所得税以外的税
|
| | | | 1,615,475 | | | | | | 1,171,381 | | | | | | 184,522 | | |
滞纳金(3)
|
| | | | 93,890,390 | | | | | | 9,499,595 | | | | | | 1,496,423 | | |
物业、厂房和设备的应付费用
|
| | | | 4,730,933 | | | | | | 48,774,134 | | | | | | 7,683,144 | | |
疾控中心运存费用
|
| | | | 12,087,830 | | | | | | 35,023,095 | | | | | | 5,517,012 | | |
保证金(4)
|
| | | | 48,732,986 | | | | | | 94,528,659 | | | | | | 14,890,624 | | |
专业服务费(5)
|
| | | | 8,694,317 | | | | | | 7,758,448 | | | | | | 1,222,149 | | |
其他应付(6)
|
| | | | 7,821,284 | | | | | | 7,653,291 | | | | | | 1,205,584 | | |
合计 | | | | | 322,750,471 | | | | | | 326,751,353 | | | | | | 51,471,496 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
工资
|
| | | | 46,263,007 | | | | | | 49,020,045 | | | | | | 7,721,881 | | |
社会保障保险
|
| | | | 39,926,173 | | | | | | 7,732,161 | | | | | | 1,218,008 | | |
工会费
|
| | | | 629,238 | | | | | | 707,067 | | | | | | 111,381 | | |
合计 | | | | | 86,818,418 | | | | | | 57,459,273 | | | | | | 9,051,270 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
所得税滞纳金
|
| | | | 53,890,577 | | | | | | — | | | | | | — | | |
所得税以外税种的滞纳金
|
| | | | 10,635,413 | | | | | | — | | | | | | — | | |
社会保险滞纳金
|
| | | | 29,364,400 | | | | | | 9,499,595 | | | | | | 1,496,423 | | |
合计 | | | | | 93,890,390 | | | | | | 9,499,595 | | | | | | 1,496,423 | | |
| | |
系列A
|
| |
系列A-1
|
| |
系列B
|
| |
合计
|
| |
合计
|
| |||||||||||||||||||||||||||||||||
| | |
个共享
|
| |
携带
值 |
| |
个共享
|
| |
携带
值 |
| |
个共享
|
| |
携带
值 |
| |
携带
值 |
| |
携带
值 |
| ||||||||||||||||||||||||
| | | | | | | | |
(人民币)
|
| | | | | | | |
(人民币)
|
| | | | | | | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||||||||
截至2020年3月31日
|
| | | | 21,548,589 | | | | | | 440,585,213 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 440,585,213 | | | | | $ | 69,403,171 | | |
可转换票据的转换
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 18,393,610 | | | | | | 131,425,527 | | | | |
|
131,425,527
|
| | | |
|
20,702,802
|
| |
可兑换项下的看涨期权
备注 |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 9,660,324 | | | | | | 131,425,290 | | | | |
|
131,425,290
|
| | | |
|
20,702,765
|
| |
新保险
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 37,360,924 | | | | | | 597,987,709 | | | | |
|
597,987,709
|
| | | |
|
94,197,995
|
| |
股份转让
|
| | | | (6,014,313) | | | | | | (68,232,451) | | | | | | 6,014,313 | | | | | | 68,232,451 | | | | | | — | | | | | | — | | | | |
|
—
|
| | | |
|
—
|
| |
增值为赎回
值 |
| | | | — | | | | | | 1,758,690 | | | | | | — | | | | | | — | | | | | | — | | | | | | 14,851,607 | | | | |
|
16,610,297
|
| | | |
|
2,616,536
|
| |
外币折算调整
|
| | | | — | | | | | | (29,449,559) | | | | | | — | | | | | | (2,567,136) | | | | | | — | | | | | | (558,770) | | | | |
|
(32,575,465)
|
| | | |
|
(5,131,449)
|
| |
截至2021年3月31日
|
| | | | 15,534,276 | | | | | | 344,661,893 | | | | | | 6,014,313 | | | | | | 65,665,315 | | | | | | 65,414,858 | | | | | | 875,131,363 | | | | | | 1,285,458,571 | | | | | $ | 202,491,820 | | |
增加到赎回价值
|
| | | | — | | | | | | 57,598,340 | | | | | | — | | | | | | 5,164,090 | | | | | | — | | | | | | 67,899,896 | | | | |
|
130,662,326
|
| | | |
|
20,582,579
|
| |
外币折算调整
|
| | | | — | | | | | | (12,696,574) | | | | | | — | | | | | | (2,318,596) | | | | | | — | | | | | | (30,884,335) | | | | |
|
(45,899,505)
|
| | | |
|
(7,230,318)
|
| |
截至2022年3月31日
|
| | | | 15,534,276 | | | | | | 389,563,659 | | | | | | 6,014,313 | | | | | | 68,510,809 | | | | | | 65,414,858 | | | | | | 912,146,924 | | | | | | 1,370,221,392 | | | | | $ | 215,844,081 | | |
| | |
共享数量
选项 |
| |
平均运动量
每股价格 选项 |
| ||||||
| | | | | | | | |
(人民币)
|
| |||
2020年3月31日
|
| | | | 11,223,795 | | | | | | 3.8807 | | |
在此期间发放的许可证
|
| | | | 10,254,198 | | | | | | 8.4631 | | |
在此期间被没收
|
| | | | (298,117) | | | | | | 6.4631 | | |
在此期间进行锻炼
|
| | | | (8,103,671) | | | | | | — | | |
在此期间过期
|
| | | | (62,783) | | | | | | 6.4631 | | |
2021年3月31日
|
| | | | 13,013,422 | | | | | | 7.3289 | | |
在此期间发放的许可证
|
| | | | — | | | | | | — | | |
在此期间被没收
|
| | | | — | | | | | | — | | |
在此期间进行锻炼
|
| | | | — | | | | | | — | | |
在此期间过期
|
| | | | — | | | | | | — | | |
2022年3月31日
|
| | | | 13,013,422 | | | | | | 7.3289 | | |
年终了
2021年3月31日 数量: 选项 |
| |
行权价
|
| |
锻炼周期
|
|
| | |
(人民币)
|
| | | |
6,133,005
|
| |
3.4845
|
| |
2021 – 2031
|
|
2,453,049
|
| |
6.4631
|
| |
2021 – 2026
|
|
4,427,368
|
| |
13.1344
|
| |
2021 – 2026
|
|
13,013,422
|
| | | | | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
研发费用
|
| | | | 4,200,464 | | | | | | 975,171 | | | | | $ | 153,614 | | |
一般和行政费用
|
| | | | 72,501,943 | | | | | | 6,789,277 | | | | | | 1,069,481 | | |
销售费用
|
| | | | 54,093 | | | | | | — | | | | | | — | | |
股票薪酬总额
|
| | | | 76,756,500 | | | | | | 7,764,448 | | | | | $ | 1,223,094 | | |
关联方名称
|
| |
与YS集团的关系
|
|
益生生物医药有限公司 | | |
张控制的实体
|
|
益生生物医药控股有限公司 | | |
张控制的实体
|
|
开封市益盛泛亚科技有限公司 | | |
张控制的实体
|
|
北京亿盛兴业科技有限公司 | | |
张控制的实体
|
|
长春百隆生物科技有限公司 | | |
张控制的实体
|
|
河南益生汇中健康服务有限公司 | | |
张控制的实体
|
|
河南益生生物制药有限公司 | | |
张控制的实体
|
|
关联方名称
|
| |
与YS集团的关系
|
|
北京华尔盾康启生物科技有限公司 | | |
张控制的实体
|
|
辽宁益生泛亚 | | |
张控制的实体
|
|
张 | | |
董事会主席
|
|
辉少 | | | 首席执行官 | |
中开实* | | | 首席医疗官 | |
张南鹏 | | | 董事长的女儿 | |
张旭 | | | 董事长的女儿 | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
关联方应付金额: | | | | | | | | | | | | | | | | | | | |
益生生物医药控股有限公司(香港)
|
| | | | 30,088,833 | | | | | | — | | | | | $ | — | | |
| | | | | 30,088,833 | | | | | | — | | | | | $ | — | | |
| | |
截至2009年3月31日的年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
关联方应付金额: | | | | | | | | | | | | | | | | | | | |
益生生物医药控股(香港)有限公司 | | | | | | | | | | | | | | | | | | | |
YS集团代收应收账款
|
| | | | 30,088,833 | | | | | | 2,966,777 | | | | | $ | 459,412 | | |
还款给YS集团
|
| | | | | | | | | | 33,055,610 | | | | | $ | 5,118,732 | | |
| | |
截至2009年3月31日的年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
当期所得税
|
| | | | — | | | | | | — | | | | | $ | — | | |
递延税金
|
| | | | 17,454,245 | | | | | | 4,937,122 | | | | | | 777,720 | | |
所得税
|
| | | | 17,454,245 | | | | | | 4,937,122 | | | | | $ | 777,720 | | |
| | |
截至2009年3月31日的年度
|
| |||||||||
| | |
2021
|
| |
2022
|
| ||||||
中华人民共和国法定所得税率
|
| | | | 25.00% | | | | | | 25.00% | | |
不同司法管辖区不同税率的影响
|
| | | | (20.56)% | | | | | | (18.26)% | | |
中华人民共和国优惠税率的效果
|
| | | | (0.77)% | | | | | | 4.56% | | |
研发费用扣除等影响
|
| | | | 7.8% | | | | | | 33.2% | | |
暂时性差异*
|
| | | | 10.01% | | | | | | 4.88% | | |
估值免税额变动
|
| | | | (11.49)% | | | | | | (44.47)% | | |
实际税率
|
| | | | 10.01% | | | | | | 4.88% | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
递延税金资产: | | | | | | | | | | | | | | | | | | | |
将存货减记为可变现净值
|
| | | | 6,195,269 | | | | | | 825,454 | | | | | $ | 130,030 | | |
财产、厂房和建筑物减值
|
| | | | 2,293,516 | | | | | | 2,031,460 | | | | | | 320,006 | | |
延期政府拨款
|
| | | | 4,950,884 | | | | | | 4,852,383 | | | | | | 764,371 | | |
可用于抵销未来应税利润的亏损
|
| | | | 32,495,322 | | | | | | 58,257,270 | | | | | | 9,176,975 | | |
减去:估值免税额
|
| | | | (32,495,322) | | | | | | (58,257,270) | | | | | | (9,176,975) | | |
递延税金资产总额,净额
|
| | | | 13,439,669 | | | | | | 7,709,297 | | | | | | 1,214,407 | | |
递延纳税义务: | | | | | | | | | | | | | | | | | | | |
因历史收购子公司而产生的公允价值调整
|
| | | | (5,463,463) | | | | | | (4,670,213) | | | | | | (735,675) | | |
递延纳税负债总额
|
| | | | (5,463,463) | | | | | | (4,670,213) | | | | | | (735,675) | | |
递延税金净资产
|
| | | | 7,976,206 | | | | | | 3,039,084 | | | | | $ | 478,732 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
政府对财产、厂房和设备的补助 | | | | | | | | | | | | | | | | | | | |
年初余额
|
| | | | 21,096,442 | | | | | | 21,847,340 | | | | | $ | 3,441,502 | | |
添加
|
| | | | 2,000,000 | | | | | | 1,552,000 | | | | | | 244,479 | | |
确认为收入
|
| | | | (1,249,102) | | | | | | (1,368,650) | | | | | | (215,597) | | |
小计 | | | | | 21,847,340 | | | | | | 22,030,690 | | | | | $ | 3,470,384 | | |
政府用于研发的拨款 | | | | | | | | | | | | | | | | | | | |
年初余额
|
| | | | 10,387,874 | | | | | | 11,158,551 | | | | | $ | 1,757,750 | | |
添加
|
| | | | 1,610,700 | | | | | | — | | | | | | — | | |
确认为收入
|
| | | | (840,023) | | | | | | (840,023) | | | | | | (132,325) | | |
小计 | | | | | 11,158,551 | | | | | | 10,318,528 | | | | | $ | 1,625,425 | | |
递延政府拨款总额
|
| | | | 33,005,891 | | | | | | 32,349,218 | | | | | $ | 5,095,809 | | |
少:当前部分
|
| | | | (2,121,645) | | | | | | (2,295,701) | | | | | | (361,630) | | |
非当前部分
|
| | | | 30,884,246 | | | | | | 30,053,517 | | | | | $ | 4,734,179 | | |
| | |
截至3月31日
|
| |||||||||
| | |
2022
|
| |
2022
|
| ||||||
| | |
(人民币)
|
| |
(美元)
|
| ||||||
其他专业服务费
|
| | | | 7,617,840 | | | | | $ | 1,200,000 | | |
研发
|
| | | | 73,894,705 | | | | | | 11,640,261 | | |
采购原材料
|
| | | | 17,664,500 | | | | | | 17,664,500 | | |
合计 | | | | | 99,177,045 | | | | | $ | 30,504,761 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
中华人民共和国
|
| | | | 288,637,839 | | | | | | 604,094,049 | | | | | $ | 95,159,896 | | |
其他国家/地区
|
| | | | 31,345,723 | | | | | | 26,777,039 | | | | | $ | 4,218,052 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
资产 | | | | | | | | | | | | | | | | | | | |
流动资产 | | | | | | | | | | | | | | | | | | | |
现金
|
| | | | 330,296,949 | | | | | | 252,611,535 | | | | |
$
|
39,792,624
|
| |
关联方应付金额
|
| | | | 495,937,171 | | | | | | 519,236,876 | | | | | | 81,792,772 | | |
流动资产总额
|
| | | | 826,234,120 | | | | | | 771,848,411 | | | | | | 121,585,396 | | |
非流动资产 | | | | | | | | | | | | | | | | | | | |
长期投资,净额
|
| | | | 150,952,826 | | | | | | 146,641,652 | | | | | | 23,099,721 | | |
非流动资产合计
|
| | | | 150,952,826 | | | | | | 146,641,652 | | | | | | 23,099,721 | | |
总资产
|
| | | | 977,186,946 | | | | | | 918,490,063 | | | | | $ | 144,685,117 | | |
负债和权益 | | | | | | | | | | | | | | | | | | | |
流动负债 | | | | | | | | | | | | | | | | | | | |
应计费用和其他负债
|
| | | | 197,324,794 | | | | | | 244,082,463 | | | | |
$
|
38,449,082
|
| |
应付关联方金额
|
| | | | 3,266,288 | | | | | | 3,155,395 | | | | | | 497,053 | | |
流动负债总额
|
| | | | 200,591,082 | | | | | | 247,237,858 | | | | | | 38,946,135 | | |
总负债
|
| | | | 200,591,082 | | | | | | 247,237,858 | | | | | | 38,946,135 | | |
夹层股权 | | | | | | | | | | | | | | | | | | | |
A系列和A-1系列可赎回可转换优先股(每股面值0.000005美元,授权50,000,000股;截至2022年和2021年3月31日已发行和已发行的21,548,589股)
|
| | | | 410,327,208 | | | | | | 458,074,468 | | | | | | 72,158,166 | | |
B系列可赎回可转换优先股(面值
每股价值0.000005美元,100,000,000股 授权;已发行65,414,858股, 截至2022年3月31日和2021年3月31日的未偿还债务) |
| | | | 875,131,363 | | | | | | 912,146,924 | | | | | | 143,685,915 | | |
夹层总股本
|
| | | | 1,285,458,571 | | | | | | 1,370,221,392 | | | | | | 215,844,081 | | |
| | |
截至3月31日
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
股东亏损: | | | | | | | | | | | | | | | | | | | |
普通股,每股票面价值0.000005美元,授权股份99.5亿股,2022年和2021年3月31日已发行和已发行股票247,311,533股*
|
| | | | 7,978 | | | | | | 7,978 | | | | | | 1,257 | | |
新增实收资本
|
| | | | 800,806,378 | | | | | | 808,502,018 | | | | | | 127,359,254 | | |
留存收益
|
| | | | (1,353,900,436) | | | | | | (1,590,567,163) | | | | | | (250,554,041) | | |
累计其他综合收益
|
| | | | 44,223,373 | | | | | | 83,087,980 | | | | | | 13,088,431 | | |
股东亏损总额
|
| | | | (508,862,707) | | | | | | (698,969,187) | | | | | | (110,105,099) | | |
总负债、夹层权益和股东亏损
|
| | | | 977,186,946 | | | | | | 918,490,063 | | | | | $ | 144,685,117 | | |
|
| | |
截至2009年3月31日的年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
子公司股权损失
|
| | | | (60,903,713) | | | | | | (75,864,722) | | | | | $ | (11,950,588) | | |
运营费用: | | | | | | | | | | | | | | | | | | | |
销售费用
|
| | | | 54,278 | | | | | | — | | | | | | — | | |
一般和行政费用
|
| | | | 104,562,058 | | | | | | 29,178,255 | | | | | | 4,596,304 | | |
研发费用
|
| | | | 4,352,356 | | | | | | 988,531 | | | | | | 155,718 | | |
总运营费用
|
| | | | 108,968,692 | | | | | | 30,166,786 | | | | | | 4,752,022 | | |
运营亏损
|
| | | | (169,872,405) | | | | | | (106,031,508) | | | | | | (16,702,610) | | |
其他收入(支出) | | | | | |||||||||||||||
财务收入/(支出),净额
|
| | | | (21,953,837) | | | | | | 27,107 | | | | | | 4,270 | | |
其他收入/(支出)合计,净额
|
| | | | (21,953,837) | | | | | | 27,107 | | | | | | 4,270 | | |
净亏损
|
| | | | (191,826,242) | | | | | | (106,004,401) | | | | | | (16,698,340) | | |
增加可转换可赎回优先股的赎回价值
|
| | | | (16,610,297) | | | | | | (130,662,326) | | | | | | (20,582,579) | | |
可归因于YS Biophma的净亏损
|
| | | | (208,436,538) | | | | | | (236,666,727) | | | | | | (37,280,919) | | |
净亏损
|
| | | | (191,826,242) | | | | | | (106,004,401) | | | | | | (16,698,340) | | |
伪造货币兑换收益
|
| | | | 22,455,217 | | | | | | 38,864,607 | | | | | | 6,122,146 | | |
全面亏损
|
| | | | (169,371,025) | | | | | | (67,139,794) | | | | | $ | (10,576,194) | | |
每股亏损*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | (0.78) | | | | | | (0.43) | | | | | $ | (0.07) | | |
已发行普通股加权平均数*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | 247,311,533 | | | | | | 247,311,533 | | | | | | 247,311,533 | | |
| | |
截至2009年3月31日的财政年度
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
净亏损
|
| | | | (191,826,242) | | | | | | (106,004,401) | | | | | $ | (16,698,340) | | |
子公司股权损失
|
| | | | 60,903,713 | | | | | | 75,864,722 | | | | | | 11,950,588 | | |
基于股份的薪酬
|
| | | | 76,756,500 | | | | | | 7,764,448 | | | | | | 1,223,094 | | |
经营性资产和负债变动: | | | | | | | | | | | | | | | | | | | |
关联方应付金额
|
| | | | (421,125,633) | | | | | | (23,299,705) | | | | | | (3,670,285) | | |
应付关联方金额
|
| | | | 2,906,881 | | | | | | (110,893) | | | | | | (17,468) | | |
应计费用和其他负债
|
| | | | 77,228,629 | | | | | | (24,732,348) | | | | | | (3,895,962) | | |
经营活动中使用的净现金
|
| | | | (395,156,152) | | | | | | (70,518,177) | | | | | | (11,108,373) | | |
投资活动现金流: | | | | | | | | | | | | | | | | | | | |
支付长期投资费用
|
| | | | (7,658,738) | | | | | | (813,776) | | | | | | (128,190) | | |
投资活动中使用的净现金
|
| | | | (7,658,738) | | | | | | (813,776) | | | | | | (128,190) | | |
融资活动的现金流:
|
| | | | | | | | | | | | | | | | | | |
发行夹层股权所得收益
|
| | | | 729,412,999 | | | | | | — | | | | | | — | | |
股东出资
|
| | | | 1,589,236 | | | | | | — | | | | | | — | | |
融资活动提供的现金净额
|
| | | | 731,002,235 | | | | | | — | | | | | | — | | |
汇率对现金的影响
|
| | | | 2,109,604 | | | | | | (6,353,461) | | | | | | (1,000,829) | | |
现金净(减)增
|
| | | | 330,296,949 | | | | | | (77,685,414) | | | | | | (12,237,392) | | |
年初现金
|
| | | | — | | | | | | 330,296,949 | | | | | | 52,030,016 | | |
年终现金
|
| | | | 330,296,949 | | | | | | 252,611,535 | | | | | $ | 39,792,624 | | |
非现金交易: | | | | | | | | | | | | | | | | | | | |
增加可转换可赎回优先股的赎回价值
|
| | | | 16,610,297 | | | | | | 130,662,326 | | | | | $ | 20,582,579 | | |
关联方的宽恕
|
| | | | 446,092,527 | | | | | | — | | | | | $ | — | | |
| | |
3月31日
2022 |
| |
9月30日
2022 |
| |
9月30日
2022 |
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
资产 | | | | | | | | | | | | | | | | | | | |
流动资产 | | | | | | | | | | | | | | | | | | | |
现金
|
| | | | 271,067,503 | | | | | | 226,765,500 | | | | | $ | 31,939,703 | | |
受限现金
|
| | | | — | | | | | | 261,766 | | | | | | 36,869 | | |
应收账款净额
|
| | | | 308,555,105 | | | | | | 468,359,388 | | | | | | 65,967,969 | | |
预付款给供应商
|
| | | | 10,648,306 | | | | | | 7,556,142 | | | | | | 1,064,275 | | |
库存,净额
|
| | | | 166,505,565 | | | | | | 161,667,187 | | | | | | 22,770,668 | | |
预付费用和其他流动资产
|
| | | | 7,987,914 | | | | | | 6,942,700 | | | | | | 977,873 | | |
流动资产总额
|
| | | | 764,764,393 | | | | | | 871,552,683 | | | | | | 122,757,357 | | |
非流动资产 | | | | | | | | | | | | | | | | | | | |
财产、厂房和设备,净额
|
| | | | 550,153,110 | | | | | | 557,366,853 | | | | | | 78,504,585 | | |
经营性租赁使用权资产,净额
|
| | | | 14,850,283 | | | | | | 13,067,129 | | | | | | 1,840,493 | | |
递延税金资产净额
|
| | | | 3,039,084 | | | | | | 2,473,459 | | | | | | 348,384 | | |
无形资产净值
|
| | | | 80,717,978 | | | | | | 81,314,933 | | | | | | 11,453,130 | | |
其他非流动资产
|
| | | | 28,228,293 | | | | | | 22,663,063 | | | | | | 3,192,071 | | |
非流动资产合计
|
| | | | 676,988,748 | | | | | | 676,885,437 | | | | | | 95,338,663 | | |
总资产
|
| | | | 1,441,753,141 | | | | | | 1,548,438,120 | | | | | $ | 218,096,020 | | |
负债、夹层股权和股东亏损
|
| | | | | | | | | | | | | | | | | | |
流动负债 | | | | | | | | | | | | | | | | | | | |
银行贷款和其他借款 - Current
|
| | | | 111,733,754 | | | | | | 163,641,078 | | | | | $ | 23,048,688 | | |
应付账款
|
| | | | 30,811,100 | | | | | | 37,394,178 | | | | | | 5,266,934 | | |
应计费用和其他负债
|
| | | | 326,751,353 | | | | | | 367,283,321 | | | | | | 51,731,502 | | |
经营租赁负债 - 流动
|
| | | | 4,322,252 | | | | | | 3,524,558 | | | | | | 496,431 | | |
延期政府拨款 - Current
|
| | | | 2,295,701 | | | | | | 3,495,701 | | | | | | 492,366 | | |
流动负债总额
|
| | | | 475,914,160 | | | | | | 575,338,836 | | | | | | 81,035,921 | | |
非流动负债 | | | | | | | | | | | | | | | | | | | |
银行贷款和其他借款 - 非流动
|
| | | | 253,928,000 | | | | | | 283,992,000 | | | | | | 40,000,000 | | |
经营性租赁负债 - 非流动
|
| | | | 10,605,260 | | | | | | 10,403,843 | | | | | | 1,465,371 | | |
延期政府拨款 - 非当前
|
| | | | 30,053,517 | | | | | | 20,826,966 | | | | | | 2,933,458 | | |
非流动负债合计
|
| | | | 294,586,777 | | | | | | 315,222,809 | | | | | | 44,398,829 | | |
总负债
|
| | | | 770,500,937 | | | | | | 890,561,645 | | | | | | 125,434,750 | | |
夹层股权 | | | | | | | | | | | | | | | | | | | |
A系列和A-1系列可赎回可转换优先股(每股面值0.000005美元,授权50,000,000股;已发行和已发行21,548,589股)
|
| | | | 458,074,468 | | | | | | 551,004,725 | | | | | | 77,608,485 | | |
B系列可赎回可转换优先股(每股面值0.000005美元
股份,授权发行100,000,000股;已发行65,414,858股, 未完成) |
| | | | 912,146,924 | | | | | | 1,057,557,002 | | | | | | 148,955,886 | | |
夹层总股本
|
| | | | 1,370,221,392 | | | | | | 1,608,561,727 | | | | | | 226,564,371 | | |
承付款和或有事项
|
| | | | — | | | | | | — | | | | | | — | | |
股东亏损 | | | | | | | | | | | | | | | | | | | |
普通股,每股票面价值0.000005美元,99.5亿股
截至3月31日,已发行和已发行股票247,311,533股 截至2022年9月30日,已发行和已发行股票246,736,533股 2022.* |
| | | | 7,978 | | | | | | 7,978 | | | | | | 1,124 | | |
新增实收资本
|
| | | | 808,502,018 | | | | | | 808,648,509 | | | | | | 113,897,365 | | |
累计亏损
|
| | | | (1,590,567,163) | | | | | | (1,673,775,766) | | | | | | (235,749,706) | | |
累计其他综合收益(亏损)
|
| | | | 83,087,979 | | | | | | (85,565,973) | | | | | | (12,051,884) | | |
股东亏损总额
|
| | | | (698,969,188) | | | | | | (950,685,252) | | | | | | (133,903,101) | | |
总负债、夹层权益和股东亏损
|
| | | | 1,441,753,141 | | | | | | 1,548,438,120 | | | | | $ | 218,096,020 | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
收入 | | | | | 269,433,426 | | | | | | 399,534,723 | | | | | $ | 56,274,081 | | |
收入成本
|
| | | | 63,599,621 | | | | | | 93,700,779 | | | | | | 13,197,665 | | |
毛利
|
| | | | 205,833,805 | | | | | | 305,833,944 | | | | | | 43,076,416 | | |
运营费用: | | | | | | | | | | | | | | | | | | | |
销售
|
| | | | 86,265,281 | | | | | | 150,228,079 | | | | | | 21,159,480 | | |
一般和行政
|
| | | | 51,664,591 | | | | | | 49,587,013 | | | | | | 6,984,283 | | |
研发
|
| | | | 124,051,209 | | | | | | 123,861,107 | | | | | | 17,445,718 | | |
总运营费用
|
| | | | 261,981,081 | | | | | | 323,676,199 | | | | | | 45,589,481 | | |
运营亏损
|
| | | | (56,147,276) | | | | | | (17,842,255) | | | | | | (2,513,065) | | |
其他收入(费用): | | | | | | | | | | | | | | | | | | | |
与所得税以外的其他税有关的滞纳金
|
| | | | (112,420) | | | | | | — | | | | | | — | | |
社保相关滞纳金
|
| | | | (1,396,221) | | | | | | (299,417) | | | | | | (42,173) | | |
政府拨款
|
| | | | 19,600,822 | | | | | | 22,456,691 | | | | | | 3,163,003 | | |
财务费用,净额
|
| | | | (352,694) | | | | | | (14,949,434) | | | | | | (2,105,613) | | |
其他(费用)收入,净额
|
| | | | (993,957) | | | | | | 74,675 | | | | | | 10,518 | | |
其他收入总额,净额
|
| | | | 16,745,530 | | | | | | 7,282,515 | | | | | | 1,025,735 | | |
所得税前亏损
|
| | | | (39,401,746) | | | | | | (10,559,740) | | | | | | (1,487,330) | | |
所得税费用
|
| | | | (5,689,586) | | | | | | (565,625) | | | | | | (79,668) | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | | (1,566,998) | | |
增加可转换可赎回优先股的赎回价值
|
| | | | (65,013,751) | | | | | | (72,083,238) | | | | | | (10,152,855) | | |
易升生物股份有限公司净亏损
|
| | | | (110,105,083) | | | | | | (83,208,603) | | | | | $ | (11,719,853) | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | $ | (1,566,998) | | |
其他综合收益(亏损):外币折算收益(亏损)
|
| | | | 11,321,167 | | | | | | (168,653,952) | | | | | | (23,754,747) | | |
全面亏损
|
| | | | (33,770,165) | | | | | | (179,779,317) | | | | | $ | (25,321,745) | | |
每股亏损*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | (0.18) | | | | | | (0.05) | | | | | $ | (0.01) | | |
已发行普通股加权平均数*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | 247,311,533 | | | | | | 247,141,861 | | | | | | 247,141,861 | | |
| | |
普通股*
|
| |
额外的
实收 大写 |
| |
赤字
|
| |
累计
其他 全面 收入(亏损) |
| |
合计
股东的 赤字 |
| |||||||||||||||||||||
| | |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||
| | | | | | | | |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |||||||||||||||
截至2022年3月31日的余额
|
| | | | 247,311,533 | | | | | | 7,978 | | | | | | 808,502,018 | | | | | | (1,590,567,163) | | | | | | 83,087,979 | | | | | | (698,969,188) | | |
增加可转换债券的赎回价值
可赎回优先股 |
| | | | — | | | | | | — | | | | | | — | | | | | | (72,083,238) | | | | | | — | | | | |
|
(72,083,238)
|
| |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | (11,125,365) | | | | | | — | | | | |
|
(11,125,365)
|
| |
基于股份的薪酬
|
| | | | (575,000) | | | | | | — | | | | | | (85,316) | | | | | | — | | | | | | — | | | | |
|
(85,316)
|
| |
外币折算调整
|
| | | | — | | | | | | — | | | | | | 231,807 | | | | | | — | | | | | | (168,653,952) | | | | |
|
(168,422,145)
|
| |
截至2022年9月30日的余额(以人民币计)(未经审计)
|
| | | | 246,736,533 | | | | | | 7,978 | | | | | | 808,648,509 | | | | | | (1,673,775,766) | | | | | | (85,565,973) | | | | | | (950,685,252) | | |
截至2022年9月30日的余额(单位:美元)(未经审计)
|
| | | | 246,736,533 | | | | | | 1,124 | | | | | | 113,897,365 | | | | | | (235,749,706) | | | | | | (12,051,884) | | | | | | (133,903,101) | | |
| | |
普通股*
|
| |
额外的
实收 大写 |
| |
赤字
|
| |
累计
其他 全面 收入 |
| |
合计
股东的 赤字 |
| |||||||||||||||||||||
| | |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||
| | | | | | | | |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |
(人民币)
|
| |||||||||||||||
截至2021年3月31日的余额
|
| | | | 247,311,533 | | | | | | 7,978 | | | | | | 800,806,378 | | | | | | (1,353,900,436) | | | | | | 44,223,373 | | | | | | (508,862,707) | | |
增加可转换债券的赎回价值
可赎回优先股 |
| | | | — | | | | | | — | | | | | | — | | | | | | (65,013,751) | | | | | | — | | | | |
|
(65,013,751)
|
| |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | (45,091,332) | | | | | | — | | | | |
|
(45,091,332)
|
| |
基于股份的薪酬
|
| | | | — | | | | | | — | | | | | | 3,128,741 | | | | | | — | | | | | | — | | | | |
|
3,128,741
|
| |
外币折算调整
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 11,321,167 | | | | |
|
11,321,167
|
| |
截至2021年9月30日的余额(单位:人民币)
(未经审计) |
| | | | 247,311,533 | | | | | | 7,978 | | | | | | 803,935,119 | | | | | | (1,464,005,519) | | | | | | 55,544,540 | | | | | | (604,517,882) | | |
截至2021年9月30日的余额(单位:美元)(未经审计)
|
| | | | 247,311,533 | | | | | | 1,124 | | | | | | 113,233,488 | | | | | | (206,203,769) | | | | | | 7,823,395 | | | | | | (85,145,762) | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
经营活动现金流: | | | | | | | | | | | | | | | | | | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | $ | (1,566,997) | | |
将净亏损与经营活动中使用的现金净额进行调整:
|
| | | | | | | | | | | | | | | | | | |
递延所得税
|
| | | | 5,689,586 | | | | | | 565,625 | | | | | | 79,668 | | |
财产、厂房和设备折旧
|
| | | | 11,560,041 | | | | | | 13,818,386 | | | | | | 1,946,306 | | |
无形资产摊销
|
| | | | 3,326,419 | | | | | | 3,409,643 | | | | | | 480,245 | | |
处置财产、厂房和设备的损失
|
| | | | 238,279 | | | | | | 64,179 | | | | | | 9,040 | | |
基于股份的薪酬
|
| | | | 3,128,741 | | | | | | (85,316) | | | | | | (12,017) | | |
应收账款减值
|
| | | | 2,888,417 | | | | | | 6,447,109 | | | | | | 908,069 | | |
非现金租赁费用
|
| | | | 1,805,910 | | | | | | 2,409,286 | | | | | | 339,346 | | |
经营性资产和负债变动: | | | | | | | | | | | | | | | | | | | |
库存
|
| | | | (40,481,983) | | | | | | 4,838,379 | | | | | | 681,481 | | |
应收账款
|
| | | | (96,243,492) | | | | | | (166,251,393) | | | | | | (23,416,349) | | |
关联方应付金额
|
| | | | 30,088,833 | | | | | | | | | | | | | | |
预付费用和其他流动资产
|
| | | | (31,314,821) | | | | | | 4,102,924 | | | | | | 577,893 | | |
应付账款
|
| | | | 16,697,346 | | | | | | 6,583,078 | | | | | | 927,220 | | |
应计费用和其他负债
|
| | | | (37,906,402) | | | | | | 37,289,942 | | | | | | 5,252,252 | | |
延期政府拨款
|
| | | | 491,177 | | | | | | (8,026,551) | | | | | | (1,130,532) | | |
经营性租赁负债
|
| | | | (1,861,093) | | | | | | (1,435,079) | | | | | | (202,129) | | |
经营活动中使用的净现金
|
| | | | (176,984,374) | | | | | | (107,395,153) | | | | | | (15,126,504) | | |
投资活动现金流: | | | | | | | | | | | | | | | | | | | |
处置财产、厂房和设备所得收益
|
| | | | 8,000 | | | | | | — | | | | | | — | | |
购置房产、厂房和设备
|
| | | | (202,828,177) | | | | | | (15,017,753) | | | | | | (2,115,236) | | |
购买无形资产
|
| | | | (570,200) | | | | | | (4,006,598) | | | | | | (564,325) | | |
投资活动中使用的净现金
|
| | | | (203,390,377) | | | | | | (19,024,351) | | | | | | (2,679,561) | | |
融资活动的现金流: | | | | | | | | | | | | | | | | | | | |
银行贷款和其他借款的收益
|
| | | | 92,719,786 | | | | | | 102,513,927 | | | | | | 14,438,988 | | |
偿还银行和其他借款
|
| | | | (48,833,921) | | | | | | (50,606,602) | | | | | | (7,127,891) | | |
融资活动提供的现金净额
|
| | | | 43,885,865 | | | | | | 51,907,325 | | | | | | 7,311,097 | | |
汇率对现金的影响
|
| | | | (4,446,301) | | | | | | 30,471,942 | | | | | | 4,291,943 | | |
现金和受限现金净减少
|
| | | | (340,935,187) | | | | | | (44,040,237) | | | | | | (6,203,025) | | |
期初现金和受限现金
|
| | | | 390,457,084 | | | | | | 271,067,503 | | | | | | 38,179,597 | | |
期末现金和受限现金
|
| | | | 49,521,897 | | | | | | 227,027,266 | | | | | $ | 31,976,572 | | |
现金和受限现金对账 | | | | | | | | | | | | | | | | | | | |
现金
|
| | | | 49,521,897 | | | | | | 226,765,500 | | | | | | 31,939,703 | | |
受限现金
|
| | | | — | | | | | | 261,766 | | | | | | 36,869 | | |
现金流量表中显示的现金总额和限制性现金
|
| | | | 49,521,897 | | | | | | 227,027,266 | | | | | | 31,976,572 | | |
现金流量信息补充披露: | | | | | | | | | | | | | | | | | | | |
已支付利息
|
| | | | 402,617 | | | | | | 12,723,051 | | | | | $ | 1,792,030 | | |
非现金交易: | | | | | | | | | | | | | | | | | | | |
增加可转换可赎回优先股的赎回价值
|
| | | | 65,013,751 | | | | | | 72,083,238 | | | | | $ | 10,152,855 | | |
|
‘法人实体
|
| |
业务性质
|
| |
注册日期
|
| |
公司注册地
|
|
|
益生生物股份有限公司
(“YS Biophma”) |
| | 控股公司 | | |
2020年11月16日
|
| | 开曼群岛 | |
|
亿盛生物(香港)控股有限公司
(“香港益生生物”) |
| | 控股公司 | | |
2020年12月28日
|
| | 香港 | |
| [br]益生生物(新加坡)有限公司有限公司
(“新加坡益生”)* |
| | 疫苗和治疗性生物制品的研究和开发 | | |
2009年11月28日
|
| | 新加坡 | |
|
益生美国生物制药有限公司
(“美国益生”) |
| | 疫苗和治疗性生物制品的研究 | | |
2009年9月29日
|
| | 美国 | |
|
海景生物科学收购有限公司
(“海景生物科学”) |
| | 用于收购 | | | 2022年8月17日 | | | 开曼群岛 | |
|
哈德逊生物医药集团有限公司
(“哈德逊生物医学”) |
| | 用于收购 | | | 2022年8月17日 | | | 开曼群岛 | |
|
辽宁益生生物制药有限公司
(“辽宁益生”)** |
| | 疫苗和治疗性生物制品的研发、制造和商业化 | | | 1994年5月26日 | | | 中华人民共和国 | |
|
北京益生生物科技有限公司
(“北京益生”) |
| | 疫苗和治疗性生物制品的研究和开发 | | | 2021年2月4日 | | | 中华人民共和国 | |
| | |
2022年9月30日
|
| |
2022年3月31日
|
| |
截至6个月的时间
9月30日 |
| |||||||||||||||
| | |
2022
|
| |
2021
|
| ||||||||||||||||||
外币
|
| |
资产负债表
|
| |
资产负债表
|
| |
损益
|
| |
损益
|
| ||||||||||||
人民币:1$
|
| | | | 7.0998 | | | | | | 6.3482 | | | | | | 6.7240 | | | | | | 6.5284 | | |
人民币:1美元
|
| | | | 4.9717 | | | | | | 4.6932 | | | | | | 4.8325 | | | | | | 4.8200 | | |
类别
|
| |
预计使用寿命
|
|
厂房和建筑 | | | 6 - 20年 | |
机械设备 | | | 5年 - 10年 | |
家具和固定装置 | | | 3年 - 7年 | |
机动车辆 | | | 4 - 5年 | |
租赁改进 | | | 资产的租赁期限或寿命较短 | |
| | |
截至2022年9月30日的六个月
|
| |||||||||||||||
| | |
(人民币)
|
| |
($)
|
| | | | | | | ||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | ||||||
供应商A
|
| | | | 21,661,500 | | | | | $ | 3,051,001 | | | | | | 38.8% | | |
供应商B
|
| | | | 10,053,600 | | | | | | 1,416,040 | | | | | | 18.0% | | |
供应商C
|
| | | | 3,005,828 | | | | | | 423,368 | | | | | | 5.4% | | |
供应商D
|
| | | | 2,009,315 | | | | | | 283,010 | | | | | | 3.6% | | |
供应商I
|
| | | | 1,859,500 | | | | | | 261,909 | | | | | | 3.3% | | |
合计 | | | | | 38,589,743 | | | | | $ | 5,435,328 | | | | | | 69.1% | | |
| | |
截至2021年9月30日的六个月
|
| |||||||||||||||
| | |
(人民币)
|
| |
($)
|
| | | | | | | ||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | ||||||
供应商A
|
| | | | 11,283,000 | | | | | $ | 1,589,200 | | | | | | 12.5% | | |
供应商F
|
| | | | 9,028,170 | | | | | | 1,271,609 | | | | | | 10.0% | | |
供应商D
|
| | | | 6,689,566 | | | | | | 942,219 | | | | | | 7.4% | | |
供应商G
|
| | | | 6,063,000 | | | | | | 853,968 | | | | | | 6.7% | | |
供应商H
|
| | | | 5,460,000 | | | | | | 769,036 | | | | | | 6.1% | | |
合计 | | | | | 38,523,736 | | | | | $ | 5,426,032 | | | | | | 42.7% | | |
| | |
计价的
币种 |
| |
2022年3月31日
|
| |
2022年9月30日
|
| ||||||||||||||||||||||||
| | |
(人民币)
|
| | | | | | | |
(人民币)
|
| |
(美元)
|
| | | | | | | ||||||||||||
| | | | | | | | | | | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | ||||||
中华人民共和国
|
| |
人民币
|
| | | | 1,155,124,790 | | | | | | 80% | | | | | | 1,316,093,351 | | | | | $ | 185,370,484 | | | | | | 85% | | |
香港
|
| |
$
|
| | | | 2,666,762 | | | | | | 0% | | | | | | 194,452,627 | | | | | | 27,388,465 | | | | | | 13% | | |
新加坡
|
| |
S$
|
| | | | 26,168,621 | | | | | | 2% | | | | | | 29,843,991 | | | | | | 4,203,497 | | | | | | 2% | | |
美国
|
| |
$
|
| | | | 5,181,433 | | | | | | 0% | | | | | | 4,104,976 | | | | | | 578,182 | | | | | | 0% | | |
开曼群岛
|
| |
$
|
| | | | 252,611,535 | | | | | | 18% | | | | | | 3,943,175 | | | | | | 555,392 | | | | | | 0% | | |
合计 | | | | | | | | 1,441,753,141 | | | | | | 100% | | | | | | 1,548,438,120 | | | | | $ | 218,096,020 | | | | | | 100% | | |
| | |
3月31日
2022 |
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
(美元)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
贸易应收账款
|
| | | | 322,170,980 | | | | | | 488,422,373 | | | | | $ | 68,793,821 | | |
坏账准备
|
| | | | (13,615,875) | | | | | | (20,062,985) | | | | | | (2,825,852) | | |
应收账款净额
|
| | | | 308,555,105 | | | | | | 468,359,388 | | | | | $ | 65,967,969 | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
4月1日的余额
|
| | | | 8,530,951 | | | | | | 13,615,875 | | | | | $ | 1,917,783 | | |
添加内容
|
| | | | 2,888,417 | | | | | | 6,447,110 | | | | | | 908,069 | | |
9月30日余额
|
| | | | 11,419,368 | | | | | | 20,062,985 | | | | | $ | 2,825,852 | | |
| | |
3月31日
2022 |
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
原材料
|
| | | | 57,926,980 | | | | | | 52,392,648 | | | | | $ | 7,379,454 | | |
正在进行的工作
|
| | | | 40,795,744 | | | | | | 39,148,872 | | | | | | 5,514,081 | | |
成品
|
| | | | 73,285,870 | | | | | | 71,235,067 | | | | | | 10,033,391 | | |
对移动缓慢或陈旧的库存进行备抵
|
| | | | (5,503,029) | | | | | | (1,109,400) | | | | | | (156,258) | | |
库存,净额
|
| | | | 166,505,565 | | | | | | 161,667,187 | | | | | $ | 22,770,668 | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
4月1日的余额
|
| | | | 41,301,797 | | | | | | 5,503,029 | | | | | $ | 775,096 | | |
存货已核销
|
| | | | (40,192,397) | | | | | | (4,393,629) | | | | | | (618,838) | | |
9月30日余额
|
| | | | 1,109,400 | | | | | | 1,109,400 | | | | | $ | 156,258 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
成本
|
| | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
施工中
|
| | | | 318,000,074 | | | | | | 333,446,243 | | | | | $ | 46,965,583 | | |
厂房和建筑物
|
| | | | 170,206,987 | | | | | | 183,372,813 | | | | | | 25,827,884 | | |
机械设备
|
| | | | 194,875,303 | | | | | | 193,846,868 | | | | | | 27,303,145 | | |
电子设备
|
| | | | 10,107,578 | | | | | | 10,794,907 | | | | | | 1,520,452 | | |
机动车辆
|
| | | | 2,978,155 | | | | | | 3,027,767 | | | | | | 426,458 | | |
办公设备和家具
|
| | | | 29,888,526 | | | | | | 21,612,891 | | | | | | 3,044,155 | | |
租赁改进
|
| | | | 4,390,980 | | | | | | 4,626,927 | | | | | | 651,698 | | |
总成本
|
| | | | 730,447,603 | | | | | | 750,728,416 | | | | | | 105,739,375 | | |
减去:累计折旧
|
| | | | (150,402,597) | | | | | | (163,469,667) | | | | | | (23,024,545) | | |
减值:资产减值
|
| | | | (29,891,896) | | | | | | (29,891,896) | | | | | | (4,210,245) | | |
财产和设备,净额
|
| | | | 550,153,110 | | | | | | 557,366,853 | | | | | $ | 78,504,585 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
存款(1)
|
| | | | 2,807,847 | | | | | | 1,622,616 | | | | | $ | 228,544 | | |
员工晋升(2)
|
| | | | 383,251 | | | | | | 303,767 | | | | | | 42,785 | | |
员工社保(3)
|
| | | | 615,581 | | | | | | 677,626 | | | | | | 95,443 | | |
可退还的增值税(4)
|
| | | | 3,442,733 | | | | | | 3,920,265 | | | | | | 552,166 | | |
其他应收账款(5)
|
| | | | 854,245 | | | | | | 534,169 | | | | | | 75,237 | | |
津贴(6) | | | | | (115,743) | | | | | | (115,743) | | | | | | (16,302) | | |
合计 | | | | | 7,987,914 | | | | | | 6,942,700 | | | | | $ | 977,873 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
成本 | | | | | | | | | | | | | | | | | | | |
专利
|
| | | | 79,608,000 | | | | | | 79,608,000 | | | | |
$
|
11,212,710
|
| |
许可证、软件和实验室信息系统
|
| | | | 6,143,880 | | | | | | 10,150,478 | | | | | | 1,429,685 | | |
土地使用权
|
| | | | 67,181,860 | | | | | | 67,181,860 | | | | | | 9,462,500 | | |
总成本
|
| | | | 152,933,740 | | | | | | 156,940,338 | | | | | | 22,104,895 | | |
减去:累计摊销
|
| | | | (72,215,762) | | | | | | (75,625,405) | | | | | | (10,651,765) | | |
无形资产净值
|
| | | | 80,717,978 | | | | | | 81,314,933 | | | | | $ | 11,453,130 | | |
| | |
3月31日
2022 |
| |
9月30日
2022 |
| |
9月30日
2022 |
| |
到期日
|
| |
利率
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| | | | | | | |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| | | | | | | ||||||
中国广发银行股份有限公司 - 沈阳分行(1)
|
| | | | 46,456,142 | | | | | | 35,509,492 | | | | | $ | 5,001,478 | | | | 2022/11/17 – 2022/12/16 | | |
5.66%
|
|
上海浦东发展银行股份有限公司沈阳分行(2)
|
| | | | 64,647,870 | | | | | | 81,486,261 | | | | | | 11,477,261 | | | | 2022/10/11 – 2023/09/22 | | |
5.30%
|
|
花旗银行(3)
|
| | | | 234,743 | | | | | | — | | | | | | — | | | | 2022/5/1 | | |
1.00%
|
|
R-Bridge Healthcare Fund,LP(4)
|
| | | | 394,999 | | | | | | — | | | | | | — | | | | 2026/9/15 | | |
4.00%
|
|
中国中信股份银行 - 沈阳
分支机构(5) |
| | | | — | | | | | | 34,295,325 | | | | | | 4,830,464 | | | | 2023/3/16 – 2023/5/19 | | |
5.2% / 3.25%
|
|
中国建设银行沈阳 -
分支机构(6) |
| | | | — | | | | | | 12,350,000 | | | | | | 1,739,485 | | | |
2023/9/8 – 2023/9/27
|
| |
4.00%
|
|
一年内到期的银行贷款
|
| | | | 111,733,754 | | | | | | 163,641,078 | | | | | $ | 23,048,688 | | | | | | | | |
R-Bridge Healthcare Fund,LP(4)
|
| | | | 253,928,000 | | | | | | 283,992,000 | | | | | | 40,000,000 | | | | 2026/9/15 | | |
4.00%
|
|
长期银行贷款
|
| | | | 253,928,000 | | | | | | 283,992,000 | | | | | | 40,000,000 | | | | | | | | |
银行贷款总额
|
| | | | 365,661,754 | | | | | | 447,633,078 | | | | | $ | 63,048,688 | | | | | | | | |
还款日
|
| |
还款
分期付款 |
| |||
2025年4月7日
|
| | | $ | 6,400,000 | | |
2025年7月7日
|
| | | | 6,400,000 | | |
2025年10月7日
|
| | | | 6,400,000 | | |
2026年1月7日
|
| | | | 6,400,000 | | |
2026年4月7日
|
| | | | 6,400,000 | | |
2026年7月7日
|
| | | | 8,000,000 | | |
合计 | | | | $ | 40,000,000 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
经营租赁ROU资产
|
| | | | 14,850,283 | | | | | | 13,067,129 | | | | | $ | 1,840,493 | | |
经营租赁负债 - 流动
|
| | | | 4,322,252 | | | | | | 3,524,558 | | | | | | 496,431 | | |
经营性租赁负债 - 非流动
|
| | | | 10,605,260 | | | | | | 10,403,843 | | | | | $ | 1,465,371 | | |
加权平均剩余租期
|
| | | | 3.4 | | | | | | 3.0 | | | | | | 3.0 | | |
加权平均贴现率
|
| | | | 4.8% | | | | | | 4.8% | | | | | | 4.8% | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
运营租赁成本
|
| | | | 2,237,633 | | | | | | 2,508,388 | | | | | $ | 373,050 | | |
经营租赁支付的现金
|
| | | | 2,276,956 | | | | | | 786,888 | | | | | $ | 110,832 | | |
截至9月30日的12个月
|
| |
截至2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
($)
|
| ||||||
2023
|
| | | | 5,748,070 | | | | | $ | 809,610 | | |
2024
|
| | | | 5,029,426 | | | | | | 708,390 | | |
2025
|
| | | | 3,921,138 | | | | | | 552,289 | | |
2026
|
| | | | 158,029 | | | | | | 22,257 | | |
租赁支付总额
|
| | | | 14,856,663 | | | | | | 2,092,546 | | |
少:利息
|
| | | | (928,262) | | | | | | (130,744) | | |
经营租赁负债现值
|
| | |
|
13,928,401
|
| | | | $ | 1,961,802 | | |
经营租赁负债 - 流动
|
| | | | 3,524,558 | | | | | | 496,431 | | |
经营性租赁负债 - 非流动
|
| | | | 10,403,843 | | | | | $ | 1,465,371 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
应付工资和社会保险(1)
|
| | | | 57,459,273 | | | | | | 55,943,773 | | | | | $ | 7,879,627 | | |
促销服务费(2)
|
| | | | 64,883,477 | | | | | | 93,688,809 | | | | | | 13,195,979 | | |
所得税以外的税
|
| | | | 1,171,381 | | | | | | 3,005,157 | | | | | | 423,273 | | |
滞纳金(3)
|
| | | | 9,499,595 | | | | | | 9,685,430 | | | | | | 1,364,183 | | |
物业、厂房和设备的应付费用
|
| | | | 48,774,134 | | | | | | 49,128,153 | | | | | | 6,919,653 | | |
疾控中心运存费用
|
| | | | 35,023,095 | | | | | | 48,656,533 | | | | | | 6,853,226 | | |
保证金(4)
|
| | | | 94,528,659 | | | | | | 94,733,524 | | | | | | 13,343,126 | | |
专业服务费(5)
|
| | | | 7,758,448 | | | | | | 2,226,221 | | | | | | 313,561 | | |
其他应付(6)
|
| | | | 7,653,291 | | | | | | 10,215,721 | | | | | | 1,438,874 | | |
合计 | | | | | 326,751,353 | | | | | | 367,283,321 | | | | | $ | 51,731,502 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
工资
|
| | | | 49,020,045 | | | | | | 47,732,121 | | | | | $ | 6,723,023 | | |
社会保障保险
|
| | | | 7,732,161 | | | | | | 7,535,447 | | | | | | 1,061,360 | | |
工会费
|
| | | | 707,067 | | | | | | 676,205 | | | | | | 95,244 | | |
合计 | | | | | 57,459,273 | | | | | | 55,943,773 | | | | | $ | 7,879,627 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
社会保险滞纳金
|
| | | | 9,499,595 | | | | | | 9,685,430 | | | | | | 1,364,183 | | |
合计 | | | | | 9,499,595 | | | | | | 9,685,430 | | | | | $ | 1,364,183 | | |
| | |
系列A
|
| | | | | | | |
系列A-1
|
| | | | | | | |
系列B
|
| |
合计
|
| |
合计
|
| |||||||||||||||||||||
| | |
个共享
|
| |
携带
值 |
| |
个共享
|
| |
携带
值 |
| |
个共享
|
| |
携带
值 |
| |
携带
值 |
| |
携带
值 |
| ||||||||||||||||||||||||
| | | | | | | | |
(人民币)
|
| | | | | | | |
(人民币)
|
| | | | | | | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||||||||
截至2021年3月31日
|
| | | | 15,534,276 | | | | | | 344,661,893 | | | | | | 6,014,313 | | | | | | 65,665,315 | | | | | | 65,414,858 | | | | | | 875,131,363 | | | | | | 1,285,458,571 | | | | | $ | 181,055,603 | | |
增加到赎回价值
|
| | | | — | | | | | | 28,042,858 | | | | | | — | | | | | | 2,566,412 | | | | | | — | | | | | | 34,404,481 | | | | |
|
65,013,751
|
| | | |
|
9,157,124
|
| |
外币折算
调整 |
| | | | — | | | | | | (4,690,126) | | | | | | — | | | | | | (875,280) | | | | | | — | | | | | | (11,666,321) | | | | |
|
(17,231,727)
|
| | | |
|
(2,427,072)
|
| |
截至2021年9月30日
|
| | | | 15,534,276 | | | | | | 368,014,625 | | | | | | 6,014,313 | | | | | | 67,356,447 | | | | | | 65,414,858 | | | | | | 897,869,523 | | | | | | 1,333,240,595 | | | | | $ | 187,785,655 | | |
截至2022年3月31日
|
| | | | 15,534,276 | | | | | | 389,563,659 | | | | | | 6,014,313 | | | | | | 68,510,809 | | | | | | 65,414,858 | | | | | | 912,146,924 | | | | | | 1,370,221,392 | | | | | $ | 192,994,365 | | |
增加到赎回价值
|
| | | | — | | | | | | 33,793,180 | | | | | | — | | | | | | 2,854,770 | | | | | | — | | | | | | 35,435,288 | | | | |
|
72,083,238
|
| | | |
|
10,152,855
|
| |
外币折算
调整 |
| | | | — | | | | | | 48,011,366 | | | | | | — | | | | | | 8,270,941 | | | | | | — | | | | | | 109,974,790 | | | | |
|
166,257,097
|
| | | |
|
23,417,151
|
| |
截至2022年9月30日
|
| | | | 15,534,276 | | | | | | 471,368,205 | | | | | | 6,014,313 | | | | | | 79,636,520 | | | | | | 65,414,858 | | | | | | 1,057,557,002 | | | | | | 1,608,561,727 | | | | | $ | 226,564,371 | | |
| | |
共享数量
选项 |
| |
平均运动量
每股价格 选项 |
| ||||||
| | | | | | | | |
(人民币)
|
| |||
2021年3月31日
|
| | | | 13,013,422 | | | | | | 7.3289 | | |
在此期间发放的许可证
|
| | | | — | | | | | | — | | |
在此期间被没收
|
| | | | — | | | | | | — | | |
在此期间进行锻炼
|
| | | | — | | | | | | — | | |
在此期间过期
|
| | | | — | | | | | | — | | |
2022年3月31日
|
| | | | 13,013,422 | | | | | | 7.3289 | | |
在此期间发放的许可证
|
| | | | — | | | | | | — | | |
在此期间被没收
|
| | | | — | | | | | | — | | |
在此期间进行锻炼
|
| | | | — | | | | | | — | | |
在此期间过期
|
| | | | — | | | | | | — | | |
2022年9月30日
|
| | | | 13,013,422 | | | | | | 7.3289 | | |
截至6个月的时间
2022年9月30日 数量: 选项 |
| |
行权价
|
| |
锻炼周期
|
|
| | |
(人民币)
|
| | | |
6,133,005
|
| |
3.4845
|
| |
2021 – 2031
|
|
2,453,049
|
| |
6.4631
|
| |
2021 – 2026
|
|
4,427,368
|
| |
13.1344
|
| |
2021 – 2026
|
|
13,013,422
|
| | | | | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
研发费用
|
| | | | 492,764 | | | | | | (1,015,055) | | | | | $ | (142,970) | | |
一般和行政费用
|
| | | | 2,635,978 | | | | | | 929,739 | | | | | | 130,953 | | |
股票薪酬总额
|
| | | | 3,128,742 | | | | | | (85,316) | | | | | $ | (12,017) | | |
关联方名称
|
| |
与YS集团的关系
|
|
益生生物医药有限公司 | | |
张控制的实体
|
|
益生生物医药控股有限公司 | | |
张控制的实体
|
|
北京亿盛兴业科技有限公司 | | |
张控制的实体
|
|
| | |
截至9月30日的六个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
关联方应付金额: | | | | | | | | | | | | | | | | | | | |
益生生物医药控股(香港)有限公司 | | | | | | | | | | | | | | | | | | | |
YS集团代收应收账款
|
| | | | 2,966,777 | | | | | | — | | | | | $ | — | | |
还款给YS集团
|
| | | | 33,055,610 | | | | | | — | | | | | $ | — | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
当期所得税
|
| | | | — | | | | | | — | | | | | $ | — | | |
递延税金
|
| | | | 5,689,586 | | | | | | 565,625 | | | | | | 79,668 | | |
所得税
|
| | | | 5,689,586 | | | | | | 565,625 | | | | | $ | 79,668 | | |
| | |
截至9月30日的六个月
|
| |||||||||
| | |
2021
|
| |
2022
|
| ||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
中华人民共和国法定所得税率
|
| | | | 25.00% | | | | | | 25.00% | | |
不同司法管辖区不同税率的影响
|
| | | | (26.82)% | | | | | | (182.62)% | | |
中华人民共和国优惠税率的效果
|
| | | | 11.98% | | | | | | (100.49)% | | |
研发费用扣除等影响
|
| | | | 30.97% | | | | | | 80.56% | | |
暂时性差异*
|
| | | | 13.42% | | | | | | 5.03% | | |
估值免税额变动
|
| | | | (41.02)% | | | | | | 177.88% | | |
实际税率
|
| | | | 13.53% | | | | | | 5.36% | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
递延税金资产: | | | | | | | | | | | | | | | | | | | |
将存货减记为可变现净值
|
| | | | 825,454 | | | | | | 166,410 | | | | | $ | 23,439 | | |
财产、厂房和建筑物减值
|
| | | | 2,031,460 | | | | | | 1,900,433 | | | | | | 267,674 | | |
延期政府拨款
|
| | | | 4,852,383 | | | | | | 4,680,205 | | | | | | 659,202 | | |
可用于抵销未来应税利润的亏损
|
| | | | 58,257,270 | | | | | | 47,805,830 | | | | | | 6,733,405 | | |
减去:估值免税额
|
| | | | (58,257,270) | | | | | | (47,805,830) | | | | | | (6,733,405) | | |
递延税金资产总额,净额
|
| | | | 7,709,297 | | | | | | 6,747,048 | | | | | | 950,315 | | |
递延纳税义务: | | | | | | | | | | | | | | | | | | | |
因历史收购子公司而产生的公允价值调整
|
| | | | (4,670,213) | | | | | | (4,273,589) | | | | | | (601,931) | | |
递延纳税负债总额
|
| | | | (4,670,213) | | | | | | (4,273,589) | | | | | | (601,931) | | |
递延税金净资产
|
| | | | 3,039,084 | | | | | | 2,473,459 | | | | | $ | 348,384 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
政府对财产、厂房和设备的补助 | | | | | | | | | | | | | | | | | | | |
年初余额
|
| | | | 21,847,340 | | | | | | 22,030,690 | | | | | $ | 3,103,001 | | |
添加
|
| | | | 1,552,000 | | | | | | 1,200,000 | | | | | | 169,019 | | |
确认为收入
|
| | | | (1,368,650) | | | | | | (727,839) | | | | | | (102,515) | | |
小计 | | | | | 22,030,690 | | | | | | 22,502,851 | | | | | $ | 3,169,505 | | |
政府用于研发的拨款 | | | | | | | | | | | | | | | | | | | |
年初余额
|
| | | | 11,158,551 | | | | | | 10,318,528 | | | | | $ | 1,453,355 | | |
添加
|
| | | | — | | | | | | | | | | | | | | |
确认为收入
|
| | | | (840,023) | | | | | | (8,498,712) | | | | | | (1,197,036) | | |
小计 | | | | | 10,318,528 | | | | | | 1,819,816 | | | | | $ | 256,319 | | |
递延政府拨款总额
|
| | | | 32,349,218 | | | | | | 24,322,667 | | | | | $ | 3,425,824 | | |
少:当前部分
|
| | | | (2,295,701) | | | | | | (3,495,701) | | | | | | (492,366) | | |
非当前部分
|
| | | | 30,053,517 | | | | | | 20,826,966 | | | | | $ | 2,933,458 | | |
| | |
截至9月30日
|
| |||||||||
| | |
2022
|
| |
2022
|
| ||||||
| | |
(人民币)
|
| |
($)
|
| ||||||
疫苗生产设施建设
生命科学办公室 |
| | | | 1,580,000 | | | | | $ | 222,541 | | |
研发
|
| | | | 6,001,375 | | | | | | 845,288 | | |
采购原材料
|
| | | | 20,236,200 | | | | | | 2,850,249 | | |
合计 | | | | | 27,817,575 | | | | | $ | 3,918,078 | | |
| | |
2022年3月31日
|
| |
2022年9月30日
|
| |
2022年9月30日
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | | | | | | | |
(未经审计)
|
| |
(未经审计)
|
| ||||||
中华人民共和国
|
| | | | 604,094,049 | | | | | | 613,613,563 | | | | | $ | 86,426,880 | | |
其他国家/地区
|
| | | | 26,777,039 | | | | | | 25,068,223 | | | | | $ | 3,530,835 | | |
| | |
3月31日
2022 |
| |
9月30日
2022 |
| |
9月30日
2022 |
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
资产 | | | | | | | | | | | | | | | | | | | |
流动资产 | | | | | | | | | | | | | | | | | | | |
现金
|
| | | | 252,611,535 | | | | | | 3,943,175 | | | | | $ | 555,392 | | |
关联方应付金额
|
| | | | 519,236,876 | | | | | | 848,379,306 | | | | | | 119,493,409 | | |
流动资产总额
|
| | | | 771,848,411 | | | | | | 852,322,481 | | | | | | 120,048,801 | | |
非流动资产 | | | | | | | | | | | | | | | | | | | |
长期投资,净额
|
| | | | 146,641,652 | | | | | | 164,003,403 | | | | | | 23,099,722 | | |
非流动资产合计
|
| | | | 146,641,652 | | | | | | 164,003,403 | | | | | | 23,099,722 | | |
总资产
|
| | |
|
918,490,063
|
| | | |
|
1,016,325,884
|
| | | | $ | 143,148,523 | | |
负债和权益 | | | | | | | | | | | | | | | | | | | |
流动负债 | | | | | | | | | | | | | | | | | | | |
应计费用和其他负债
|
| | | | 244,082,463 | | | | | | 354,920,428 | | | | | $ | 49,990,201 | | |
应付关联方金额
|
| | | | 3,155,395 | | | | | | 3,528,981 | | | | | | 497,054 | | |
流动负债总额
|
| | | | 247,237,858 | | | | | | 358,449,409 | | | | | | 50,487,255 | | |
总负债
|
| | | | 247,237,858 | | | | | | 358,449,409 | | | | | | 50,487,255 | | |
| | | | | | | | | | | | | | | | | | | |
夹层股权 | | | | | | | | | | | | | | | | | | | |
A系列和A-1系列可赎回可转换优先股(每股面值0.000005美元,授权50,000,000股;已发行和已发行21,548,589股)
|
| | | | 458,074,468 | | | | | | 551,004,725 | | | | | | 77,608,485 | | |
B系列可赎回可转换优先股(面值
每股价值0.000005美元,100,000,000股 授权;已发行65,414,858股, 未完成) |
| | | | 912,146,924 | | | | | | 1,057,557,002 | | | | | | 148,955,886 | | |
夹层总股本
|
| | | | 1,370,221,392 | | | | | | 1,608,561,727 | | | | | | 226,564,371 | | |
股东亏损: | | | | | | | | | | | | | | | | | | | |
普通股,每股面值0.000005美元,授权股份99,50,000,000股,截至2022年3月31日已发行和已发行股票247,311,533股,截至2022年9月30日已发行和已发行股票246,736,533股
|
| | | | 7,978 | | | | | | 7,978 | | | | | | 1,124 | | |
新增实收资本
|
| | | | 808,502,018 | | | | | | 808,648,509 | | | | | | 113,897,365 | | |
累计亏损
|
| | | | (1,590,567,163) | | | | | | (1,673,775,766) | | | | | | (235,749,706) | | |
累计其他综合收益(亏损)
|
| | | | 83,087,980 | | | | | | (85,565,973) | | | | | | (12,051,886) | | |
股东亏损总额
|
| | | | (698,969,187) | | | | | | (950,685,252) | | | | | | (133,903,103) | | |
总负债、夹层权益和股东亏损
|
| | | | 918,490,063 | | | | | | 1,016,325,884 | | | | |
$
|
143,148,523
|
| |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
子公司股权损失
|
| | | | (27,562,274) | | | | | | (5,703,582) | | | | | $ | (803,346) | | |
运营费用: | | | | | | | | | | | | | | | | | | | |
销售
|
| | | | | | | | | | | | | | | | | | |
一般和行政
|
| | | | 17,037,618 | | | | | | 6,356,204 | | | | | | 895,265 | | |
研发
|
| | | | 492,764 | | | | | | (934,367) | | | | | | (131,605) | | |
总运营费用
|
| | | | 17,530,382 | | | | | | 5,421,837 | | | | | | 763,660 | | |
| | | | | | | | | | | | | | | | | | | |
运营亏损
|
| | | | (45,092,656) | | | | | | (11,125,419) | | | | | | (1,567,006) | | |
其他收入: | | | | | | | | | | | | | | | | | | | |
财务收入,净额
|
| | |
|
1,324
|
| | | |
|
54
|
| | | |
|
8
|
| |
其他收入总额,净额
|
| | | | 1,324 | | | | | | 54 | | | | | | 8 | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | | (1,566,998) | | |
增加可转换可赎回优先股的赎回价值
|
| | | | (65,013,751) | | | | | | (72,083,238) | | | | | | (10,152,855) | | |
可归因于YS Biophma的净亏损
|
| | | | (110,105,083) | | | | | | (83,208,603) | | | | | | (11,719,853) | | |
| | | | | | | | | | | | | | | | | | | |
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | | (1,566,998) | | |
伪造货币兑换收益
|
| | | | 11,321,167 | | | | | | (168,653,952) | | | | | | (23,754,747) | | |
全面亏损
|
| | | | (33,770,165) | | | | | | (179,779,317) | | | | | $ | (25,321,745) | | |
| | | | | | | | | | | | | | | | | | | |
每股亏损*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | (0.18) | | | | | | (0.04) | | | | | $ | (0.01) | | |
已发行普通股加权平均数*: | | | | | | | | | | | | | | | | | | | |
-基本版和稀释版
|
| | | | 247,311,533 | | | | | | 247,311,533 | | | | | | 247,311,533 | | |
| | | | | | | | | | | | | | | | | | | |
| | |
截至9月30日的6个月
|
| |||||||||||||||
| | |
2021
|
| |
2022
|
| |
2022
|
| |||||||||
| | |
(人民币)
|
| |
(人民币)
|
| |
($)
|
| |||||||||
| | |
(未经审计)
|
| |
(未经审计)
|
| |
(未经审计)
|
| |||||||||
净亏损
|
| | | | (45,091,332) | | | | | | (11,125,365) | | | | | $ | (1,566,998) | | |
子公司股权损失
|
| | | | 27,562,274 | | | | | | 5,703,582 | | | | | | 803,346 | | |
基于股份的薪酬
|
| | | | 3,128,741 | | | | | | (85,316) | | | | | | (12,017) | | |
经营性资产和负债变动: | | | | | | | | | | | | | | | | | | | |
关联方应付金额
|
| | | | (298,261,642) | | | | | | (328,910,623) | | | | | | (46,326,745) | | |
应付关联方金额
|
| | | | (42,697) | | | | | | 373,586 | | | | | | 52,619 | | |
应计费用和其他负债
|
| | | | (7,357,523) | | | | | | 55,467,639 | | | | | | 7,812,564 | | |
经营活动中使用的净现金
|
| | | | (320,062,179) | | | | | | (278,576,497) | | | | | | (39,237,231) | | |
汇率对现金的影响
|
| | | | (4,446,303) | | | | | | 29,908,137 | | | | | | 4,212,531 | | |
现金净减少
|
| | | | (324,508,482) | | | | | | (248,668,360) | | | | | | (35,024,700) | | |
期初现金
|
| | | | 330,296,949 | | | | | | 252,611,535 | | | | | | 35,580,092 | | |
期末现金
|
| | | | 5,788,467 | | | | | | 3,943,175 | | | | | $ | 555,392 | | |
非现金交易: | | | | | | | | | | | | | | | | | | | |
增加可转换可赎回优先股的赎回价值
|
| | | | 65,013,751 | | | | | | 72,083,238 | | | | | $ | 10,152,855 | | |
| | |
第
页
|
| |||
文章I某些定义
|
| | | | A-3 | | |
第1.1节
定义
|
| | | | A-3 | | |
第1.2节
施工
|
| | | | A-15 | | |
第二条交易;关闭
|
| | | | A-16 | | |
第2.1节
关闭前操作。
|
| | | | A-16 | | |
第2.2节
合并。
|
| | | | A-17 | | |
第2.3节
正在关闭。
|
| | | | A-20 | | |
第2.4节
注销SPAC股权证券并支付合并对价。
|
| | |
|
A-21
|
| |
第2.5节
进一步保证
|
| | | | A-22 | | |
第2.6节
持不同政见者权利
|
| | | | A-22 | | |
第2.7节
代扣代缴
|
| | | | A-23 | | |
第三条公司的陈述和保证
|
| | | | A-23 | | |
第3.1节
组织、信誉和资质
|
| | | | A-23 | | |
第3.2节
子公司
|
| | | | A-24 | | |
第3.3节
公司市值
|
| | | | A-24 | | |
第3.4节
子公司的资本化。
|
| | | | A-25 | | |
第3.5节
授权。
|
| | | | A-25 | | |
第3.6节
同意;无冲突
|
| | | | A-26 | | |
第3.7节
遵守法律;同意;许可
|
| | | | A-26 | | |
第3.8节
税务事宜。
|
| | | | A-28 | | |
第3.9节
财务报表。
|
| | | | A-29 | | |
第3.10节
没有更改
|
| | | | A-29 | | |
第3.11节
操作
|
| | | | A-29 | | |
第3.12节
负债
|
| | | | A-30 | | |
第3.13节
重要合同和承诺。
|
| | | | A-30 | | |
第3.14节
标题;属性。
|
| | | | A-30 | | |
第3.15节
知识产权。
|
| | | | A-31 | | |
第3.16节
劳工和员工问题。
|
| | | | A-32 | | |
第3.17节
经纪人
|
| | | | A-34 | | |
第3.18节
环境问题
|
| | | | A-34 | | |
第3.19节
保险
|
| | | | A-34 | | |
第3.20节
公司关联方
|
| | | | A-34 | | |
第3.21节
代理/注册声明
|
| | | | A-34 | | |
第3.22节
外国私人发行商
|
| | | | A-34 | | |
第3.23节
没有额外的陈述或保修
|
| | | | A-34 | | |
第四条SPAC的陈述和保证
|
| | | | A-34 | | |
第4.1节
组织、信誉、企业实力和资质
|
| | | | A-35 | | |
第4.2节
大写和投票权。
|
| | | | A-35 | | |
第4.3节
公司结构;子公司
|
| | | | A-36 | | |
第4.4节
授权。
|
| | | | A-36 | | |
| | |
第
页
|
| |||
第4.5节
同意;无冲突
|
| | | | A-37 | | |
第4.6节
税务事宜。
|
| | | | A-37 | | |
第4.7节
财务报表。
|
| | | | A-38 | | |
第4.8节
没有更改
|
| | | | A-39 | | |
第4.9节
操作
|
| | | | A-39 | | |
第4.10节
经纪人
|
| | | | A-39 | | |
第4.11节
代理/注册声明
|
| | | | A-39 | | |
第4.12节
美国证券交易委员会备案文件
|
| | | | A-39 | | |
第4.13节
信托帐户
|
| | | | A-39 | | |
第4.14节
投资公司法;就业法案
|
| | | | A-40 | | |
第4.15节
业务活动
|
| | | | A-40 | | |
第4.16节
纳斯达克报价
|
| | | | A-41 | | |
第4.17节
远期购买订阅。
|
| | | | A-41 | | |
第4.18节
SPAC相关方
|
| | | | A-41 | | |
第4.19节
无外部依赖
|
| | | | A-41 | | |
第五条合并子公司的陈述和担保
|
| | | | A-42 | | |
第5.1节
组织、信誉、企业实力和资质
|
| | | | A-42 | | |
第5.2节
大写和投票权。
|
| | | | A-42 | | |
第5.3节
公司结构;子公司
|
| | | | A-42 | | |
第5.4节
授权
|
| | | | A-43 | | |
第5.5节
同意;无冲突
|
| | | | A-43 | | |
第5.6节
没有更改
|
| | | | A-43 | | |
第5.7节
操作
|
| | | | A-43 | | |
第5.8节
经纪人
|
| | | | A-43 | | |
第5.9节
代理/注册声明
|
| | | | A-43 | | |
第5.10节
业务活动
|
| | | | A-44 | | |
第5.11节
税种
|
| | | | A-44 | | |
第5.12节
无外部依赖
|
| | | | A-44 | | |
公司与某些其他方的第六条契约
|
| | | | A-44 | | |
第6.1节
开展业务
|
| | | | A-44 | | |
第6.2节
信息访问
|
| | | | A-46 | | |
第6.3节
收购建议和替代交易
|
| | | | A-47 | | |
第6.4节
D&O赔偿和保险。
|
| | | | A-47 | | |
第6.5节
开发通知
|
| | | | A-48 | | |
第6.6节
财务。
|
| | | | A-49 | | |
第6.7节
禁止交易
|
| | | | A-49 | | |
第6.8节
纳斯达克上市
|
| | | | A-49 | | |
第6.9节
公司激励计划
|
| | | | A-49 | | |
第6.10节
公司收盘后董事及高级管理人员
|
| | | | A-49 | | |
第6.11节
公开备案
|
| | | | A-50 | | |
第6.12节
更改名称。
|
| | | | A-50 | | |
| | |
第
页
|
| |||
SPAC和合并子公司第七条公约
|
| | | | A-50 | | |
第7.1节
纳斯达克上市
|
| | | | A-50 | | |
第7.2节
开展业务
|
| | | | A-50 | | |
第7.3节
收购建议和替代交易
|
| | | | A-51 | | |
第7.4节
空间的公开备案文件
|
| | | | A-51 | | |
第7.5节
信息访问
|
| | | | A-51 | | |
第八条联合公约
|
| | | | A-52 | | |
第8.1节
监管审批;其他备案。
|
| | | | A-52 | | |
第8.2节
代理/注册声明的准备;SPAC股东大会和批准。
|
| | |
|
A-53
|
| |
第8.3节
交易支持
|
| | | | A-55 | | |
第8.4节
税务问题
|
| | | | A-55 | | |
第8.5节
股东诉讼
|
| | | | A-56 | | |
第8.6节
远期认购订阅
|
| | | | A-56 | | |
第8.7节
使用剩余信托基金收益
|
| | | | A-57 | | |
第九条义务的条件62
|
| | | | A-57 | | |
第9.1节
SPAC、合并子公司和公司的义务条件
|
| | | | A-57 | | |
第9.2节
关闭时SPAC义务的条件
|
| | | | A-58 | | |
第9.3节
公司和合并子公司在交易完成时的义务条件
|
| | | | A-58 | | |
第9.4节
条件的挫折
|
| | | | A-59 | | |
第X条终止/生效
|
| | | | A-59 | | |
第10.1节
终止
|
| | | | A-59 | | |
第10.2节
终止影响
|
| | | | A-60 | | |
第十一条其他
|
| | | | A-60 | | |
第11.1节
信托账户豁免
|
| | | | A-60 | | |
第11.2节
弃权
|
| | | | A-61 | | |
第11.3节
通知
|
| | | | A-61 | | |
第11.4节
作业
|
| | | | A-61 | | |
第11.5节
第三方权利
|
| | | | A-62 | | |
第11.6节
费用
|
| | | | A-62 | | |
第11.7节
治国理政
|
| | | | A-62 | | |
第11.8节
同意司法管辖权;陪审团放弃审判
|
| | | | A-62 | | |
第11.9节
标题;对应项
|
| | | | A-63 | | |
第11.10节
公开信
|
| | | | A-63 | | |
第11.11节
完整协议
|
| | | | A-63 | | |
第11.12节
修改
|
| | | | A-63 | | |
第11.13节
宣传。
|
| | | | A-64 | | |
第11.14节
保密
|
| | | | A-64 | | |
第11.15节
可分割性
|
| | | | A-64 | | |
第11.16节
强制执行
|
| | | | A-64 | | |
第11.17节
无追索权
|
| | | | A-64 | | |
第11.18节
陈述、保证和契诺无效
|
| | | | A-64 | | |
第11.19节
冲突和权限。
|
| | |
|
A-65
|
| |
|
操作
|
| |
第1.1节
|
|
|
分支机构
|
| |
第1.1节
|
|
|
协议
|
| |
前言
|
|
|
修改后的《幸存公司章程》
|
| |
第2.2(E)节
|
|
|
修改后的幸存实体文章
|
| |
第2.2(E)节
|
|
|
修改后的公司章程
|
| |
第2.1(B)节
|
|
|
修订后的公司激励计划
|
| |
第6.9节
|
|
|
反腐败法
|
| |
第3.7(D)节
|
|
|
反洗钱法
|
| |
第1.1节
|
|
|
经审计的财务报表
|
| |
第3.9(A)节
|
|
|
授权通知
|
| |
第2.6(C)(I)节
|
|
|
可用期末现金金额
|
| |
第1.1节
|
|
|
福利计划
|
| |
第1.1节
|
|
|
蓝天
|
| |
第8.2(A)(I)节
|
|
|
美国银行弃权书
|
| |
第1.1节
|
|
|
业务组合
|
| |
独奏会,第1.1节
|
|
|
工作日
|
| |
第1.1节
|
|
|
开曼群岛法案
|
| |
独奏会
|
|
|
关闭
|
| |
第2.3(A)节
|
|
|
截止日期
|
| |
第2.3(A)节
|
|
|
代码
|
| |
第1.1节
|
|
|
商业化
|
| |
第1.1节
|
|
|
商业化
|
| |
第1.1节
|
|
|
商业化
|
| |
第1.1节
|
|
|
商业化
|
| |
第1.1节
|
|
|
公司
|
| |
前言
|
|
|
公司收购建议
|
| |
第1.1节
|
|
|
公司董事会
|
| |
独奏会
|
|
|
公司资本重组
|
| |
独奏会
|
|
|
公司章程
|
| |
第1.1节
|
|
|
公司合同
|
| |
第1.1节
|
|
|
公司董事
|
| |
第2.2(G)节
|
|
|
公司公开信
|
| |
第三条
|
|
|
公司IP
|
| |
第1.1节
|
|
|
公司租赁
|
| |
第3.14(B)节
|
|
|
公司贷款人批准
|
| |
第3.5(B)节
|
|
|
公司重大不良影响
|
| |
第1.1节
|
|
|
公司物资租赁
|
| |
第3.14(B)节
|
|
|
公司选项
|
| |
第1.1节
|
|
|
公司普通股
|
| |
第1.1节
|
|
|
公司优先股
|
| |
第1.1节
|
|
|
公司产品
|
| |
第1.1节
|
|
|
公司系列A类优先股
|
| |
第1.1节
|
|
|
公司B系列优先股
|
| |
第1.1节
|
|
|
公司股东
|
| |
第1.1节
|
|
|
公司股东批准
|
| |
第3.5(B)节
|
|
|
公司股东大会
|
| |
第3.5(B)节
|
|
|
公司股份
|
| |
第1.1节
|
|
|
公司系统
|
| |
第3.15(E)节
|
|
|
公司交易费用
|
| |
第1.1节
|
|
|
公司保证书
|
| |
第2.2(H)(Iii)节
|
|
|
竞争空间
|
| |
第1.1节
|
|
|
机密信息
|
| |
第11.14节
|
|
|
继续选项
|
| |
第2.1(A)(三)节
|
|
|
合同
|
| |
第1.1节
|
|
|
控制
|
| |
第1.1节
|
|
|
受控
|
| |
第1.1节
|
|
|
控制
|
| |
第1.1节
|
|
|
转换
|
| |
第2.1(A)(I)节
|
|
|
库利
|
| |
第11.19(A)节
|
|
|
新冠肺炎
|
| |
第1.1节
|
|
|
新冠肺炎措施
|
| |
第1.1节
|
|
|
D&O补偿方
|
| |
第6.4(A)节
|
|
|
D&O保险
|
| |
第6.4(B)节
|
|
|
D&O尾部
|
| |
第6.4(B)节
|
|
|
开发
|
| |
第1.1节
|
|
|
开发
|
| |
第1.1节
|
|
|
公开信
|
| |
第1.1节
|
|
|
持不同意见的SPAC股东
|
| |
第2.6(A)节
|
|
|
持不同意见的Spac共享
|
| |
第2.6(A)节
|
|
|
DTC
|
| |
第1.1节
|
|
|
保留款
|
| |
第1.1节
|
|
|
可执行性例外情况
|
| |
第3.5(A)节
|
|
|
环境法
|
| |
第1.1节
|
|
|
股票证券
|
| |
第1.1节
|
|
|
ERISA
|
| |
第1.1节
|
|
|
ERISA分支机构
|
| |
第1.1节
|
|
|
员工持股计划
|
| |
第1.1节
|
|
|
事件
|
| |
第1.1节
|
|
|
《交换法》
|
| |
第1.1节
|
|
|
Exchange代理
|
| |
第2.4(A)节
|
|
|
首次合并
|
| |
独奏会
|
|
|
首次合并生效时间
|
| |
第2.2(C)(I)节
|
|
|
首次合并申请文件
|
| |
第2.2(C)(I)节
|
|
|
远期采购协议
|
| |
独奏会
|
|
|
远期进货投资额
|
| |
第4.17(A)节
|
|
|
远期买入投资者
|
| |
独奏会
|
|
|
远期购买订阅
|
| |
独奏会
|
|
|
完全稀释的公司股份
|
| |
第1.1节
|
|
|
公认会计原则
|
| |
第1.1节
|
|
|
政府官员
|
| |
第1.1节
|
|
|
政府权威机构
|
| |
第1.1节
|
|
|
政令
|
| |
第1.1节
|
|
|
组
|
| |
第1.1节
|
|
|
集团公司
|
| |
第1.1节
|
|
|
香港
|
| |
第1.1节
|
|
|
负债
|
| |
第1.1节
|
|
|
知识产权
|
| |
第1.1节
|
|
|
中期财务报表
|
| |
第6.6(A)节
|
|
|
过渡期
|
| |
第6.1节
|
|
|
《投资公司法》
|
| |
第1.1节
|
|
|
首次公开募股
|
| |
第11.1节
|
|
|
就业法案
|
| |
第4.14节
|
|
|
空间知识
|
| |
第1.1节
|
|
|
对公司的了解
|
| |
第1.1节
|
|
|
法律
|
| |
第1.1节
|
|
|
租赁房产
|
| |
第1.1节
|
|
|
递送函
|
| |
第2.4(B)节
|
|
|
负债
|
| |
第1.1节
|
|
|
可用
|
| |
第1.1节
|
|
|
主要客户
|
| |
第1.1节
|
|
|
主要供应商
|
| |
第1.1节
|
|
|
枫树
|
| |
第11.19(B)节
|
|
|
材料合同
|
| |
第1.1节
|
|
|
材料许可证
|
| |
第3.7(G)节
|
|
|
最高年度保费
|
| |
第6.4(B)节
|
|
|
合并考虑因素
|
| |
第1.1节
|
|
|
合并备案文件
|
| |
第2.2(C)(Ii)节
|
|
|
合并子公司I
|
| |
前言
|
|
|
合并分部股份
|
| |
第5.2(A)节
|
|
|
合并分会书面决议
|
| |
独奏会
|
|
|
第二次兼并
|
| |
前言
|
|
|
合并子公司股份
|
| |
第5.2(A)节
|
|
|
第二次合并书面决议
|
| |
独奏会
|
|
|
兼并子公司(S)
|
| |
前言
|
|
|
合并子股份
|
| |
第5.2(A)节
|
|
|
合并
|
| |
独奏会
|
|
|
保密协议
|
| |
第1.1节
|
|
|
无追索权交易方
|
| |
第11.17节
|
|
|
非赎回SPAC股票
|
| |
第1.1节
|
|
|
普通课程
|
| |
第1.1节
|
|
|
组织文档
|
| |
第1.1节
|
|
|
拥有知识产权
|
| |
第1.1节
|
|
|
专利
|
| |
第1.1节
|
|
|
允许的保留款
|
| |
第1.1节
|
|
|
允许的股权融资收益
|
| |
第1.1节
|
|
|
人
|
| |
第1.1节
|
|
|
PFIC
|
| |
第1.1节
|
|
|
首次合并计划
|
| |
第2.2(C)(I)节
|
|
|
第二次合并计划
|
| |
第2.2(C)(Ii)节
|
|
|
合并计划
|
| |
第1.1节
|
|
|
被禁止的人
|
| |
第1.1节
|
|
|
代理/注册声明
|
| |
第8.2(A)(I)节
|
|
|
代理报表
|
| |
第1.1节
|
|
|
公示7
|
| |
第1.1节
|
|
|
公示7税
|
| |
第1.1节
|
|
|
合格选举基金
|
| |
第8.4(C)节
|
|
|
赎回SPAC股票
|
| |
第1.1节
|
|
|
兑换率
|
| |
第1.1节
|
|
|
注册IP
|
| |
第1.1节
|
|
|
注册证券
|
| |
第1.1节
|
|
|
注册声明
|
| |
第1.1节
|
|
|
监管审批
|
| |
第8.1(A)节
|
|
|
监管机构
|
| |
第1.1节
|
|
|
关联方
|
| |
第1.1节
|
|
|
剩余信托基金收益
|
| |
第2.3(B)(Vii)(2)节
|
|
|
代表
|
| |
第1.1节
|
|
|
所需的政府授权
|
| |
第1.1节
|
|
|
股份合并
|
| |
第2.1(A)(Ii)节
|
|
|
股份合并生效时间
|
| |
第2.1(A)(三)节
|
|
|
股票合并系数
|
| |
第1.1节
|
|
|
制裁
|
| |
第1.1节
|
|
|
《萨班斯-奥克斯利法案》
|
| |
第1.1节
|
|
|
美国证券交易委员会
|
| |
第1.1节
|
|
|
第二次合并
|
| |
独奏会
|
|
|
第二次合并生效时间
|
| |
第2.2(C)(Ii)节
|
|
|
第二次合并申请文件
|
| |
第2.2(C)(Ii)节
|
|
|
证券法
|
| |
第1.1节
|
|
|
股东诉讼
|
| |
第8.5节
|
|
|
股东支持协议
|
| |
独奏会
|
|
|
股东协议
|
| |
第1.1节
|
|
|
SMH集团
|
| |
第11.19(A)节
|
|
|
Smih
|
| |
第4.16节
|
|
|
SMIHU
|
| |
第4.16节
|
|
|
SMIHW
|
| |
第4.16节
|
|
|
雪湖基金
|
| |
独奏会
|
|
|
软件
|
| |
第1.1节
|
|
|
空格
|
| |
前言
|
|
|
SPAC帐户日期
|
| |
第1.1节
|
|
|
SPAC收购方案
|
| |
第1.1节
|
|
|
SPAC板
|
| |
独奏会
|
|
|
SPAC董事会建议
|
| |
第8.2(B)(Ii)节
|
|
|
SPAC宪章
|
| |
第1.1节
|
|
|
SPAC A类交换比率
|
| |
第1.1节
|
|
|
SPAC A类普通股
|
| |
第1.1节
|
|
|
SPAC B类普通股
|
| |
第1.1节
|
|
|
空间董事
|
| |
第2.2(G)节
|
|
|
SPAC公开信
|
| |
第四条
|
|
|
SPAC财务报表
|
| |
第4.7(A)节
|
|
|
SPAC内部人士
|
| |
独奏会
|
|
|
SPAC材料的不良影响
|
| |
第1.1节
|
|
|
SPAC普通股
|
| |
第1.1节
|
|
|
SPAC优先股
|
| |
第1.1节
|
|
|
SPAC美国证券交易委员会备案文件
|
| |
第4.12节
|
|
|
SPAC证券
|
| |
第1.1节
|
|
|
SPAC股东
|
| |
第1.1节
|
|
|
SPAC股东赎回金额
|
| |
第1.1节
|
|
|
SPAC股东赎回权
|
| |
第1.1节
|
|
|
SPAC股东批准
|
| |
第1.1节
|
|
|
SPAC股东大会
|
| |
第8.2(B)(I)节
|
|
|
SPAC共享
|
| |
第1.1节
|
|
|
SPAC交易费用
|
| |
第1.1节
|
|
|
空间单元
|
| |
第1.1节
|
|
|
SPAC保修
|
| |
第1.1节
|
|
|
赞助商
|
| |
独奏会
|
|
|
子公司
|
| |
第1.1节
|
|
|
幸存公司
|
| |
独奏会
|
|
|
幸存实体
|
| |
独奏会
|
|
|
个税
|
| |
第1.1节
|
|
|
纳税申报表
|
| |
第1.1节
|
|
|
终止公司违规行为
|
| |
第10.1(F)节
|
|
|
终止SPAC违规
|
| |
第10.1(G)节
|
|
|
商业秘密
|
| |
第1.1节
|
|
|
商标
|
| |
第1.1节
|
|
|
交易单据(S)
|
| |
第1.1节
|
|
|
交易建议
|
| |
第1.1节
|
|
|
交易记录
|
| |
第1.1节
|
|
|
转让税
|
| |
第1.1节
|
|
|
国库条例
|
| |
第1.1节
|
|
|
信托帐户
|
| |
第4.13节
|
|
|
信托协议
|
| |
第4.13节
|
|
|
受托人
|
| |
第4.13节
|
|
|
美国
|
| |
第1.1节
|
|
|
承销协议
|
| |
第1.1节
|
|
|
联合
|
| |
第1.1节
|
|
|
单元分离
|
| |
第2.2(H)(I)节
|
|
|
保修协议
|
| |
第1.1节
|
|
|
认股权证转让协议
|
| |
独奏会
|
|
|
流动资金贷款
|
| |
第1.1节
|
|
|
书面反对意见
|
| |
第2.6(C)节
|
|
|
WSGR
|
| |
第11.19(B)节
|
|
|
YSB集团
|
| |
第11.19(B)节
|
|
|
《文章》
|
| |
指根据《公司法》和本章程不时修改或增加的本公司章程;
|
|
|
“董事会”、“董事会”和“董事”
|
| |
指当其时的公司董事,或作为董事会或委员会组成的董事;
|
|
|
“主席”
|
| | 指董事会主席; | |
|
“类”或“类”
|
| |
指本公司可能不时发行的任何一类或多类股份;
|
|
|
“佣金”
|
| |
指美利坚合众国证券交易委员会或当时管理《证券法》的任何其他联邦机构;
|
|
|
“通信设施”
|
| |
指自然人能够相互倾听和被倾听的技术(包括但不限于视频、视频会议、互联网或在线会议应用、电话或远程会议和/或其他视频通信、互联网或在线会议应用或电信设施);
|
|
|
“公司”
|
| |
指开曼群岛豁免公司YS Biophma Co.,Ltd.;
|
|
|
《公司法》
|
| |
指开曼群岛的《公司法》(经修订)及其任何法定修正案或重新颁布;
|
|
|
“公司网站”
|
| |
指公司的主要公司/投资者关系网站,其地址或域名已在公司向证监会提交的与其首次公开发行股票相关的任何登记声明中披露,或已以其他方式通知股东;
|
|
|
“指定证券交易所”
|
| |
指任何股票在美国上市交易的证券交易所;
|
|
|
《指定证券交易所规则》
|
| |
指因任何股票在指定证券交易所原有和继续上市而适用的经不时修订的相关守则、规则和规定;
|
|
|
“电子”
|
| |
具有《电子交易法》及其当时有效的任何修正案或重新制定的法律所赋予的含义,并包括与之合并或取代的所有其他法律;
|
|
|
“电子通信”
|
| |
指以电子方式张贴到公司网站、发送到任何号码、地址或互联网站或其他经董事会不少于三分之二投票决定和批准的电子交付方式;
|
|
|
《电子交易法》
|
| |
指开曼群岛的《电子交易法》(经修订)及其任何法定修正案或重新颁布;
|
|
|
“电子记录”
|
| |
具有《电子交易法》及其当时有效的任何修正案或重新制定的法律所赋予的含义,并包括与之合并或取代的所有其他法律;
|
|
|
《公司章程》
|
| |
指不时修订或取代的公司组织章程大纲;
|
|
|
“普通分辨率”
|
| |
表示解决方案:
(a)
在根据本章程细则举行的公司股东大会上,有权亲自投票的股东,或在允许委托代表的情况下,由其正式授权的代表投票的股东,以简单多数票通过;或
|
|
| | | |
(b)
由所有有权在公司股东大会上表决的股东在一份或多份由一名或多名股东签署的文书中书面批准,如此通过的决议的生效日期为文书的签立日期,如果文书多于一份,则为最后一份此类文书的签立日期;
|
|
|
“普通股”
|
| |
是指面值为美元的公司股本中的普通股[0.00002]每个;
|
|
|
“已付清”
|
| |
指已缴足的任何股票发行的面值,包括入账列为缴足的;
|
|
|
“人”
|
| |
指任何自然人、商号、公司、合资企业、合伙企业、公司、协会或其他实体(无论是否具有单独的法人资格)或其中任何一个,如上下文所需;
|
|
|
“呈现”
|
| |
就任何人士而言,指该人士出席股东大会(或任何类别股份持有人的任何会议),并可透过该人士或(如属公司或其他非自然人)其正式授权代表(或就任何股东而言,由该股东根据本章程细则有效委任的代表)出席,即:(A)亲临召开会议通知所指定的地点;或(B)如属根据本章程细则获准使用通讯设施的任何会议,包括任何虚拟会议,而该等通讯设施是根据召开该等大会的通知所指明的程序使用该等通讯设施而连结的;而“出席”应据此解释;
|
|
|
“注册”
|
| |
是指根据《公司法》保存的公司成员名册;
|
|
|
“注册办公室”
|
| |
指《公司法》规定的公司注册办事处;
|
|
|
“印章”
|
| |
指公司的公章(如果采用),包括其任何传真件;
|
|
|
“秘书”
|
| |
指由董事委任以履行本公司秘书任何职责的任何人士;
|
|
|
《证券法》
|
| |
指经修订的美利坚合众国1933年证券法,或任何类似的联邦法规以及委员会在该法令下的规则和条例,均应在当时有效;
|
|
|
“分享”
|
| |
指公司股本中的股份。凡提及“股份”,应视为任何或所有类别的股份,视上下文需要而定。为免生疑问,在本章程中,“股份”一词应包括一小部分股份;
|
|
|
“股东”或“成员”
|
| |
指在登记册上登记为一股或多股持有人的人;
|
|
|
“共享高级帐户”
|
| |
指根据本章程和《公司法》设立的股份溢价账户;
|
|
|
“已签署”
|
| |
指带有以机械方式或电子符号或程序附加在电子通信上或与电子通信逻辑相关并由意图签署该电子通信的人执行或采用的签名或签名的表示;
|
|
|
“特殊解决方案”
|
| |
是指公司根据《公司法》通过的特别决议,即:
(a)
在公司股东大会上,有权亲自投票的股东,或在允许委托代表的情况下,由其正式授权的代表或(如属公司)其正式授权的代表,以不少于三分之二的票数通过,而该股东已妥为发出通知,指明拟提出该决议作为特别决议;或
(b)
由所有有权在公司股东大会上表决的股东在一份或多份由一名或多名股东签署的文书中书面批准,如此通过的特别决议的生效日期为该文书或最后一份此类文书(如多于一份)签立的日期;
|
|
|
“国库股”
|
| |
是指根据《公司法》以公司名义作为库存股持有的股份;
|
|
|
“美国”
|
| |
指美利坚合众国、其领土、财产和受其管辖的所有地区;和
|
|
|
“虚拟会议”
|
| |
指允许股东(和任何其他获准出席该会议的人,包括但不限于会议主席和任何董事)仅通过通信设施出席的任何股东大会。
|
|
39.
|
(a)
|
董事可行使绝对酌情权拒绝登记任何未缴足股款或本公司有留置权的股份转让。 |
56.
|
(a)
|
本公司可(但无义务)于每一历年举行股东周年大会,并须在召开大会的通告中指明该大会为股东周年大会。股东周年大会将于董事决定的时间及地点举行。 |
57.
|
(a)
|
主席或过半数董事(根据董事会决议案行事)可召开股东大会,并应股东要求立即召开本公司特别股东大会。 |
| 签署并代表 | | | ) | | | 正式授权的签字人 | |
|
Summit Healthcare Acquisition Corp.:
|
| | ) | | | | |
| | | | ) | | |
名称:
|
|
| | | | ) | | | | |
| | | | ) | | |
标题:
|
|
| | | | ) | | | | |
| | | | ) | | | | |
| 签署并代表 | | | ) | | | 正式授权的签字人 | |
|
海景生物科学收购有限公司:
|
| | ) | | | | |
| | | | ) | | |
名称:
|
|
| | | | ) | | | | |
| | | | ) | | |
标题:
|
|
| | | | ) | | | | |
| | | | ) | | | | |